

A Demonstration of 4D Digital Avatar Infrastructure for Access of Complete Patient Information

Project acronym: MyHealthAvatar

Deliverable No. 7.1
Description of scenarios and use cases
for MyHealthAvatar







Grant agreement no: 600929

Dissemination Level		
PU	Public	Х
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
СО	Confidential, only for members of the consortium (including the Commission Services)	

COVER AND CONTROL PAGE OF DOCUMENT		
Project Acronym:	MyHealthAvatar	
Project Full Name:	A Demonstration of 4D Digital Avatar Infrastructure for Access of	
	Complete Patient Information	
Deliverable No.:	D7.1	
Document name:	Description of scenarios and use cases for MyHealthAvatar	
Nature (R, P, D, O) ¹	R	
Dissemination Level (PU, PP, RE, CO) ²	, PU	
Version: 1		
Actual Submission Date: 29/08/2014		
Editor:	Prof. Dr. Norbert Graf	
Institution:	USAAR	
E-Mail:	graf@uks.eu	

ABSTRACT:

This document describes the final Scenarios / Use Cases that are relevant for MyHealthAvatar (MHA). As scenarios are based on the results of WP2, the work on this document has started at month 10, after the finalization of WP2. According to the different stakeholders (citizens, patients clinicians, and researchers) the final set Scenarios / Use Cases have been updated, ranked, clustered and presented.

KEYWORD LIST:

Scenario, use case, stakeholder, end user needs, requirements.

¹ **R**=Report, **P**=Prototype, **D**=Demonstrator, **O**=Other

² **PU**=Public, **PP**=Restricted to other programme participants (including the Commission Services), **RE**=Restricted to a group specified by the consortium (including the Commission Services), **CO**=Confidential, only for members of the consortium (including the Commission Services)

The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 600929.

The author is solely responsible for its content, it does not represent the opinion of the European Community and the Community is not responsible for any use that might be made of data appearing therein

MODIFICAT	MODIFICATION CONTROL				
Version	Date	Status	Author		
0.1	04/12/2013	Draft	Ruslan David, USAAR		
0.2	10/03/2014	Draft	Norbert Graf, USAAR Ruslan David, USAAR		
0.3	26/03/2014	Draft Norbert Graf, USAAR Ruslan David, USAAR Sarah Jensen, LUH			
0.4	30/05/2014	Draft	Ruslan David, USAAR		
0.5	10/06/2014	Draft	Norbert Graf, USAAR Ruslan David, USAAR		
0.8	18/08/2014	Draft	Draft Norbert Graf, USAAR Ruslan David, USAAR		
0.9	09/09/2014	Pre-final Version	Feng Dong, BED		
1.0	30/09/2014	Final Version	Feng Dong, BED Norbert Graf, USAAR Ruslan David, USAAR Emmanouil G. Spanakis, FORTH Sarah Jensen, LUH		

List of contributors

- Norbert Graf, USAAR
- Ruslan David, USAAR
- Yvonne Braun, USAAR
- Holger Stenzhorn, USAAR
- Feng Dong, BED
- Sarah Jensen, LUH
- Eleni Georgiadi, ICCS
- Georgios Stamatakos, ICCS
- Fay Misichroni, ICCS
- Emmanouil G. Spanakis, FORTH
- Evangelia Maniadi, FORTH
- Dr. Apostolos Karantanas, FORTH
- Vangelis Sakkalis, FORTH
- Kostas Marias, FORTH

Contents

1	EXECUTIVE SUMMARY	6
2	SCENARIO / USE CASE BASED DESIGN	6
	2.1 Scenario / Use Case Approach	6
	2.2 SCENARIO / USE CASE TEMPLATE	7
	2.3 ARCHITECTURE AND INTEGRATION	8
3	MHA SCENARIOS / USE CASES SUMMARY	9
	3.1 The final set of MHA Scenarios / Use Cases	9
	3.2 STAKEHOLDERS MHA SCENARIOS / USE CASES	
	3.3 MHA Scenarios / Use Cases Ranking	10
	3.4 REQUIREMENT ANALYSIS	11
4	MHA SCENARIOS / USE CASES DESCRIPTION	14
	4.1 MHA USER ACCOUNTS (UC-UAC)	14
	4.2 AVATAR VISUALIZATION (UC-3DS)	
	4.3 MHA DATA BROWSE (UC-DB)	
	4.4 MHA VIRTUAL COMMUNITY (UC-VC)	
	4.5 SELF DATA COLLECTION (UC-DCU)	
	4.6 MHA TOOLBOX (UC-TOOL)	
	4.7 LINK MHA TO HIS AND CTMS (UC-HIS)	
	4.9 OSTEOARTHRITIS (UC-OST)	
	4.10 PRE-DIABETES (UC-DIAB)	
	4.11 NEPHROBLASTOMA (WILMS TUMOUR) SIMULATION MODEL AND CLINICAL TRIAL (UC-NEPH)	
	4.12 EMERGENCY CONTACT (UC-EME)	
	4.13 Brain Trauma (UC-TBI)	40
	4.14 ANTI-PLATELET & ANTICOAGULATION THERAPY IN THE PRE-OPERATIVE PATIENTS (UC-APLA)	43
5	MHA GRANULAR SCENARIOS / USE CASES CLUSTERING	48
	5.1 Introduction	48
	5.2 LEGAL AND ETHICAL SCENARIOS / USE CASES	48
	5.2.1 User Information Sheet and Privacy Policy	
	5.2.2 Information Sheet / Privacy Policy Draft	
	5.3 SCENARIOS / USE CASES FOR DATA ACCESS AND COLLECTION	
	5.3.1 MHA User Accounts (UAC)	
	5.3.2 MHA Data Browse (DB)	
	5.3.4 Link MHA to HIS and CTMS (HIS)	
	5.3.5 3D Avatar Visualization (3DS)	
	5.4 MHA VIRTUAL COMMUNITY (VC)	
	5.5 MHA TOOLBOX (TOOL)	
	5.5.1 Remote Monitoring	
	5.5.2 MHA Simulation Models	
	5.5.3 Knowledge Discovery	59
6	HIGH-END SCENARIOS / USE CASES	60
	6.1 Introduction	60
	6.2 SCENARIOS / USE CASES FOR PATIENT EMPOWERMENT	
	6.2.1 Pre-Diabetes (UC-DIAB)	60

	6.2.2 Personalized CHF Related RISK Profiles and Real-Time Monitoring Services (UC-CHF)	60
	6.2.3 Osteoarthritis (UC-OST)	60
	6.2.4 Brain Trauma (UC-TBI)	61
	6.2.5 Anti-Platelet & Anticoagulation Therapy in the Pre-Operative Patients (UC-APLA)	61
	6.3 Scenarios / Use Cases for Clinical Researchers	61
	6.3.1 Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial (UC-NEPH): In-silico	
	Profiling of Patients and Predictions	61
	6.3.2 Emergency Contact (UC-EME)	64
	6.4 Granularity of the High-End Scenarios / Use Cases	64
7	FURTHER LINKS WITH EXTERNAL PROJECTS	65
	7.1 MYLIFEHUB	65
	7.2 CARRE	66
8	CONCLUSIONS	67
	8.1 MyHealthAvatar Global Meeting	
	8.2 MyHealthAvatar Scenarios / Use Cases with 'High' Development Priority	
_	EFERENCES	
		_
	PPENDIX 1 – ABBREVIATIONS AND ACRONYMS	
A	PPENDIX 2 – THE INITIAL SET OF MHA SCENARIOS / USE CASES	72
	ENTER, IMPORT, STORE AND EXPORT PERSONAL MEDICAL DATA	
	Informed Consent and Privacy	
	INTERACTIVE 3D MODEL OF THE HUMAN BODY (PATIENT EDUCATION & SERIOUS GAME)	
	COLLECTING, SAVING AND SHARING DATA FROM THIRD PARTY SOCIAL NETWORKS	
	REMOTE MONITORING	
	Mobile Driven 3D Virtual Lung	
	Mobile Lifestyle and Social media	
	COMPILE AND PERFORM A SIMULATION USING A BIOLOGICAL MODEL	
	MANAGE THE CONTENT OF THE MODEL REPOSITORY AND THE CLINICAL DATA REPOSITORY	
	TOOLS FOR BROWSING MEDICAL IMAGES IN AVATAR	
	TOOLS FOR THE ANALYSIS OF MEDICAL IMAGES IN AVATAR	
	UTILIZATION OF PERSONAL GENOMIC INFORMATION FOR THE INDIVIDUALIZATION OF MHA PLATFORM	
	ANTI-PLATELET THERAPY IN PRE-OPERATING PERIOD.	
	MULTI-SCALE VISUALIZATION OF BIOMEDICAL DATA	
	BIDIRECTIONAL LINKAGE TO OBTIMA	
	CONSULTATION SCENARIO: INTERACTION BETWEEN THE PATIENT AND PHYSICIAN	
	Patient Diary	
	PATIENT DEVICES SDK	
	SEARCH FOR SIMILAR PATIENTS	
	KNOWLEDGE DISCOVERY	
	BUILDING PATIENT COMMUNITY AMONG USERS	
	AVATAR DATA BROWSE	
	AVATAR DATA COLLECTION	
	KNOWLEDGE AVATAR	
	WEB LOGIN	
	BRAIN TRAUMA	
	PERSONALISED CHF RISK ANALYSIS	
	DIABETES	
Δ	PPENDIX 3 – MYHFAI THAVATAR GLOBAL MEETING AGENDA	126



1 Executive Summary

This document describes the final Scenarios / Use Cases that are relevant for MyHealthAvatar (MHA). As scenarios are based on the results of WP2, the work on this document has started at month 10, after the finalization of WP2. According to the different stakeholders (citizens, clinicians, researchers and IT people) the final set Scenarios / Use Cases have been updated, ranked, clustered and provided.

In addition, the Scenarios / Use Cases updated from WP2 are described in linkage to external sources such as social networks and research infrastructures. All Scenarios / Use Cases have been developed in an interactive process between all beneficiaries of the project and described in a standardized way by using the updated template from WP2. Interoperability issues are taken into account to allow a seamless interaction between different scenarios and to guarantee data sharing. Tools that need to be developed in those scenarios are prioritized according to the user needs and requirements under a clinical perspective. Criteria for prioritization are given via Scenarios / Use Cases clustering approach and it could serve as a background for the required timeframes for realization of selected scenarios within MHA.

MHA high-end Scenarios / Use Cases have been defined and predictably divided in two major groups:

- Scenarios / Use Cases for Clinical Researchers
- Scenarios / Use Cases for Patients empowerment for long term disease treatment
- Scenarios for emergency contact

The final set of the agreed MHA High-End Scenarios / Use Cases, marked with 'High' ranking and top development priority is presented below.

ID	Scenario / Use Case Name
CHF	Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services
OST	Osteoarthritis
DIAB	Diabetes
NEPH	Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial
EME	Emergency contact

The linkage and references to other WPs have been mentioned, a special attention has been paid to data collection utilities and data repository to store health related data of individual citizens. Furthermore the user requirements and specifications for the linkage to external sources such as social networks and for the collaboration with other existing research projects are described.

2 Scenario / Use Case Based Design

2.1 Scenario / Use Case Approach

According to the D 2.2 [1] our approach is to integrate as much as possible the described Scenarios in the frames of the related Use Cases. We designed a complex template which has a section dedicated to Scenario description, named 'Basic Flow'. As consequence, we are using the term



'Scenario / Use Case', it allows us to describe the MHA Scenarios with minimum technical information in linkage to more complex and rich in technical requirements Use Cases. Despite the complexity of this approach it has been accepted by all project partners and it serves as a powerful guideline for further MHA platform development activities. Additionally, this approach allows us, close to the precise identification of the end-user's needs and requirements, to underline the MHA platform architecture and the related ICT requirements.

2.2 Scenario / Use Case Template

The template for Scenarios / Use Cases , presented and described in the frames of D 2.2, has been first updated in the frames of the MHA project 1st Progress Meeting in Budapest, Hungary (September 12, 2013). The last updated version has been discussed and agreed in the frames of the MHA project meeting in Homburg, Germany (September 2014). The final, updated version of Scenario / Use Case template is presented below.

Use Case ID:	UC-1		
Use Case Name:	Use case name		
Technical Collaborators:	Clinical C	ollaborator:	
Description:	Use case description. Ensure that you use an active voice.		
Actors:	Who will be taking part in this pro	ocess? If you want to write descriptions, it	
	makes the use case even more va	luable.	
Trigger:	What is making the use case begi	in? For instance, User presses a button.	
Preconditions:		use case can begin (i.e. execution of other	
	use cases prior to this use-case).		
Successful End condition:			
Fail End condition:			
Basic Flow:	What are the basic steps		
Alternate Flows:	Are there any deviations to the bo		
Postconditions:	-	his use case as the precondition for the next.	
Dependencies:	This use case extends to the following use cases:		
	Is this part of a bigger use case?		
	This use case includes the following use cases:		
Danish d Fatamal	Does this include other use cases?		
Required External Resources:	[] Data, please specify:	What type of data do we need to collect? Please be as specific as	
Resources.		possible at this point of time.	
		Who owns those data/where they	
		will come from?	
		What type of analysis we need to	
		support?	
	[] Tools, please specify:	What type of tools?	
		Who owns those tools?	
		How they can be used in the MHA?	
	[] Services, please specify:	What type of Services?	
		Who owns those Services?	
		How they can be used in the MHA?	
	[] Models, please specify:	What type of Models?	
		Who owns those Models?	
		How they can be used in the MHA?	



	[] Other, please specify:		
How this use-case is going	Include how the aforementioned use-case will be integrated possibly with		
to be validated?	clinicians workflow		
Frequency of Use:	How often will this be executed?		
Who are the users?	The main end-user categories are: Clinicians and Patients but feel free to add		
other end-use categories If necessary.			
Special Requirements:	Please detail any specific requirements demanded by the use case (e.g.		
performance, usability, interaction, storage requirements)			
Assumptions:	Any other detail that you feel relevant.		
Questions: Please detail all issues and questions that need to be answered prior to			
completion of the use-case description.			

2.3 Architecture and Integration

The D 3.2 [2] defined and described the architecture of the MHA platform. Additionally it presents the rationale and the process for designing the architecture based on the requirements and the user scenarios of the project. This effort was focused on the identification of the major stakeholders, their concerns, and viewpoints following well-known best practices for documenting software architecture. Additionally an Architectural Description (AD) document has been presented; it defined the high level architecture of the platform. The architecture definition process is nevertheless a continuous task as the system evolves and new requirements arise or other issues emerge.



3 MHA Scenarios / Use Cases Summary

This chapter presents the summary of all final Scenarios / Use Cases that relevant for MHA platform. All Scenarios / Use Cases are ranked and aligned to different stakeholders (citizens, clinicians, basic researchers and IT people).

3.1The final set of MHA Scenarios / Use Cases

The final set of MHA Scenarios / Use Cases is presented in **Table 1** are in details described in **Chapters 4, 5** and **6** of this document.

ID	Scenario / Use Case Name	
UAC	MHA User Accounts	
3DS	3D Avatar Visualization	
DB	MHA Data Browse	
VC	MHA Virtual Community	
DCU	Self Data Collection	
TOOL	MHA Toolbox and MHA Simulation Models	
HIS	Link MHA to HIS and CTMS	
CHF	Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services	
OST	Osteoarthritis	
DIAB	Pre-Diabetes	
NEPH	Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial	
EME	Emergency contact	
TBI	Brain Trauma	
APLA	Anti-Platelet & Anticoagulation Therapy in the Pre-Operative Patients	

Table 1. The final set of MHA Scenarios / Use Cases

3.2Stakeholders MHA Scenarios / Use Cases

According to the different stakeholders (citizens, patients, clinicians and researchers) Scenarios / Use Cases are provided for each of them (**Table 2**) by taking into account the clustering approach described in **Chapter 5** of this document.

ID	Scenario / Use Case Name	Stakeholders	
UAC	MHA User Accounts	Granular Scenario / Use Case for Data Access and Collection:	
		Citizens and Patients	
		Clinicians and Researchers	
3DS	3D Avatar Visualization	Granular Scenario / Use Case for Data Access and	
		Collection:	
		 Citizens and Patients 	
		 Clinicians and Researchers 	
DB	MHA Data Browse	Granular Scenario / Use Case for Data Access and	
		Collection:	
		 Citizens and Patients 	
		 Clinicians and Researchers 	
VC	MHA Virtual Community	Granular Scenario / Use Case for Data Access and	
		Collection:	
		Citizens and Patients	

		Clinicians and Researchers	
DCU	Self Data Collection	Granular Scenario / Use Case for Data Access and Collection:	
TOOL	MHA Toolbox and MHA Simulation Models	Granular Scenario / Use Case for Data Access and Collection:	
HIS	Link MHA to HIS and CTMS	Granular Scenario / Use Case for Data Access and Collection: Citizens and Patients Clinicians and Researchers	
CHF	Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services	High-End Scenario / Use Case for patient empowerment and clinicians	
OST	Osteoarthritis	High-End Scenario / Use Case for patient empowerment and clinicians	
DIAB	Diabetes	High-End Scenario / Use Case for patient empowerment and clinicians	
NEPH	Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial	High-End Scenario / Use Case for Clinical Researchers, Patients	
EME	Emergency contact	High-End Scenario / Use Case for clinicians and patients	
ТВІ	Brain Trauma	High-End Scenario / Use Case for patient empowerment and clinicians	
APLA	Anti-Platelet & Anticoagulation Therapy in the Pre-Operative Patients	High-End Scenario / Use Case for patient empowerment and clinicians	

Table 2. Stakeholders' MHA Scenarios / Use Cases

3.3MHA Scenarios / Use Cases Ranking

According to the need of different use cases in high-end scenarios a ranking of granular use cases is required. This ranking (low, medium, high) is used to prioritize the MHA platform development activities (**Table 3**).

'High' priority Scenarios / Use Cases aims to provide the end users with the basic MHA platform functionalities. The main prioritisation criteria was to have in place the core functionalities able to integrate more complex Scenarios / Use Cases ranked with 'Medium' state.

The ranking of MHA Scenarios / Use Cases is used mainly for internal platform development process with direct impact on next project's tasks and in special the **T9.1**: **Definition of demos**.

MHA Scenarios / Use Cases ranking has been defined and agreed with all project partners in the frames of the last consortium meeting on September 2014 (Homburg, Germany).

ID	Scenario / Use Case Name	Ranking
UAC	MHA User Accounts	High
3DS	3D Avatar Visualization	High



DB	MHA Data Browse	High
VC	MHA Virtual Community	High
DCU	Self Data Collection	High
TOOL	MHA Toolbox and MHA Simulation Models	High
HIS	Link MHA to HIS and CTMS	High
CHF	Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services	High
OST	Osteoarthritis	High
DIAB	Diabetes	High
NEPH	Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial	High
EME	Emergency contact	High
TBI	Brain Trauma	Medium
APLA	Anti-Platelet & Anticoagulation Therapy in the Pre-Operative Patients	Medium

Table 3. Ranking of MHA Scenarios / Use Cases

3.4 Requirement Analysis

Top user requirements have been successfully defined in the frames of D 2.2 [1], these are:

- The Usage, management and sharing of a wide spectrum of heterogeneous data from multiple platforms to provide a comprehensive and longitudinal collection of data regarding the citizen's and patient's health status
- 2. The need for smart and easily accessible data collection methods
- 3. Entire data ownership and control by citizens
- 4. Secure, legal and regulatory compliant deployment of services
- 5. Integrated ICT for data navigation, search, visualization and analysis to support user understanding and education
- 6. Coordinated personal healthcare services with medical professionals and healthcare systems to allow knowledge discovery and assessment and prediction of the health status of patients by statistical analysis and simulation
- 7. Interfaces for the usage of external tools, models and services
- 8. Links to external data warehouse sources
- 9. Links to external hospital records
- 10. Links to social media networks and services and to support building of patient communities among patients with similar conditions
- 11. MHA API development for services interaction

All these requirements have been addressed in the updated versions of MHA's Scenarios / Use Cases (Chapters 4, 5, 6).

The D 2.3 [5] presented the user requirements and specifications for the linkage to external sources such as social networks and for the collaboration with other existing research projects. All presented resources have been analysed in the terms of the identified end user needs and requirements. As result, the concluding D 2.3 **Table 6** has been refreshed with new data and insights. Additionally, new, potential collaboration opportunities are described in **Chapter 7** (MyLifeHub and CARRE projects).



End User(s)	Needs	Requirements	Priority
Researchers, healthcare professionals	Integrate the results and achievements of the VPH Network of Excellence (VPH-NOE project)	Access, integration and usage of the VPH ToolKit elements	Medium
Researchers, healthcare professionals, patients, citizens	ObTiMA integration (p-medicine Project)	Implementation of the UC-HIS	High
All end-users	Data protection and data security framework (p-medicine Project)	Usage and integration of the p- medicine project deliverable D5.1 Setting up of the data protection and data security framework	High
Researchers, healthcare professionals	3D visualised cancer models (p-medicine Project)	Integration of the p-medicine's re- usable clinical trial driven multi-scale cancer models	High
Researchers, healthcare professionals, patients	3D visualised cancer models (CHIC project)	Implementation of the UC-NEPH	High
Researchers, IT professionals	Digital Patient Roadmap (DISCIPULUS project)	Usage and integration of the DISCIPULUS project's Digital Patient Roadmap	High
Researchers, IT professionals	Computer-based predictive models (MD-Paedigree project)	Usage and integration of the MD- Paedigree project's computer-based predictive models of various paediatric diseases	Low
Researchers, IT professionals, patients	Virtual reality based rehabilitation platform (REWIRE project)	Linkage and/or integration of the REWIRE project's virtual reality based rehabilitation platform	Low
Researchers, healthcare professionals, general public	Experience and linkage with Facebook Profile Access Timeline activity Post/Get/Share	Facebook platform components integration: Social Plugins Login OpenGraph	Medium
Researchers, healthcare professionals, general public	Experience and linkage with LinkedIn Profile Access Timeline activity Post/Get/Share	LinkedIn services integration: Share Plugin Sign in with LinkedIn	Low
Researchers, healthcare professionals, general public	Experience and linkage with Google+ Profile Access Timeline activity	Google+ services integration: Interactive posts Integrated Hangouts Google+ plugins	Low



	Post/Get/Share		
Researchers, healthcare professionals, general public	Experience and linkage with Twitter Profile Access Timeline activity Post/Get/Share	Twitter services integration: Twitter Cards Embedded Timelines Embedded Tweets Tweet Button Follow Button	Medium
General public, patients	PatientsLikeMe health data import, export	To identify the tools and services able to import/export health data	Low
General public, patients	PHR systems (e.g. Indivo, Microsoft HealthVault) health data import/export	Implementation of the UC-HIS	High

Table 6: The refreshed, concluding table on End-User Needs and Requirements from D 2.3.



4 MHA Scenarios / Use Cases Description

This chapter presents the detailed description of the final set of the MHA Scenarios / Use Cases. These cases evolved from the original case description on D2.2, which is attached in Appendix 2 as a reference.


4.1 MHA User Accounts (UC-UAC)

Use Case ID:	UC-UAC		
Use Case Name:	MHA User Accounts		
Technical Collaborators:	BED, FORTH, ICCS Clinical Collaborator: USAAR		
Description:	Users (citizens) will be able to log onto the system using their username and password. New users will be able to sign up to the system by creating basic personal information including security questions.		
	Informed consent and privacy: Users will need to accept the privacy policy and the "terms and conditions" of using the MyHealthAvatar platform.		
	Upon log into the system, users will be able to enter, browse their data, explore medical information, communicate with other fellow patients.		
	Users will be able to view and interact with an avatar - a 3D representation of the human body. It will allow the End User to click with the computer mouse on a particular part of the avatar "body" to trigger a search of medical records to retrieve relevant information		
	MyHealthAvatar is a platform for End-Users who want to share their health information to create collective knowledge about disease, health, and treatments. In order to achieve this goal advanced Informed Consent and Privacy Policy Scenario / Use Case should be implemented.		
	End User has the GUIs, functionalities and tools in the frames of MyHealthAvatar platform to accept, reject, print or revise at any time the Privacy and Informed Consent settings.		
	There will be two types of users, the first type includes patients and citizens for their life time data collection, the second type includes doctors who will be linked to the avatars from citizens/patients for clinical practices and medical research purpose		
Actors:	Two types of users: Type 1: Patients/citizens Type 2: doctors/medical researchers		
Trigger:	n/a		
Preconditions:	n/a		
Successful End condition	n/a		
Fail End condition	n/a		
Basic Flow:	Sign up and log in		
	1. After press a sign up button, new users will provide basic		
	information (user name, age, gender etc.) and some security		
	questions. They will also have to accept the privacy policy and the "terms and conditions" of using the MyHealthAvatar platform.		
	2. Upon log in, users will be able to access the system		
	3. Users will be able to perform the system operations (e.g. data		
	browsing, sharing etc.)		
	Privacy policy setting		

	Successful Log-In (or New account creation) by using Username or Email and Password		
	Click Accept/Revise link named "Privacy and Informed Consent" of your Avatar		
	3. The Privacy and Informed Consent description with checkboxes is shown.		
	4. End User has the option to select any checkbox according his/her preferences		
	 End User has the option to "Edit", "Save" and "Print" the Accepted "Privacy and Informed Consent" preferences. 		
	Note: the sign up interface for padifferent.	atients and doctors will be slightly	
Alternate Flows:	n/a		
Postconditions:	N/a		
Dependencies:	n/a		
Required External Resources:	[] Data, please specify:	n/a	
	[] Tools, please specify:	n/a	
	[] Services, please specify:	n/a	
	[] Models, please specify:	n/a	
	[] Other, please specify:	n/a	
How this use-case is going to be validated?			
Frequency of Use:			
Who are the users?	Two types of users: Type 1: Patients/citizens		
	Type 2: doctors/medical researchers		
Special Requirements:			
Assumptions:			
Questions:			

4.2 Avatar Visualization (UC-3DS)

Use Case ID:	UC-3DS		
Use Case Name:	3D Avatar Visualization		
Technical Collaborators:	BED Clinical Collaborator: USAAR		
Description:	the human patient me The avatar to the citize Users will be information food.	watar platform would propose an avata body - to allow End Users (e.g. patient dical records in a new way. will be used as a means for presenting en users. be able to select individual parts and sen such as anatomy. The information maidualization of the 3D model is desirable	general medical knowledge e related medical ay also include medicine and



Resources:		
	[] Tools, please specify:	n/a
	[] Services, please specify:	n/a
	[] Models, please specify:	n/a
	[] Other, please specify:	n/a
How this use-case is going		
to be validated?		
Frequency of Use:		
Who are the users?	This will be mainly for citizens/patients to view their own data	
	The doctors can also load the avatars from their patients to see patient data	
Special Requirements:		
Assumptions:		
Questions:		

4.3 MHA Data Browse (UC-DB)

Use Case ID:	UC-DB			
Use Case Name:	MHA Data Browse			
Technical Collaborators:	BED, LIN, FORTH, ICCS Clinical Collaborator: USAAR			
Description:	Upon log in to their own account, users will be able to browse their own data, including all the personal health status data collected through the avatar system, plus medical records and clinical data from the hospitals The avatar system will need to offer tools that support effective data query and search, such as filtering.			
	The 4D avatar will play an important role in presenting the data. Users will be able to select individual parts of the avatar body to view the data associated to the selected parts.			
	Different colours or textures will be assigned to individual parts of the 4D avatar to represent their health status. For example, if the heart has a serious problem it will be highlighted using a unique colour or texture			
	Patients/citizens will use the data browser to view their own data; Doctors will be able to view data from all his/her patients connected to the avatar.			
	The avatar system will also need tools which will help users to analyze medical images			
Actors:	Patients/citizens will use the data browser to view their own data Doctors will be able to view data from all his/her patients connected to the avatar.			
Trigger:	n/a			
Preconditions:	n/a			
Successful End condition	n/a			
Fail End condition	n/a			
Basic Flow:	The basic steps are: 1. Successful Log-In (or New account creation) by using Username and Password 2. Use user interface (menus, dialog boxes etc) to view data			

	3. Allow to use filters for data selection		
	4. Allow data presentation at different level of details (e.g. use small		
	text box, large textbox, or even open a new page)		
	5. View health status through the colours/textures of the 4D avatar		
	6. Click on individual parts of the avatar to view relevant data		
	7. For image data browsi	ng:	
	Select a set of medic	cal images within the avatar	
	 Load and Browse the 		
	 Allow zoom in/out a 	t particular areas of the images	
	 Indicate the images 	at corresponding part of the avatar body	
	Perform basic image	processing, such as Image filtering, and	
	enhancement, etc.		
	 Perform segmentation 	on of region of interests (lesions or	
	anatomies) on selected images		
Alternate Flows:	n/a		
Postconditions:	N/a		
Dependencies:	n/a		
Required External	[] Data, please specify:	n/a	
Resources:			
	[] Tools, please specify:	n/a	
	[] Services, please specify:	n/a	
	[] Models, please specify:	n/a	
	[] Other, please specify:	n/a	
11			
How this use-case is going			
to be validated?			
Frequency of Use:			
Who are the users?	Patients/citizens will use the data browser to view their own data		
	Doctors will be able to view data from all his/her patients connected to the avatar.		
Special Requirements:	uvutur.		
Assumptions:			
Assumptions:			

4.4 MHA Virtual Community (UC-VC)

Use Case ID:	UC-VC		
Use Case Name:	MHA Virtual Community		
Technical Collaborators:	BED, FORTH Clinical Collaborator: USAAR		
Description:	This case describes the search framework from end-users' perspective and it		
	is focused on listing all MHA registered end-users with ability to apply		
	advanced search filters:		
	• Age		
	Gender		
	Votes (Likes)		
	Treatment		
	Symptom		
	 Interests 		

	• Country
	• City
	• etc.
	It is important to mention that every end-user should confirm the possibility
	to visualize his/her profile publically or privately. Only public profiles should
	be visible in search results.
	Additionally, the ecouple forestion is everywheal to be economial and of the end
	Additionally, the search function is suggested to be accessible only for end-
	users with public profiles.
	This case also provides a social media that allows patients to build up a
	virtual community by sharing their daily activities (e.g. how many exercises
	they have done), exchanging their experiences. It should also provide a link
	to Facebook/Twitter.
	The social media service will be used to allow the interconnection of end
	users. This social media service, accessible by smart phones, will be used in
	a dual mode allowing the users to insert information about themselves (like
	they do in common social media technologies) but also will be a mean of
	supporting personalized services to them from the system in the form of
	alerts and guidance (i.e. post therapy monitoring of user's behaviours after
	orthopaedics operation, cancer patients reaction to treatment, etc.).
	More specifically, patients will be able to
	1) Find patients with similar condition, symptom and treatments
	2) Find out symptoms and treatment for their conditions by looking at
	other fellow patients
	3) Find out possible conditions for their symptoms by looking at other
	fellow patients
	4) Find out possible treatments for their conditions by looking at other
	fellow patients
	5) Find out "friends" and allow "followers" as in Facebook/Twitter
	6) Share activities, exercise experiences etc with friends and followers.
	End User has the related tools in the frames of MyHealthAvatar platform to
	collect, save and share data from third party social networks (Facebook,
	Twitter, etc.). The interface allows the End Users to attach to his/her own
	Avatar his/her own Facebook and/or Twitter account. The End-User's Avatar
	will have the frames to show the last updates, status messages or short
	texts from the related Facebook and/or Twitter accounts. The Avatar (End-
	User) has the option to share data to the added (only own!) Twitter and/or
	Facebook channels
Actors:	Patients/citizens will use this to build patient communities
	Doctors can also have the option to join in the patient communities
Trigger:	n/a
Preconditions:	n/a
Successful End condition	n/a
Fail End condition Basic Flow:	n/a Upon successful Log-In (or New account creation) by using Username and
Dasil Fiuw.	Password, users will be able to carry out search among all the users of the
	avatar system for the following purposes:
	8. Search for patients with specific conditions, symptoms and
	treatments
	Find out symptoms and treatments for specific conditions
	and a deather to appear to contain the

	10. Find out conditions from specific symptoms.		
	11. Search for treatments for specific conditions		
	12. Find out "friends" and allow "followers" as in Facebook/Twitter		
	13. Share activities, exercise ex	•	
	followers.	periences etc with menus and	
Alternate Flows:	n/a		
Postconditions:	n/a		
Dependencies:	n/a		
Required External	[] Data, please specify:	n/a	
Resources:			
	[] Tools, please specify:	n/a	
	[] Services, please specify:	n/a	
	[] Models, please specify:	n/a	
	[] Other, please specify:	n/a	
How this use-case is going			
to be validated?			
Frequency of Use:			
Who are the users?	Patients/citizens will use this to build patient communities		
	Doctors can also have the option to join in the patient communities		
Special Requirements:			
Assumptions:			
Questions:			

4.5 Self Data Collection (UC-DCU)

Use Case ID:	UC-DCU		
Use Case Name:	Self Data Collection		
Technical Collaborators:	BED, FORTH	Clinical Collaborator:	USAAR
Description:	This case seeks new solutions for increasing the quality and sustainability of future healthcare systems by actively engaging citizens in monitoring their own health through self collection of lifelogging data.		
	The development and treatment of many diseases are affected by our life styles and environment. A long term monitoring of these factors, especially through the self-involvement of patients, is extremely valuable in supporting individualised health prediction and treatment. Many studies have shown compelling needs in self-lifelogging and self monitoring of patients, which has great potential in leading to preventive medicine, cost saving and enhanced quality in future healthcare.		
	We aim to create a symbiotic relationship of available technology today and MyHealthAvatar platform. The goal is to respond to the fast growing demand for developing new technologies and services for self monitoring for supporting wellness, fitness and prevention of the most common chronic diseases (i.e. cardio-vascular and stroke, diabetes, rheumatic problems, respiratory problems and COPD, etc.). Mobile applications will monitor user's "health-status", "lifestyle" and "wellness" and upload data to the MyHealthAvatar system for close monitoring of health conditions and		



prevention of many diseases. The system then will be able to analyse user's lifestyle and medical data. Special "alerts" will be applied to support end users with feedback supporting and assisting their daily activities and wellbeing.

An interface for patients writing a diary is very helpful to collect patient specific data related to their disease. This can be partly structured: e.g. body weight, heart rate, blood pressure, temperature, medicine taken, etc. It can also include structured data of scoring systems, e.g. physical and/or psychological and/or emotional status. In addition free text entry needs to be allowed.

More specifically, we explores various ways for the data collection in the avatar to monitor users' health-status, lifestyle and wellness. These include:

- Web interface for data entry
- Sensors (e.g. blood glucose, blood pressure, heart rate, locations, steps, sleep)
- Mobile apps

For example, users uses a glucose meter and MyHealthAvatar platform to monitor his/her blood sugar levels. The data is saved that maintains the Avatar's long-term history and looks for possible abnormal events. If the saved data is unusual, or the End-User skips a test, the MyHealthAvatar platform automatically generates an alert message

Mobile apps will be used to monitor the health status of the users (e.g. mood, food).

We will also explore the possibility to extract health related information from electronic cards (e.g. purchase of food and drink, daily exercises in gyms), as well as from social network.

We will also look into the possibility of implementing an advanced Patient Devices Software Development Kit (SDK or "devkit"). A SDK will represent a set of software development tools that will allow healthcare it professionals the creation of applications for MHA able to access and strore data from any patient monitoring device. Patient Devices SDK may be something as simple as an application programming interface (API) in the form of some files to interface to a particular programming language or include sophisticated hardware to communicate with MHA platform. SDK may also include sample code and supporting technical notes or other supporting documentation to help clarify points from the primary reference material.

Some diary entries could be in linkage with avatar appearance.

	and the property of the proper	
Actors:	Patients/citizens	
Trigger:	n/a	
Preconditions:	n/a	
Successful End condition	n/a	
Fail End condition	n/a	
Basic Flow:	The basic steps are:	
	For manual data entry:	
	 Successful Log-In (or New account creation) by using Username and Password 	
	Click relevant section from your Avatar	
	 The interface is shown with ability to enter and or visualize data by date, week, month, year. 	
	 End User has the option to select any date or any diary entry with possibility to update it (in case of updates the update date is shown) 	

	 End User has the option to "Edit", "Save", "Print" or "Share" the Diary info. 	
	 End-User has the optinitial stage only a gliant of the stage of th	fremote monitoring devices" tion to "Add" the monitoring device, at the ucose meter could be added ces parameters (Bluetooth or USB) are settled. e to switch on/off the automatic data collection to visualize the collected data change the appearance of the Avatar and/or ent if the End-User skipped a test
Alternate Flows:	n/a	
Postconditions:	N/a	
Dependencies:	n/a	
Required External Resources:	[] Data, please specify:	n/a
	[] Tools, please specify:	n/a
	[] Services, please specify:	n/a
	[] Models, please specify:	n/a
	[] Other, please specify:	n/a
How this use-case is going to be validated?		
Frequency of Use:		
Who are the users?	Citizens/patients	
Special Requirements:		
Assumptions:		
Questions:		

4.6 MHA Toolbox (UC-TOOL)

Use Case ID:	UC-TOOL		
Use Case Name:	MyHealthAvatar Toolb	оох	
Technical Collaborators:	ICCS, FORTH Clinical Collaborator: USSAR		
Description:	information from supp (preferably selected by End User uses a glucos his/her blood sugar leventhe blood sugar regular able seamlessly to train The data is saved that possible abnormal eventhes	ng tool/frame collects and ported healthcare devices the year the Continua Health Allian se meter and MyHealthAvatar planty during the day, and the pasmit the measurements to maintains the Avatar's longents. If the saved data is unuvatar platform automatically	ar platform to standards ce). ar platform to monitor latform reminds to check glucose meter should be the Avatar after each useterm history and looks for sual, or the End-User skips



Actors:

Trigger:

Preconditions:

The monitoring data will be made available through the citizen self-monitoring case (which is another use case). To allow for remote monitoring from the doctors using the avatar system, we need to link the avatar system to the hospital information system (which is again another use case). This will subsequently allow the transfer of the avatar data into the hospital records.
Simulation End-User has the GUIs, functionalities and tools in the frames of MyHealthAvatar platform to create and execute a biological simulation scenario.
End-User selects one of the biological simulation models available in the Model Repository and one of the sets of clinical data available in the Clinical Data Repository (or uploads a set from his computer). Afterwards he/she executes a biological simulation. Finally he/she retrieves the results of the simulation and proceeds to their evaluation.
Knowledge discovery Patients are interested in the most recent and personalized information about their disease, treatment and prognosis. MHA platform could contain a ontology-based Knowledge Discovery (KD) module able to connects highly heterogeneous data and textual information. The semantic framework could be based on gene, tissue, disease and compound ontologies (important for drugs and clinical research frames). This framework could contain information from different organisms, platforms, data types and research areas that is integrated into and correlated within a single searchable environment using search algorithms. It could provide a unified interface for all MHA users to formulate, explore and identify new information (according to specific preferences and needs) across vast collections of available experimental and research data.
KD module could combine classical keyword-based search with text-mining and ontologies to navigate large results sets (internal & external) and facilitate information and/or knowledge discovery.
End users could be provided with an advanced ontology based (Gene Ontology (GO) and Medical Subject Headings (MeSH)) 'Table of Contents' in order to access, explore, structure (quickly) the millions of available resources (PubMed abstracts, news, clinical trials info) according to the predefined topics of interest (Allergy, Cancer, etc.).
Remote consultation: doctors (GPs) and patients Simulation: researchers, clinicians, patients
Knowledge discovery: medical researchers, doctors
 User accesses the section "Simulation Interface". User "clicks" on a specific area of the 3-D avatar of the human body, for example the kidney, is directly or indirectly (by a menu) redirected to the "Simulation Interface" and is guided to the proper biological simulation model/-s (for example the kidney

Simulation: • The

- The User has to Log-in or to create a New Account (New Avatar).
 - The option to "perform simulations using biological models" must be enabled in the user's profile.

simulation model/-s



Successful End condition	 The user must have the proper access rights in order to use a biological simulation model from the Model Repository. The biological simulation model must be already imported to the Model Repository. The user must have the proper access rights in order to use a set of clinical data from the Clinical Data Repository. The clinical data that the biological simulation model needs in order to run must be already imported into the Clinical Data Repository or it must be provided (uploaded) by the user just before the start of the simulation. The clinical data must be compatible, in terms of format and content, with the selected biological simulation model. The user must have the proper access rights to a computational platform. The computational platform must have enough available resources in order for the simulation to be performed successfully
Fail End condition	n/a
Basic Flow:	n/a
	 The basic steps in case of simulation are: Successful Log-In (or New account creation) by using Username or Email and Password. Select the Avatar. The flow ends here if the End-User doesn't have the option "Perform simulations using biological models" enabled. The flow continues if the End-User has the option "Perform simulations using biological models" enabled. End-User creates a biological simulation scenario, by selecting a simulation model from the Model Repository and a set of data from the Clinical Data Repository. End-User starts the simulation process. When the simulation is completed, the proper ending code is displayed, either a success message or an erroneous message. End-User user has the possibility to download the results of the simulation to his computer, either the simulation ended successful or with errors".
Alternate Flows:	1. In step 5 of the basic flow, the selection of the simulation model can be guided by narrowing the available simulation models to only the ones related to a specific part of the human body, by clicking on the 3-D representation of human body. 2. In step 6 of basic flow, End-User can upload a set of data from his computer instead of using a set of data provided by the Clinical Data Repository
Postconditions:	N/a
Dependencies:	Simulation: • The option to perform simulations using biological models must be enabled in the user's profile. • The user must have the proper access rights to the Model.
	 The user must have the proper access rights to the Model Repository. The user must have the proper access rights to the Clinical data repository. The user must have the proper access rights to a Computational

r	T	T
Required External	[] Data, please specify:	Clinical data (already preprocessed),
Resources:		ready to be used by the simulation
		models
	[] Tools, please specify:	 Model Repository
		 Clinical Data Repository
		(related to simulation
	models)	
	[] Services, please specify:	Query the Model
		Repository for available
		models.
		Query the Clinical Data
		Repository (related to
		biological simulation
		models).
		Copy a selected model to
		the computational
		platform.
		Copy a set of selected
		preprocessed data to the
		computational platform.
		Execute the simulation
		scenario (by sending a
		computational job to the
		computational platform).
		Retrieve the result of the
		execution of a simulation
	[] Models, please specify:	model. Simulation Models
	[] Other, please specify: Computational Platform: Can be	
	either a personal computer, a cloud	
	virtual machine, a High Performance	
	Computer (HPC) or any other	
	system able to perform	
		computational simulations.
How this use-case is going		
to be validated?	Medium	
Frequency of Use: Who are the users?		nd nationts
willo are the users:	Remote consultation: doctors (GPs) and patients Simulation: researchers, clinicians, patients	
	Knowledge discovery: medical researchers, doctors	
Special Requirements:	Knowicage aiscovery. Incarcar research	eners, doctors
Assumptions:	Simulation:	
7.554	The biological simulation model is already imported in the model	
	repository.	
	A set of clinical data compatible with the aforementioned	
	biological simulation model is already imported in the clinical data	
	repository.	
	 Appropriate computational resources are available for running the 	
	simulation.	
	 The security framework is responsible for controlling the access to 	
	the model repository, the clinical data repository and the	
	computational platform.	
Questions		odel (nenhrohlastoma) planned to be
Questions:	Although the biological simulation me	oder (nephrobiastoma) planned to be



used in the MyHealthAvatar demonstrator doesn't use proprietary software, what if a model uses proprietary software, like a model developed in Matlab (licensing issues)?

4.7 Link MHA to HIS and CTMS (UC-HIS)

Use Case ID:	UC-HIS		
Use Case Name:	Link MHA to HIS (Hospital Management System) and CTMS (Clinical Trials		
	Management System)		
Technical Collaborators:	FORTH, ICCS Clinical Collaborator: USAAR		
Description:	End User has the GUIs, functionalities and tools in the frames of		
·		r, import, store and export personal	
	One option is to use ObTiMA as a system.	dummy system to mimic external hospital	
	ObTiMA, an ontology-based clinical trial management system, has been developed as a proof-of-concept application to highlight the possibilities of ontology based creation and managing of clinical trials within the ACGT (Advancing Clinico-Genomic Trials on Cancer) project. ObTiMA has a modular architecture with a core basic module for data management of clinical trials. Different other modules are under development in the frames of p-medicine project.		
	The data stored in ObTiMA are relevant for the Health Avatar to enhance the system with relevant clinical trial data. On the other hand the info stored in MHA might be of relevance for a clinical trial. As result, the bidirectional data upload from MHA to ObTiMA is needed. This Scenario / Use Case describes the bilateral linkage between ObTiMA and MHA by being focused on the Operational Data Model (ODM).		
	There are also a few other dummy systems available at FORTH, which can be used to mimic the external hospital system.		
Actors:	Patients/citizens will see their own health records from the hospitals Doctors will be able to see patient data in their avatars		
Trigger:	n/a		
Preconditions:	n/a		
Successful End condition	n/a		
Fail End condition	n/a		
Basic Flow:	The basic steps are:		
	Access the data export/import interface		
	Specify data export/import from ObTiMA (or other dummy		
	systems)		
	Specify data export/import from MHA		
	Confirmation message of data/export		
Alternate Flows:	n/a		
Postconditions:	N/a		
Dependencies:	n/a		
Required External	[] Data, please specify: eCRF with filed in data from ObTiMA		
Resources:		Health Avatar with clinical trial	

	[] Tools, please specify:	related data (i.e. laboratory results, pre-operative state, etc.) ObTiMA platform
	[] Services, please specify:	n/a
	[] Models, please specify:	The Operational Data Model (ODM) is designed to facilitate the archive and interchange of the metadata and data for clinical research, its power being fully unleashed when data are collected from multiple sources.
	[] Other, please specify:	n/a
How this use-case is going to be validated?		1
Frequency of Use:		
Who are the users?	Patients/citizens will see their own health records from the hospitals Doctors will be able to see patient data in their avatars	
Special Requirements:		
Assumptions:		
Questions:		

4.8 Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services (UC-CHF)

Use Case ID:	UC-CHF		
Use Case Name:	Personalized CHF Rela	ted Risk Profiles and "Real-T	Time Monitoring" Services
Technical Collaborators:	FORTH	Clinical Collaborator:	University of Crete, Faculty of Medicine
Description:	early detection of exact significance. In this see the prevention, monit Generally, cardiovascue everyday record for particular following pillars: 1) Real-time patient mandition to the above immediately and possic changing medication, safety. There is a need diagnosed with congestechnologies, may hos information. To this embuilt according to rule dedicated physician in	cerbations of the disease that enario we focus on methodo oring, and treatment of headlar disorders as chronic diseatient's status. The proposed onitoring we the dedicated clinical per	cologies that would facilitate rt disease on a daily basis. Eases require a continuous discenario is built on the sonnel should be contacted an acute state is reached, by in order to ensure patient the monitoring of patients and the enhanced with semantic discentification of the alarming process will be



	timetry, and Blood Pressure acquisition, adapted according each specific tient's medical history and age, and even risk predictor's outcome (described
be	low).
	CHF Risk Assessment
	order to tailor the proposed system to the patient's profile and assist ysicians in selecting people who are predisposed by coronary disease,
	pertension, or valvular heart disease; we build a CHF related risk profile
th up dis as pu	sed on a risk appraisal function that is based on the diagnostic criteria [i.e. e Framingham Heart Study (486 heart failure cases during 38 years of follow-)]. The predictors used are based on Age, Coronary heart disease and Valve sease status provided by the patient Electronic Health Record (EHR), as well on HR, on blood pressure and on Body Mass Index (BMI) provided by the lse oximeter, the blood pressure monitor and the weight scale, respectively. e calculated risk probability may be used to alter the default threshold values
	gher risk probability adds more constraint on the physiological patterns).
be	rthermore, we present what else data regarding patients' health status could embed into the platform towards the creation of a profile with necessary formation for both patient and treating physicians. To this respect an
	proach of presenting data regarding demographic, physiology, diagnostic test
re	sults and disease management (i.e. prescribed drugs) is provided.
3)	Comorbidities and Drug Interaction
	ere are many cases where more than one medications are prescribed due to
	sease progression or due to the wide appearance of both cardiac and non-
	rdiac co-morbidities (respiratory comorbidities, renal dysfunction, cognitive sfunction, depression and in some cases arthritis). To this respect, there is an
-	gent need for providing information in both the treating physicians, but also
	e patient him/ herself regarding negative drug interactions.
Actors: Av	atar1 (Doctor), Avatar2 (Patient)
Trigger: Pa	tient is diagnosed with CHF according to:
	 Patient's physiological, imaging, blood test results data and past diagnoses, uploaded in patient's electronic health record or during creation of patient's Avatar in MHA platform.
	Patient physical examination and confirmation with differentiating
- 11.1	diagnostic tests (i.e. echocardiography)
	e major precursor of all cardiovascular diseases is attributed in congenital or quired factors that lead to atherosclerosis disorders and in some cases to
	mplications from diabetes, kidney disease and hypercholasterolaemia. Heart
	lure is caused by any condition, which reduces the efficiency of the
	yocardium, or heart muscle, through damage or overloading. As such, it can
	caused by a diverse array of conditions, including myocardial infarction (in nich the heart muscle is starved of oxygen and dies), hypertension (which
	creases the force of contraction needed to pump blood) and amyloidosis (in
	nich protein is deposited in the heart muscle, causing it to stiffen).
Basic Flow: Ba	sic steps
	Generation of patient's avatar
	Register life style factors (i.e. diet habit, alcohol, smoking) Register of physiology, pathology, genetic information (i.e.
	 Register of physiology, pathology, genetic information (i.e. pharmacogenomics) regarding patient's health
	Age
	Height
	Weight



Pulse (possible need for creating time graphs) Register life style factors (i.e. diet habit, alcohol, smoking physical activity) Embed in Avatar platform of patient's examination results Update of patient's basic examination outputs regarding cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) Joignosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) Record of patient's drug prescription (dose regiments) provided by the treating physician Record of patient's compliance regarding provided treatment Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic		1	
Pulse (possible need for creating time graphs) Register life style factors (i.e. diet habit, alcohol, smoking physical activity) 2. Embed in Avatar platform of patient's examination outputs regarding cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) Anathing of possible compositiotites or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information frog patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform		Body Mass Index(BMI)/Body Surface Area (BSA) Blood prossure	
Register life style factors (i.e. diet habit, alcohol, smoking physical activity) 2. Embed in Avatar platform of patient's examination results ∪ Update of patient's basic examination outputs regarding cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) ○ Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment ○ Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternative flows will be followed if patient data are not provided in full. Postconditions: Alternative flows will be followed if patient data are not provided in full. • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case inclu			
physical activity) 2. Embed in Avatar platform of patient's examination results O Update of patient's basic examination outputs regarding cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) O Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment O Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MIA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decisi			
2. Embed in Avatar platform of patient's examination results O Update of patient's basic examination outputs regarding cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) O Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment O Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. O Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision			
O Update of patient's basic examination outputs regarding cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. ○ Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-plate			
cardiovascular system (blood test results, blood pressure, EEG results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) o Matching of possible compolitations or setting alarns for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment o Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. o Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation thera		· · · · · · · · · · · · · · · · · · ·	
results, imaging and physical exam) 3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc.) This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in t			
3. Diagnosis of the heart failure and classification of patient according to one (or if possible more) categories (i.e. Framingham and or NYHA) o Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment O Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc.) Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the follow			
one (or if possible more) categories (i.e. Framingham and or NYHA) o Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment o Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable			
o Matching of possible co-morbidities or setting alarms for possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment ○ Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. ○ Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personnal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practic. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our		· · · · · · · · · · · · · · · · · · ·	
possible complications due to disease progression (i.e. kidney function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment Oupdate avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. Ocreation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information fro the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: O He			
function) 4. Record of patient's drug prescription (dose regiments) provided by the treating physician 5. Record of patient's compliance regarding provided treatment • Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring			
treating physician 5. Record of patient's compliance regarding provided treatment O Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable th			
5. Record of patient's compliance regarding provided treatment Oudate avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alert		4. Record of patient's drug prescription (dose regiments) provided by the	
O Update avatar during last drug prescription for other diseases and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		treating physician	
and alarm for possible interactions between medications (i.e. antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		5. Record of patient's compliance regarding provided treatment	
antibiotic medicines that could interact with cardiovascular treatments) 6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		 Update avatar during last drug prescription for other diseases 	
Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		·	
6. Real-time patient vital signs and data updates (if available) and processing to detect possible deviations from normal values Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		antibiotic medicines that could interact with cardiovascular	
Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Postconditions: • Remote monitoring of patient health status after diagnosis. • Risk assessment and update data in MHA platform. • Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring, application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		· ·	
Alternate Flows: Alternative flows will be followed if patient data are not provided in full. Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
Postconditions: Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		processing to detect possible deviations from normal values	
Postconditions: Remote monitoring of patient health status after diagnosis. Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.	Alternate Flows:	Alternative flows will be followed if patient data are not provided in full.	
Risk assessment and update data in MHA platform. Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		·	
Creation of graphs with data values in time (i.e. BP, pulse, time of drug administration etc.) Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
time of drug administration etc.) • Basic information for patient regarding health status during treatment. • Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		· · · · · · · · · · · · · · · · · · ·	
Basic information for patient regarding health status during treatment. Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
Information regarding administration of other medications prescribed regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		-	
regarding drug-drug interactions and also in cases of over-the-counter medication that can be taken from the patient etc. Dependencies: This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
medication that can be taken from the patient etc. This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
This case tries to integrate information from the potential architecture of the platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
platform including data from ontologies (linking of information regarding disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
disease progression, side effects, drug interactions, genomic data, environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.	Dependencies:	This case tries to integrate information from the potential architecture of the	
environmental factors, regulatory organizations guidance etc.) This use case includes or is part of the following use cases: • Utilization of personal genomic information for the individualization of MHA platform • Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
 This use case includes or is part of the following use cases: Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are:			
 Utilization of personal genomic information for the individualization of MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are:			
 MHA platform Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are:			
 Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are:		· · · · · · · · · · · · · · · · · · ·	
practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.		· ·	
pre-operative patients To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
To achieve a good functionality as proposed in this set the following device and technologies should also be available: • Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: • Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
 technologies should also be available: Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process. 			
 Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Heart Rate (HR), SpO2, body weight and real time ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process. 			
vital signs. In our reference implementation the supported measurements are: o Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
measurements are: O Heart Rate (HR), SpO2, body weight and real time ECG monitoring. • Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process.			
 monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process. 			
 Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process. 		 Heart Rate (HR), SpO2, body weight and real time ECG 	
hosting risk assessment algorithms to enable the alerting process.		monitoring.	
		Monitoring application recording the aforementioned bio signals and	
Ontology-driven application intelligence capable of reasoning on the		Ontology-driven application intelligence capable of reasoning on the	

Poquired External	patient's and drug dat	I
Required External	[] Data, please specify:	Patient's data
Resources:		 Demographic
		■ Gender
		■ Age
		■ Height
		■ Weight
		■ BMI/BSA
		o Genetic
		 CHF related genome data
		Pharmacogenomic data
		 Physiology- Pathology
		■ Blood pressure
		Cardiac flow (BP and pulse)
		Kidney function
		■ Blood test results
		■ Coagulation factors
		Atherosclerosis level
		 Differentiating tests
		 Associated diseases
		 Physical examination
		Imaging
		Electrocardiography
		Echocardiogram
		_
		Protocols/References regarding
		disease diagnosis/treatment
		 Available regimens for
		prescription and potential
		alternatives
		 Medline references
		 Patients hand out from
		regulatory organizations for
		disease management
	[] Tools, please specify:	For Physician
	[] Tools, please specify.	
		PC hosting MHA platform with access to EHR
		 Links of Avatar's internal
		organs with diagnostic tools
		(i.e. linking of heart with ultra-
		sound image of the patient or
		ECG)
		Medline references
		o i.e. drug interactions
		Availability to store part of the
		data as case study
		For Patient
		 PC hosting MHA platform with access to EHR
		Smartphone with MHA
		interface capable of updating
		necessary data (i.e. daily diet)
		Wireless vital signs monitoring
		devices
		Information on disease progression

		with/without compliance (i.e.		
		visualization of heart function)		
	[] Services, please specify:	Links with EHR and PACS		
		Links with external databases (i.e.		
		DrugBank)		
	[] Models, please specify:	Risk Assessment model		
		2. Real Time Alarming model		
		3. Visualization models		
		4. Disease progression models		
	[] Other, please specify:			
Frequency of Use:	The proposed application can be use	l even in real time or selected time		
	intervals, depending on the patient's	initial diagnosis.		
	Frequency of use can be categorized	in two parts:		
	 Patient's information regard 	ng health status, disease progression,		
	improvement etc.			
	Any treating physician which	is going to prescribe a specific treatment		
	for the patient and has acce	s to MHA platform		
Special Requirements:		the medical staff with MHA technologies		
	Linking of MHA data between research	ch and medical organizations and		
	personnel applying MHA technologic	Il tools and services.		
Assumptions:	Some basic assumptions are:	assumptions are:		
	 Necessary physiological and clinical data to run the model. 			
	 Detailed patient's health his 	tory record		
	 Linking of MHA platform wit 			
	that contribute in the health care system			
	 Linking of the platform with 	external resources for providing		
	information regarding CHF diagnosis and treatment			
	Monitoring Devices/ Sensors, if available			
	Patient's compliance in keeping update information in MHA platform			
		ompliance in updating patient's examination info in MHA		
	platform			
	Full and detailed patient's hearth.	c's health history record.		
Questions:	·	·		

4.9 Osteoarthritis (UC-OST)

Use Case ID:	UC-OST		
Use Case Name:	Osteoarthritis		
Technical Collaborators:	FORTH	Clinical Collaborator:	University of Crete,
			Faculty of Medicine
Description:	Osteoarthritis (OA) is a disabling degenerative joint disease leading		
	to joint pain, stiffness and loss of function predominantly in the		
	knees, hips, hands, and spine. The major histological finding in OA is		
	degeneration and loss of the articular cartilage that acts as a		
	protective cushion between bones within a joint. Imaging methods		
	including weight bearing radiographs and in selected cases Magnetic		
	Resonance Imaging (MRI,) may be used to study morphological and		
	inflammatory changes occurring in the articular cartilage, menisci,		
	extra-articular soft tissues and the subchondral bone marrow. Health		
	care professionals support assessment and management of patients		
	with OA in order	to modify their nutrition	n and exercise lifestyle



	behaviour. Hereditary factors (genetic) increase the risk for developing OA.			
	It is worth pointing out that an estimated 75% of adults over the age of 65 years have OA resulting to impaired quality of life, and considerable healthcare costs. Moreover, about 100% of adults over the age of 80 years old have OA.			
	The avatar system will monitor patient's daily diary and ambulatory activity and warn the patient, if she/he does not meet the special medical guidelines. The monitoring will rely on techniques of self-life logging, enhancing the patient engagement. Also, the platform will function as a supportive system to the patients by means of offering advice and assistance.			
	Moreover, the avatar system will offer a useful input to doctors, as the related heterogeneous data (i.e. imaging and semi-quantitative data) will be properly visualized and presented using interactive, multi-scale visualization techniques. This will help doctors for data reasoning and for carrying out personalized healthcare.			
	Advanced personalized healthcare will also be enhanced by existing genomic predisposition evaluation and health risk estimation. Thus, this use case is strongly related with the UC-09 (MHA Personal Genomic Information).			
Actors:	Doctors and citizens/patients			
Trigger:	 A citizen is diagnosed with Osteoarthritis Avatar platform reveals for a citizen an increased risk of developing OA 			
Preconditions:	n/a			
Successful End condition	n/a			
Fail End condition	n/a			
Basic Flow:	The patient visits the doctor complaining for knee joint pain, stiffness, particularly after rest, crepitus, and swelling (soft from joint effusion or hard from osteophyte formation). The diagnosis of OA is based on the:			
	 A number recorded with regard to a certain pain-scale Range of motion of the knee joint (in degrees), Genetic predisposition evaluation for examining if an increased risk of developing OA exists (according to available genomic data). The above data, imaging and evaluation metrics, are collected and 			
<u>L</u>				



stored through the avatar system, which has novel ways for representing this multi-scale and heterogeneous information to medical professionals.

Self-care: The treatment includes drugs and in more severe cases local injections, use of knee braces and knee replacement surgery. In addition, the doctor advices patient to modify or change the lifestyle. This includes weight reduction, exercise (quadriceps muscle strengthening, resistance training, aerobic exercisewalking, and flexibility exercise) and aquatic exercise. Too little movement can lead to stiffness and weak joints, whereas strong muscles protect joints. An OA management plan also involves following a healthy diet, managing stress and depression, and getting a good balance of rest and activity each day.

Monitoring: The avatar system will monitor patient's daily dietary and ambulatory activity (using activity trackers) and warn the patient, if he does not meet the special medical guidelines (e.g. losing weight, exercise etc.). The monitoring will rely on techniques of self-life logging, which will monitor a wide range of daily activities and behaviours of the patients, including their locations, movements, diet, quality of life, environment, and other symptoms, etc. Visual analytics will be used to display individual/aggregated data items to allow easy interpretation of the data from the patients. With the search bar of the system, the users can easily send queries about their activities, movements, diet, etc.

Patient education: The avatar system will also allow patient education on the knowledge of the diseases. It will also test the knowledge of the patients. It is expected that a good knowledge of the disease will lead to enhanced patient behaviours.

- 2. The patient visits the doctor again complaining for recurrence and deterioration of symptoms.
 - The semi-quantitative metrics are collected again and compared with the previous ones stored through the avatar system.
 - b. A new weight baring radiograph is taken.
 - c. The doctor examines if the patient was compliant with the treatment guidelines.

If the radiograph reveals severe structural changes, the doctor will discuss the surgical replacement of the joint. If the radiographic findings do not explain the clinical symptoms, a new MRI is required to explore other than internal derangement causes, such as insufficiency fracture of the subchondral bone.

Due to the temporal nature of the data the representation is obtained by "animating" the visualization over time. Each frame will display the value of each parameter at a given time point.

Alternate Flows:

1. Avatar system reveals for a citizen an increased risk of developing



Postconditions: Dependencies:	OA through comparison to existing genomic predisposition data and warns the patient. 2. Avatar system advices citizen to modify or change his lifestyle. This includes weight reduction, exercise (quadriceps muscle strengthening, resistance training, aerobic exercise-walking, and flexibility exercise) and aquatic exercise.		
Required External Resources:	[] Data, please specify:	 Patients' data from MyHealthAvatar, including patient's history, imaging data, genomic data, semi-quantitative metrics, daily activities, exercises, diet over the time 	
	[] Tools, please specify:	 Multi-scale visualization & visual analytics tools for the visual representation of the multi-scale, heterogeneous data related to OA Genomic analysis tools for evaluating the genomic predisposition and health risk 	
	[] Services, please specify:	 Links to data repository for retrieving the patients' clinical data 	
	[] Models, please specify:	•	
	[] Other, please specify:	Visualization server for performing the multi-scale data representation: can be either a personal computer or a high performance computer	
How this use-case is going to be validated?	By citizens with OA and medical	experts	
Frequency of Use:	When a citizen is diagnosed with OA or has an increased risk of developing OA		
Who are the users?	Doctors and citizens/patients		
Special Requirements:	-		
Assumptions:	-		
Questions:	-		

4.10 Pre-Diabetes (UC-DIAB)

Use Case ID:	UC-DIAB		
Use Case Name:	Pre-Diabetes		
Technical Collaborators:	BED Clinical Collaborator:		
Description:	Diabetes is the world's fastest growing disease with substantial costs at		
	individual and social economic level. It is estimated diabetes affect more		
	than 32 million EU citizens (nearly 10% of the total EU population), and an		
	additional 32 million citizens have not yet been diagnosed, or with pre-		
	diabetes. Globally, the main risk factors for chronic disease, such as		
	diabetes, are hypertension, tobacco use, high cholesterol, low fruit and		



	vegetable intake, overweight and obesity, sedentary lifestyle and alcohol abuse. Strategies for tracking chronic disease include prevention and early detection; people with high risk of developing diabetes are suggested to carry out many self-care behaviours. These include dietary change, exercise, regular self-medication, and regular attendance at clinic and for screening programmes. If diagnosed with diabetes, additional care, such as insulin injection, self-manage of blood glucose, and insulin dose adjustment are needed. Self-management means that people can take a more active role in decisions about their own treatment and about healthy lifestyle. It is a shared responsibility between individuals and service provider. Service providers recognise the individual's role in managing their health and wellbeing. MyHealthAvatar provides a unique citizen/patient empowered system that can be used, in particular for pre-diabetes care where the citizens with high risk of diabetes but not yet been diagnosed, and therefore not yet been known to the health care system. The functionalities of MyHealthAvatar provides a one-stop service for citizens in terms of data collection, and self-management services, such as monitor, record, and education.		
	The avatar system will support the storage the behaviours and daily activities of citizen. The platform will function as a supportive environment from healthcare providers to the individual by means of offering advice, assistance and assessments; and by means of allowing for health promotion.		
Actors:	Doctors and citizen/patient		
Trigger:	Citizen takes risk analysis, and has been predicted with high risk		
Preconditions:			
Successful End condition			
Fail End condition	-		
Basic Flow:	 Personal Diary: Storage and management of the health status of the individual and their behaviours. This will rely on techniques of self-lifelogging, which will monitor a wide range of daily activities and behaviours of the citizen/patient, including their locations, movements, diet, quality of life, environment, mood, blood pressure, glucose, alcohol, smoking, and other symptoms, etc. Visual analytics will be used to display individual/aggregated data items to allow easy interpretation of the data from the patients. With the search bar of the system, the users can easily send queries about their activities, movements, diet, etc. Intervention: allowing for multi-modal intervention of lifestyle in a shared decision manner between the doctor and citizens/patients. In the case of pre-diabetes, MyHealthAvatar will be able to demonstrate to the citizens/patients the relations between the outcomes of the self-management/treatment using prediction models "Behaviour prescription" will be issued based on clinical guidelines and trusted sources (such as NICE), which is expected to include a set of targets in terms of daily activities, calorie intake and energy consumption, etc. Monitoring: allowing for the progress review of the individual by comparing the personal diary with the behaviour prescription as mentioned above. Warning: The avatar system will send reminder messages at various priorities in one of the following occasions: medication 		



	reminder, due hospital visit (for screening etc.), sign of change of conditions, early sign of one of developing diabetes with constant		
	scored as high risk.		
	 Complication: The avatar system will have patients' clinical records and history, which will facilitate the management of complications from other possible conditions. The long term records will also help define personalised care plan. 		
Alternate Flows:	-		
Postconditions:	-		
Dependencies:	-		
Required External Resources:	[x] Data, please specify:	Citizen/Patients' data from MyHealthAvatar, including daily activities, exercises, diet, mood, etc.	
	[x] Tools, please specify:	Visual analytics tools for data visualization & analysis	
		Statistical tools for computing standard indexes & charts (e.g. BMI, SAD)	
		Prediction tolls for 'good' or 'bad' behaviours.	
	[] Services, please specify:		
	[x] Models, please specify:	Statistical tools for computing standard indexes & charts(e.g. BMI, SAD)	
	[] Other, please specify:		
How this use-case is going to be validated?		,	
Frequency of Use:			
Who are the users?	Citizen/patients		
Special Requirements:			
Assumptions:			
Questions:			

4.11 Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial (UC-NEPH)


Use Case ID:	UC-NEPH			
Use Case Name:	Nephroblastoma (Wilms tumour) Simulation Model and Clinical Trial:			
	In-silico profiling of patients and prediction simulations			
Technical Collaborators:	ICCS Clinical Collaborator: USAAR			
Description:	Nephroblastoma diagnosis is based on a variety of multiscale data. These data can be used in the creation of a clinical multiscale profile of the tumour. After the necessary pre-processing of the available data, the data are fed into a nephroblastoma simulation model. The nephroblastoma simulation model is a predominantly discrete, clinically-oriented multiscale model of solid tumour response to treatment. Preoperative chemotherapy is the simulated form of treatment. A "top-down" simulation approach is adopted. The simulation method starts from the macroscopic imaging data, representing a high biocomplexity level, and proceeds towards			

lower biocomplexity levels.

Clinical orientation of the model has been a fundamental guiding principle throughout its development. Available medical data (imaging, histopathological, molecular) can be exploited, in order to strengthen patient individualized modeling.

Stage 1 (in-silico profile of patients):


Semi-automatic adaptation of the model parameters could be conducted in case of efficient availability of clinical data (many data sets at different time points). The determined model parameters serve as a patient record for in silico tumor characteristics and form the 'in-silico profile' of the patient.



Stage 2 (prediction simulatations):

The paediatric oncologist using the 'in-silico profile' of the patient runs a number of experiments in silico (= on the computer), to simulate the most likely response of the tumour to the most relevant candidate chemotherapeutic schemas. The outcomes of the simulations (predictions) help the oncologist decide the appropriate treatment plan.

The 'in-silico profile' could be further used from clinicians as a tool to provide insight into individualized biological characteristics of the tumor, an input for future model use and an input for the use of other models. It could also serve as a statistical tool to categorize the patients (by associating their clinical and in silico profiles) and define a range for model parameters to lead adaptations of new patients.



References:

- G.S.Stamatakos, E.Ch.Georgiadi, N.Graf, E.A.Kolokotroni, and D.D.Dionysiou., Exploiting Clinical Trial Data Drastically Narrows the Window of Possible Solutions to the Problem of Clinical Adaptation of a Multiscale Cancer Model. 2011, PLOS ONE
- Georgiadi EC, Stamatakos GS, Graf NM, Kolokotroni EA, Dionysiou DD et al., Multilevel Cancer Modeling in the Clinical Environment:



	Simulating the Behaviour of Wilms Tumour in the Context of the SIOP 2001/GPOH Clinical Trial and the ACGT Project. in.: Proceedings of the 8th IEEE International Conference on Bioinformatics and Bioengineering. 8-10 Oct 2008. Athens, Greece. CFP08266, ISBN: 978-1-4244-2845-8, Library of Congress: 2008907441, Paper No. BE-2.1.2. • Graf N, Hoppe A, Georgiadi E, Belleman R, Desmedt C et al., In Silico
	Oncology for Clinical Decision Making in the Context of Nephroblastoma. Klinische Paediatrie , Vol. 221, pp. 141-149.
Actors:	End User & MyHealthAvatar platform
Trigger:	Stage1: Enrich the patient record with an "in silico" profile Stage2: Prognosis is needed for nephroblastoma response to treatment.
Preconditions:	 The availability of clinical data that is compatible, in terms of format and content, with the nephroblastoma simulation model. The availability of sufficient computational resources in order for the simulation to be performed.
Successful End condition	-
Fail End condition	The basic steps for stage 1 are:
	 The End-User places the already preprocessed data to the location where the model expects to find them. The Technical partner adapts the model parameters according to the available clinical data The End-User starts the simulation process. When the simulation is completed, the End-Users use the appropriate tools in order to read or/and visualize the outcome of the simulation. The End-Users evaluate the adaptation by comparing simulation results with clinical reality. In case of a successful adaptation, the defined model parameters are recorded by the End Users and form the "in-silico patient profile" In case of not satisfying adaptation, steps 2-5 are repeated. The basic steps for stage 2 are: The End-User places the already preprocessed data to the location
	where the model expects to find them. 2. The End-User starts the simulation process.
	When the simulation is completed, the End-User uses the appropriate tools in order to read or/and visualize the outcome of the simulation.
Alternate Flows:	-
Postconditions:	Stage 1: The in-silico profile of the patient is recorded. Stage 2: A treatment plan is drawn.

Dependencies:	This use case will be used as test case for UC-TOOL (MHA Toolbox).	
Required External Resources:	[x] Data, please specify:	Clinical data (already preprocessed), ready to be used by the simulation model. The SIOP 2001/GPOH clinical trial, including microRNA data, if available, will be used.
	[x] Tools, please specify:	Open source tools (e.g. ImageJ) can be used for visualization purposes.
	[] Services, please specify:	
	[] Models, please specify:	
	[] Other, please specify:	
How this use-case is going to be validated?	Technical validation of the use case will be performed by the responsible technical partner.	
Frequency of Use:	When a prognosis in needed for nephroblastoma patients.	
Who are the users?	Clinicians, Researchers	
Special Requirements:	-	
Assumptions:	-	
Questions:	-	

4.12 Emergency Contact (UC-EME)

Use Case ID:	UC-EME		
Use Case Name:	MHA Emergency Contact		
Technical Collaborators:	BED, USAAR	Clinical Collaborator:	USAAR
Description:	This use case describes the situation where a patient is unconscious in Accident and Emergency Units in hospitals. The patient is not able to authorize the doctors to access his data in the avatar. However, some of the information within the avatar can be crucial for the clinical decisions by the doctors. For example, the doctor needs to know a health profile of the patient, including his previous medical history, etc.		
	We envisage a Europe-wide MHA service centre is needed to offer a solution to this case. Each avatar user will have the option to sign an agreement to authorize the data access to doctors, who may treat him/her under a future emergency circumstance. For the signed users, doctors can contact the MHA service centre to obtain their data in the MHA for the treatment purpose under an emergency situation.		
Actors:	Doctors at emergency Patients Worker in the MHA ser	·	
Trigger:	n/a		
Preconditions:	n/a		
Successful End condition:			
Fail End condition:			
Basic Flow:	Users	<u>-</u>	

	 New users will grant access to the doctors for emergency data access during the sign up process. 	
	 The users can also log in the existing account first and then to grant 	
	the access	
	3. The users can change their de	ecisions at anytime
	_	out their legal rights and risks for giving
	or not giving the access	
	In an emergency situation where	
	 The doctors will contact the N 	MHA service centre
	The IDs of the doctors and th	e hospital will be checked
	3. The service centre will sear	ch for the patient information in the
	MHA system according to th	ne patient information provided by the
	doctors	
	4. The patient information will be provided to the doctors by either	
	direct download, or granting access to the account	
Alternate Flows:	n/a	
Postconditions:	n/a.	
Dependencies:	n/a	
Required External	[] Data, please specify:	n/a
Resources:		
	[] Tools, please specify: n/a	
	[] Services, please specify:	n/a
	[] Models, please specify:	n/a
	[] Other, please specify:	
How this use-case is going	We will create a virtual citizen who will provide the authorization during his	
to be validated?	MHA amount, and will simulate the case where a doctor contact the MHA	
	service centre and will be checked and granted access to the patient data by	
	the service centre.	
Frequency of Use:	Only in medical emergency	
Who are the users?	Patients who give authorization through their user account	
	Doctors from emergency units	
	The MHA service center staff	
Special Requirements:	no	
Assumptions:	The authorization from the users will be	pe given
Questions:	n/a	

4.13 Brain Trauma (UC-TBI)

Use Case ID:	UC-TBI		
Use Case Name:	Brain Trauma		
Technical Collaborators:	LIN	Clinical Collaborator:	BED
Description:	clinicians by providing outcomes by circumve traumatic brain injurie based on patients' dat and also from the clini outcomes and better to establish models of pathoanatomic preser A clinical phenotype o	ofile of patient is a critical ai a better insight and possible enting the barriers imposed es. Individualized treatment as a are imperative both from icians point of view and can prediction and prevention. So pathphysiologic mechanism netations of brain injuries. If the patient has to be devel atients' past medical history,	y improve the clinical by the heterogeniety of and targeted therapies the patients' perspective ensure more promising such a profile can be used as significant to



Actors: Trigger: Preconditions:

Successful End condition

Fail End condition
Basic Flow:

demographic information, family history, socioeconomic status and life style and habits contribute significantly towards accurate assessment and management in case of brain trauma or cerebrovascular accident. In cases requiring surgical intervention, pertinent medical history can provide information about any co-existing brain lesions or any medical condition that contra-indicates general anesthesia or surgery e.g., patients on anticoagulation therapy. Studies show that prognosis after TBI is strongly correlated to the medical history of the patient and characteristics like age, alcoholism, drugs, cardiac problems, hypertension, liver dysfunction, diabetes and renal impairment etc. can affect the treatment regimen and morbidity and mortality. For example, subdural haematomas (SDH)can be difficult to differentiate from extradural haematomas (EDH) if the size is small, however, the aetiology, management and outcomes can be significantly different. History of repeated brain injury, e.g., sports related, can exacerbate the symptoms. Small children and old people are prone to falls and history of head trauma may be difficult to identify, while road traffic accidents are more common in young and middle aged people with associated skull fractures. Family history of brain aneurysms is an important consideration for suspected subarachnoid haemorrhage (SAH). Junior doctors in A&E who do not have adequate experience in interpreting ct scans can sometime misdiagnose and this undertriage or overtriage can lead to a treatment which is different than what is required. An automated system providing second opinion to the radiologist can help improve the sensitivity and specificity of diagnoses and reduce inter-observer variability. The data repository available within MyHealthAvatar can allow researchers develop mathematical and computational models based on gender, race, ethnicity categories, age, lifestyle, education and medical data and this can significantly contribute to innovative healthcare practices. These data from M
to develop a prognostic model for traumatic brain injuries (TBI).
Doctors and patients .
Prognosis is needed for patients with suspected brain injury.
The availability of demographic data, past medical history, drug history, clinical phenotypes (from clinical and neurological examination) and image phenotypes (from neuroimaging modalities like CT scans)
Differential diagnosis of the type of injury and prognosis for traumatic brain injuries are reported. The information is undated in MyHealthAyatar.
injuries are reported. The information is updated in MyHealthAvatar.
The basic steps include:
 The patients share their avatar data with the doctors. The pre- injury profile of the patient is developed including life style factors, medical history, drug history and clinical examination data like age, height, weight, vital signs and neurological assessment.
 The doctor accesses the data of the patient to identify life style, habits, existing or suspected medical conditions, drug usage and/ or occupational hazards which can affect the prognosis and outcome in case of brain injury. The assessments by the doctors are updated in the MyHealthAvatar system. The doctor accesses the clinical and image data of the patient from



	the hospital system (e.g. PACS) when a patient with suspected brain injury comes to A&E. The physical mechanism of injury, presenting complaints, clinical and neurological examination results and imaging interpretation are combined with the MyHealthAvater data to derive differential diagnosis e.g., ischaemia, EDH, SDH, SAH, contusion, IVH or DAI etc., and a management plan is drawn for targeted therapy and surgical intervention. 4. The doctor assesses the patients' condition using a prognosis model such as Rotterdam Scale or Glasgow Outcome Scale to ascertain possible outcomes. A second opinion is provided by the		
	automated system in MyH	lealthAvatar.	
Alternate Flows:			
Postconditions:	 developed Future monitoring of the patient Risk assessment and prediction pathoanatomic and pathophysic 	 Future monitoring of the patient after injury and discharge from hospital Risk assessment and prediction of long-term outcomes of TBI including pathoanatomic and pathophysiologic sequelae Classification of patients in cohorts with common characteristics likely to 	
Dependencies:		watar system and their medical history	
	and other characteristics data are a	vailable in their avatars.	
Required External Resources:	[] Data, please specify: [] Tools, please specify:	 Patients' data from MyHealthAvatar Clinical and neurological examination data at the time of admission to hospital Related studies on patient cohorts, such as IMPACT, CRASH Prognosis models, data mining tools and image segmentation tools for doctors 	
		 MyHealthAvatar access for the doctors and patients 	
	[] Services, please specify:	Links with PACS and electronic health records Links with TBI databases like TARN and FITBIR Related studies on patient cohorts, such as IMPACT, CRASH, ADNI	
	[] Models, please specify:	 Prognosis and outcome models such as Rotterdam Scale and Glasgow Outcome Scale Risk assessment model for predisposition to and outcomes from TBI 	
	[] Other, please specify:	 Normal values and ranges of clinical and neurological assessments Neurological atlas for image interpretation and segmentation tools 	

How this use-case is going	By experts with clinical background in BED	
to be validated?		
Frequency of Use:	When a prognosis is needed for patients with suspected brain injury	
Who are the users?	Doctors and patients	
Special Requirements:	Creating awareness and familiarizing doctors and patients with the MyHealthAvatar services	
Assumptions:	Patients' clinical and neurological data are available	
	Patients' imaging data and interpretations are available	
Questions:		

4.14 Anti-Platelet & Anticoagulation Therapy in the Pre-Operative Patients (UC-APLA)

Use Case ID:	UC-APLA		
Use Case Name:	Decision making tools regarding emergency situations in clinical practice. The example of anti-platelet & anticoagulation therapy in the pre-operative patients		
Technical Collaborators:	FORTH	Clinical Collaborator:	FORTH
Description:	individual's platelets of bleeding disorders (hethrombosis. Dysfunction morbidities such as call angina, congestive heatstroke and transient is vascular disease (PVD) diagnosed with overcoplatelet therapies as a polymorpshisms (SNPs enzymes (mainly of Cytherapies. Some well-kcomplex subunit 1 (VK with deficiencies in Vitanticoagulant therapies the metabolizing enzymenzyme for the activate pro-drug activated in the Genetic polymorphism CYP2C19 expression, wpopulations being pool above, anti-platelet and practice, appear to have pharmacokinetics and anticoagulation therapies information are taken order to integrate data emergency cases such should be applied for properties.	rdiovascular disorders (coro art failure and valve disease) chemic attacks, deep vein the phlebitis and in some case lotting deficiencies are treat preventive care. Several sin so are known regarding drug tochrome P450 family) of an known examples are the Vita ORC1) where specific general amin-K-depedent clotting facts as of warfarin and acenocou mes of P450 family, CYP2C1 ion of the anti-platelet agen the liver by cytochrome P450 a (CYP2C19*2, CYP2C19*3 an with approximately 5% of Car ar metabolizers with no CYP2 and anticoagulant agents that we a wide inter-subject variation thus in pharmacodynamics. Dies are typical examples whom a cypical exa	functions can lead either in a disorders such as ormation can be related with mary disease, heart attack, and pulmonary embolism, hrombosis, peripheral is obesity. Patients that are ted with anticoagulant or antingle nucleotide in the provide reductase mutations have been related actors and the response to marol. In addition, regarding is the main metabolic in the clopidogrel. The latter, is a concept of enzymes, mainly CYP2C19. In CYP2C19*17) exists for nucasian and 20% of Asian and 20% of Asian are administered in clinical ability in their. Antiplatelet and here therapeutic drug contains the contains and anti-platelet are are are an adjustment in dose ulation and anti-platelet.



	Cummarising the above information there are coses where additional	
	Summarizing the above information there are cases where additional information are needed but not easily attainable due to lack of clinical data. To this respect in silico approaches (such as Physiologically-based pharmacokinetic/pharmacodynamic modeling) seem capable in providing evidence regarding possible treatment outcomes and organized in order treating physicians will be able to avoid as much as possible "guesswork" for a specific patient. The availability of creating "virtual cohorts" of patients and in silico approaches can assist in generating predictive approaches towards improved personalized medicine. A typical use-case scenario: "A male 55 years old that follows anti-platelet therapy, needs to go on surgery. The doctor has to re-adjust the administration of the anti-platelet therapy for the up-coming surgery and needs to schedule the operation as soon as possible. General guidelines are known for pre-operative care but how could the doctor avoid any guesswork and apply a personalized approach for this	
	patient but also for future patients?"	
Actors:	Avatar1(Doctor),Avatar2 (patient), (Avatar3) Research staff for in silico clinical trials platforms, genome information platform/tool, MyHealthAvatar platform	
Trigger:	Upload of diagnosis in patient's electronic health record or during creation of	
	patient's Avatar in MHA platform.	
	Alternative the use case can be triggered after the medical examination and the	
Preconditions:	decision that patient should go on surgery.	
Preconditions:	The facts that are true in this case are:	
	 i) Anti-platelet therapy may lead in bleeding during the perioperative or the postoperative period 	
	ii) Anti-platelet and anti-thrombotic agents that are administered in	
	clinical practice, appear to have a wide inter-subject variability in their	
	pharmacokinetics and thus in pharmacodynamics due to genetic and	
	epigenetic factors.	
	iii) Anti-platelet therapy is a clinical case in which personalized medicine	
	tools are essential. Therapeutic drug monitoring is usually followed for	
	the proper adjustment of the applied treatment	
	iv) There are not many data available regarding the time that the	
	treatment will stop being active after the discontinuation	
	v) Clinical trials regarding the above situation cannot be performed	
Basic Flow:	Basic steps:	
	1. Gathering all the necessary data required from patients health records.	
	This step can run during the therapeutic drug monitoring and dose	
	adjustment prior to the emergency situation. Also this step can run	
	during utilization of personal genomics (Use-case 12)	
	2. Creating of MyHealthAvatar profile for this patient	
	Embed results of pharmacogenomics information in MHA profile for patient	
	4. Clustering patients in appropriate cohorts and creation of "virtual	
	population" based on demographic, physiology and genomic data	
	0. The creation of "virtual population" is based in the	
	distribution of the several parameters and the relation with	
	each other (i.e. weight modeled against height) according to	
	specific algorithms followed by a platform for in silico clinical	
	specific algorithms followed by a platform for in silico clinical	
	specific algorithms followed by a platform for in silico clinical trials	
	specific algorithms followed by a platform for in silico clinical	
	specific algorithms followed by a platform for in silico clinical trials 1. Distribution of pharmacogenomics data in the population of	



6. Development of a workspace in a platform for in silico clinical trials The basic required information are: 1. Drug data regarding the pharmacokinetic and/or pharmacodynamic parameters including toxicity II. Population data including demographic, genetic, biochemical and physiological parameters Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the body should be considered. Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatra profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 11. Identification of the data from One the time that anti-platelet's drug concentration is below the minimum effective concentration is below the minimum effective concentration of the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternate Flows: Alternative flows can be considered, tak			
I. Drug data regarding the pharmacokinetic and/or pharmacodynamic parameters including toxicity Population data including demographic, genetic, biochemical and physiological parameters Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the body should be considered. Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, ant		6. Development of a workspace in a platform for in silico clinical trials The basic required information are:	
pharmacodynamic parameters including toxicity II. Population data including demographic, genetic, biochemical and physiological parameters Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the body should be considered. Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) Simulation of virtual clinical trials in the specific "virtual population" Embed results in an appropriate worksheet or in a different platform of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial obdew the minimum effective concentration I. Levaluation for the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, secdatives, antacids, anticoagulants administered subcuta			
II. Population data including demographic, genetic, biochemical and physiological parameters - Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the body should be considered. - Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data - Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial concentration of the time that anti-platelet's drug concentration is below the minimum effective concentration 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (
and physiological parameters - Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the body should be considered. - Data for (i) and (ii) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data - Data for (ii) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.)			
- Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the body should be considered Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data - Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile - III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) - 7. Simulation of virtual clinical trials in the specific "virtual population" - 8. Embed results in an appropriate worksheet or in a different platform - 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial - 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration - 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery - 13. Surgery performing and re-introduction of the anti-thrombotic treatment - Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency - Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.)			
which can influence drug concentrations in the body should be considered. Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.)			
should be considered. Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
- Data for (I) and (II) could be available from literature and can be in the default parameters of the platform or can be enriched from patient's data - Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
can be in the default parameters of the platform or can be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
be enriched from patient's data Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
- Data for (II) can be created from clustering of MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
MyHealthAvatar profiles of patients with same or similar disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		·	
disease profile III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial on the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
III. Clinical trial protocol and design. In this case the clinical trial will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
will need to estimate the drug concentrations in the body for a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		·	
a period of time following the last administration (i.e. 48 hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
hours) 7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
7. Simulation of virtual clinical trials in the specific "virtual population" 8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration is below the minimum effective concentration of the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		-	
8. Embed results in an appropriate worksheet or in a different platform 9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		· ·	
9. Matching and identification of the Avatar from MHA with the "virtual patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		, , ,	
patient" from the "virtual population" of the simulated clinical trial 10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
10. Identification of the time that anti-platelet's drug concentration is below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
below the minimum effective concentration 11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		· · · · · · · · · · · · · · · · · · ·	
11. Evaluation for the time needed after the sub-therapeutic concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
concentrations of the drug in order the clotting activity to start returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
returning to the default values. 12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
12. Evaluation of the obtained results and decision of the time that the patient will be ready for surgery 13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
13. Surgery performing and re-introduction of the anti-thrombotic treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
treatment Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		patient will be ready for surgery	
Note: This basic flow can be created during therapeutic drug monitoring of patient's status after the diagnosis of clotting-deficiency Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		13. Surgery performing and re-introduction of the anti-thrombotic	
Alternate Flows: Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
Alternative flows will be followed if the patient is receiving treatments for other co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
co-existing diseases in order to assess any interactions and/or any modulations regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		patient's status after the diagnosis of clotting-deficiency	
regarding the basic flow. Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data	Alternate Flows:	·	
Alternative flows can be considered, taking into account the adding therapies applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		, , , , , , , , , , , , , , , , , , , ,	
applied after or during surgery for this patient (e.g. antibiotics, analgesics, sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
sedatives, antacids, anticoagulants administered subcutaneous or intravenous such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
such as heparin etc.) Postconditions: Monitoring of patients status after surgery. Evaluating results and update data			
Postconditions: Monitoring of patients status after surgery. Evaluating results and update data		_	
	- 100		
in MHA and in clinical trial simulator platform. Re-adjust the therapy on the	Postconditions:		
		in MHA and in clinical trial simulator platform. Re-adjust the therapy on the	
recovery stage		recovery stage	
Embed results in MHA platform so both patient and physicians could have		Embed results in MHA platform so both patient and physicians could have	
access in necessary information.			
Example dose adjustment was based in the pharmacogenomics data		·	
regarding metabolizing enzyme CYP2C19. In case of modulation of			
dose the concentration-time profile for this Avatar (patient) is			
expected to follow this trend (show graph).			
expected to follow this trend (show graph).		expected to follow this trend (show Braph).	
Dependencies: This case refers to the administration of drugs in emerging situations in the	Dependencies:	This case refers to the administration of drugs in emerging situations in the	



	clinical setting of the preoperative and ICU patients. However it represents a typical example of how data can be created and organized through in silico clinical trials approaches particularly in clinical cases where clinical trials cannot be performed. It also attempts to represent how personalized information regarding drugs, diseases and health status information can be introduced and exploited through MHA in order to create decision making tools and approaches. Dependencies of this case can be related with use cases 1, 2, 3 and 5. This case follows and it is related with the use case-12 and utilization of personal genomic information for the individualization of MHA platform		
Required External	[] Data, please specify:	Drug data	
Resources:		 Pharmacokinetic properties Pharmacodynamic properties Population data Demographic Genetic Physiology Pathology Clinical trials protocols and parameters (as they described in regulatory organizations FDA and EMA) 	
	[] Tools, please specify:	 MHA platform Genomic platforms/tools Bio-informatics tools PCs with related software installed regarding in silico clinical trials PB/PK/PD platforms with license of use 	
	[] Services, please specify:	Links with databases: Genomic databases (see use-case 12) Drug databases (PharmKGB, Pubmed, DrugBank) Links with internal/external research laboratories providing data regarding PB/PK/PD and TDM	
	[] Models, please specify:	 Physiologically-Based Pharmacokinetic/Pharmacodyn amic models Therapeutic drug monitoring models 	
	[] Other, please specify:	Normal values of hemostatic factors in general and/or specific population	
Frequency of Use:	The in silico application of virtual clinical trials can be used in every emergency case where a following treatment may influence the post-operating recovery of a patient after surgery. The development of databases and generation of data prior to the emergency situation could be more helpful regarding the faster fitting of the patient with Avatar. End-users of this approach are physicians and research personnel focusing to in silico clinical trials approaches. Especially for physicians it could provide them		
	with results through in silico approa	with results through in silico approaches of treatment outcomes in patient group that fit with the patients that are monitoring and not with a general	



	"virtual population". This approach and the data provided could be hepofit for					
	"virtual population". This approach and the data provided could be benefit for					
	the treating physicians giving them tools of decision making options towards an					
	improved personalized medicine approach.					
	End-users will also be the patients with MHA profile since they can have access					
	to information regarding the provided treatment and the modulations that					
	could be occurred. It could be possible also to provide them with explanations					
	and answers regarding different treatment outcomes in patient groups that					
	would be able to participate through MHA platform.					
	Moreover, under their approval, they could be able in providing their MHA					
	profile in research facilities towards creating of in silico research approaches in					
	drug development processes and therapeutic drug monitoring as they would do					
	if they would choose to participate in a clinical trial process.					
Special Requirements:	Familiarity of doctors and generally of the medical staff with MHA technologies					
	Linking of MHA data between research and medical organizations and					
	personnel applying MHA technologies					
Assumptions:	Some basic assumptions are:					
	 Necessary drug data for the generation of the in silico clinical trials are 					
	available in the literature and easily accessed					
	Full and detailed patient's health history record					
	Platforms used for in silico clinical trials have been evaluated with					
	clinical results from other studies (Validity of the platform)					
	Continuous development and simulation of clinical trials from in silico					
	platforms in order to create databases for patient's avatar fitting					
Questions:	The new era in health care towards the "stratified medicine" and					
	personalization of treatment demands the development of approaches and					
	tools such as MHA platform. The question that rises is how an education					
	program could be introduced for medical society (especially staff that work in					
	the point of service such as hospitals etc) in order to get familiar with user-					
	friendly platforms and tools and also stay up to date with these approaches?					

5 MHA Granular Scenarios / Use Cases Clustering

5.1Introduction

In this deliverable different MHA Scenarios / Use Cases are described. All are clustered under 2 different topics:

- 1. Granular Scenarios / Use Cases
 - a. Legal and Ethical Scenarios / Use Cases
 - b. Scenarios / Use Cases for Data Access and Collection (including user accounts, data browsing, 3D visualization, self-data collection. Link to HIS)
 - c. Virtual community
 - d. Toolbox
- 2. High-End Scenarios / Use Cases
 - a. Scenarios / Use Cases for Clinicians and Researchers
 - b. Scenarios / Use Cases for Citizens and Patients

This chapter presents the narrative description of the granular use cases according to the decisions taken by the consortium in response to the reviewer's comments after the first review.. High-end Scenarios / Use Cases are described in this chapter with aim to demonstrate the MHA platform as a whole.

The clustering is important, as demos will be presented in each of these areas at the end of the project. Deliverable 9.1 'Definition of Demos' will be based on this allocation.

5.2Legal and Ethical Scenarios / Use Cases

MHA proposes a solution for access, collection and sharing of long-term and consistent personal health status data through an integrated environment, which will allow more sophisticated clinical data analysis, prediction, prevention and treatment simulations tailored to you as an individual citizen.

It is intended that the information provided by the avatar will be both valuable for clinical decisions concerning your own care, as well as offer a promising approach to acquiring population data to support clinical research, leading to strengthened multidisciplinary research excellence in supporting innovative medical care.

5.2.1 User Information Sheet and Privacy Policy

Both documents, the user information sheet as well as the Privacy Policy are in the progress of drafting. These shall firstly explain the purpose of the MHA platform, including the explanation of what data the user can upload to the platform and how the data will be used. Here it will be desirable to develop and present the user with different sharing and/or usage options from which they may select.

After this, it should be explained to the user how his or her data will be protected and, following that, the rights of the user, as a "data subject" under data protection law should be explained and described.

Moreover, the roles such as controller and processor should be explained in the information sheet/Privacy Policy and the applicable national law should be pointed out.

Lastly, the user should be referred to the need for registration and the agreement of the General Terms and Conditions. The latter should pop up after the user has confirmed that he or she has read the User Information Sheet/Privacy Policy.

It should be made technically impossible for persons to enter the site unless they have first agreed to the terms and conditions.

The rights of the data subject are, in particular:

- the right to information;
- the right of access;
- · the right of rectification, erasure or blocking; and
- the right to object.

5.2.2 Information Sheet / Privacy Policy Draft

At this early point in the project's development, prior to concrete decisions or conclusions that fix the platform and avatar functionalities and/or use modalities, it is difficult to draft a specified information sheet or a Privacy Policy. But in broad outline a user information sheet/Privacy Policy could contain terms of the kind presented in the following preliminary draft:

I. General information

This information sheet describes the functionalities of MHA, what kind of data you can store at the platform and how your rights are protected. By this, we hope that you can better decide if you want to contribute data to the proto-platform as a volunteer and/or later become a user of the MHA platform. Please take your time when you make your decision.

Please read the information provided carefully and discuss it with others if you wish. Feel free to ask us if there is anything that is unclear or if you wish more information.

If you decide to contribute your data to the proto-platform as a volunteer/become a user of MHA, you have to give consent in the processing of the data that you will upload. You can withdraw your consent at any time without any disadvantages. In this case, your uploaded data will be permanently deleted from the MHA platform.

By registering as a user, after confirming that you have read the Information Sheet/ Privacy Policy and the General Terms and Conditions, you will confirm that you were properly informed about this platform.

A copy of the Information Sheet/Privacy Policy and the General Terms and Conditions will be sent to your e-mail-address or postal address (as specified by you) for you to keep.

II. Purpose of MHA

MHA proposes a solution for access, collection and sharing of long-term and consistent personal health status data through an integrated environment, which will allow more sophisticated clinical data analysis, prediction, prevention and treatment simulations tailored to you as an individual citizen.

It is intended that the information provided by the avatar will be both valuable for clinical decisions concerning your own care, as well as offer a promising approach to acquiring population data to support clinical research, leading to strengthened multidisciplinary research excellence in supporting innovative medical care.

III. Functionalities of MHA

Your data is collected for the purposes of allowing more sophisticated clinical data analysis, prediction, prevention and treatment simulations tailored to you as an individual citizen.

This can be achieved by using the functions offered by the avatar as:

- a lifetime collection of your health status data,
- a tool to allow you to be active in promoting your own healthcare,
- allowing you to access a rich set of relevant health and other data from various sources,
- an interface to access hospital data and healthcare resources,
- a toolbox for data analysis, fusion and visualization for both you and the clinicians responsible for your care,
- the option to register for predictive risk assessment, and
- the opportunity to share your data on a variety of platforms, either for promoting your own health interests, to help particular other persons, or for general altruistic reasons (such as contributing to current and future medical research).

In order to use MHA to its full extent, you should ideally be prepared to upload data concerning personal information as gender, age, ethnic, symptoms, diagnosis, treatment and response to drugs, health indicators as blood pressure, pulses and body temperature, medical data as images, biological data, multi-scale data. It could be also helpful to upload data concerning your life style, e.g. drinking and smoking habits and to organise all uploaded data in a timeline.

But nevertheless you should only upload data that you are sure you want to have included in your personalised avatar.

IV. Security measures to protect your data

We are aware of the fact that the uploaded data are highly sensitive.

All necessary state-of-the-art security measures are incorporated in the platform to protect your data against accidental or unlawful destruction or accidental loss, alteration, unauthorized disclosure

or access or any other misuse. Other users of the MHA platform will only be able to access your data after connecting with them as "friends".

V. Your rights

Firstly, we would like to inform you that your data will not be further processed without your consent or in any way incompatible with the purposes you specify. If you would like to allow us to use your data for a further purpose that you did not initially agree to, such as other health-related projects, you can later give a separate consent for this.

It is your decision whether to disclose the information to physicians or added "friends". Only the persons you want to will have the opportunity to access this data, like added "friends" or physicians you allow to have access to your data.

Secondly, we would like to point out to you that the Data Protection Directive establishes the following special rights through which you as the data subject can protect your privacy:

- right to be informed;
- right of access;
- right of rectification, erasure or blocking; and
- · right to object

Right to information

You have the right to inform yourself about the identity of the controller who hosts this platform and of his representative, if any. The controller is the University of Bedfordshire (to be decided).

When storing data at the platform, this data will be processed. In this context, we point out that you have the right to inform yourself about the purposes of the processing for which the data are intended.

As already mentioned, the purpose of MHA is to access, collect and share long-term and consistent personal health status data in order to analyse, predict, prevent and simulate treatment tailored to you as an individual citizen.

Finally, we would point out to you that you may inform yourself about any further information, e.g. about the recipients of the data and if you have the right of access to and the right to rectify the data concerning you.

Right of access, rectification, erasure or blocking

At any time, you can receive information about the personal data stored and request that corrections be made if the data are incorrect or outdated. Furthermore, you can demand to block or delete your data.

Whenever you wish to make use of the above mentioned rights, please feel free to contact the University of Bedfordshire. It will be happy to inform you.

Exceptions and restrictions



Right to object

You have the right to object to the processing of your data at any time.

In this case we will delete your data as soon as reasonably practicable from the MHA platform and/or your avatar. An exception may occasionally have to be made when the data is collected in order to comply with a legal obligation, or when it is necessary for the performance of a contract to which you are a party, or is already being used for a purpose for which you gave your consent, where significant investment has occurred, and the deletion would prejudice the fulfilment of that purpose.

VI. Roles as controller and processor

The host of this platform is the University of Bedfordshire and complies with the duties it has as a controller in terms of Article 2d of the Data Protection Directive. The processors are... (who will process personal data on behalf of the controller will be decided)

VII. Applicable national law

The data controller is on the territory of the United Kingdom (if the University of BED will be the data controller). Therefore, our Privacy Policy meets the requirements stipulated in the Data Protection Act of 16th July 1998³ which implements the requirements of the Data Protection Directive into national law.

VIII. Need for registration

If you decide to become a volunteer/user of the MHA platform, you may register at the platform.

Therefore, you have to tick the box by which you confirm that you have read and understood this information sheet/Privacy Policy.

Afterwards, you will still need to complete the consent form. Before doing so, you should also read and familiarise yourself with the MHA General Terms and Conditions.

Thank you for reading this Information Sheet/Privacy Policy.

5.3Scenarios / Use Cases for Data Access and Collection

5.3.1 MHA User Accounts (UAC)

End-users will be able to log onto the system using their username and password. New users will be able to sign up to the system by creating basic personal information including security questions (**Figure 1**).

Informed consent and privacy: Users will need to read and accept the Information Sheet and Privacy Policy. (Please see Chapter 5.2.2: Information Sheet / Privacy Policy Draft)

Upon log into the system, users will be able to enter, browse their data, explore medical information, and communicate with other end-users.

³ http://www.legislation.gov.uk/ukpga/1998/29/contents (March, 2014)



Users will be able to view and interact with an avatar - a 3D representation of the human body. It will allow the End User to click with the computer mouse on a particular part of the avatar "body" to trigger a search of medical records to retrieve relevant information

MHA is a platform for End-Users who want to share their health information to create collective knowledge about disease, health, and treatments. In order to achieve this goal advanced Informed Consent and Privacy Policy Scenario / Use Case should be implemented.

End-user has the GUIs, functionalities and tools in the frames of MHA platform to accept, reject, print or revise at any time the Information Sheet and Privacy Policy settings.

There will be two types of end-users; the first type includes patients and citizens for their life time data collection, the second type includes clinicians and researchers who will be linked to the avatars from citizens/patients for clinical practices and medical research purpose.




Figure 1. The sequence diagram for 'MHA User Accounts' Scenario / Use Case (Source: D 3.2)

5.3.2 MHA Data Browse (DB)

Upon successful log in to their own account, users will be able to browse their own data, including all the personal health status data collected through the avatar system, plus medical records and clinical data from the hospitals (**Figure 2**).

The avatar system will need to offer tools that support effective data query and search, such as filtering.



The 4D avatar will play an important role in presenting the data. Users will be able to select individual parts of the avatar body to view the data associated to the selected parts.

Different colours or textures will be assigned to individual parts of the 4D avatar to represent their health status. For example, if the heart has a serious problem it will be highlighted using a unique colour or texture

Patients/citizens will use the data browser to view their own data; Doctors will be able to view data from all his/her patients connected to the avatar.

The avatar system will also need tools which will help users to analyse medical images

Patients/citizens will use the data browser to view their own data. Clinicians will be able to view data from all their patients connected to the avatar.




Figure 2. The sequence diagram for 'MHA Data Browse' Scenario / Use Case (Source: D 3.2)

5.3.3 Self-Data Collection (DCU)

This case seeks new solutions for increasing the quality and sustainability of future healthcare systems by actively engaging citizens in monitoring their own health through self-collection of life logging data (**Figure 3**).

The development and treatment of many diseases are affected by our life styles and environment. A long term monitoring of these factors, especially through the self-involvement of patients, is extremely valuable in supporting individualised health prediction and treatment. Many studies have shown compelling needs in self-life logging and self-monitoring of patients, which has great potential in leading to preventive medicine, cost saving and enhanced quality in future healthcare.

We aim to create a symbiotic relationship of available technology today and MyHealthAvatar platform. The goal is to respond to the fast growing demand for developing new technologies and services for self monitoring for supporting wellness, fitness and prevention of the most common chronic diseases (i.e. cardio-vascular and stroke, diabetes, rheumatic problems, respiratory problems and COPD, etc.). Mobile applications will monitor user's "health-status", "lifestyle" and "wellness" and upload data to the MyHealthAvatar system for close monitoring of health conditions and prevention of many diseases. The system then will be able to analyse user's lifestyle and medical data. Special "alerts" will be applied to support end users with feedback supporting and assisting their daily activities and well-being.

An interface for patients writing a diary is very helpful to collect patient specific data related to their disease. This can be partly structured: e.g. body weight, heart rate, blood pressure, temperature, medicine taken, etc. It can also include structured data of scoring systems, e.g. physical and/or psychological and/or emotional status. In addition free text entry needs to be allowed.

More specifically, we explores various ways for the data collection in the avatar to monitor users' health-status, lifestyle and wellness. These include:

- Web interface for data entry
- Sensors (e.g. blood glucose, blood pressure, heart rate, locations, steps, sleep)
- Mobile apps

For example, users uses a glucose meter and MyHealthAvatar platform to monitor his/her blood sugar levels. The data is saved that maintains the Avatar's long-term history and looks for possible abnormal events. If the saved data is unusual, or the End-User skips a test, the MyHealthAvatar platform automatically generates an alert message

Mobile apps will be used to monitor the health status of the users (e.g. mood, food).

We will also explore the possibility to extract health related information from electronic cards (e.g. purchase of food and drink, daily exercises in gyms), as well as from social network.

We will also look into the possibility of implementing an advanced Patient Devices Software Development Kit (SDK or "devkit"). A SDK will represent a set of software development tools that will allow healthcare it professionals the creation of applications for MHA able to access and strore data from any patient monitoring device. Patient Devices SDK may be something as simple as an application programming interface (API) in the form of some files to interface to a particular programming language or include sophisticated hardware to communicate with MHA platform. SDK may also include sample code and supporting technical notes or other supporting documentation to help clarify points from the primary reference material.




Figure 3. The sequence diagram for 'Self-Data Collection' Scenario / Use Case (Source: D 3.2)

5.3.4 Link MHA to HIS and CTMS (HIS)

End User has the GUIs, functionalities and tools in the frames of MHA platform to enter, import, store and export personal medical data with hospital information systems (Figure 4).

One option is to use ObTiMA as a dummy system to mimic external hospital system.

ObTiMA, an ontology-based clinical trial management system, has been developed as a proof-of-concept application to highlight the possibilities of ontology based creation and managing of clinical trials within the ACGT (Advancing Clinico-Genomic Trials on Cancer) project. ObTiMA has a modular architecture with a core basic module for data management of clinical trials. Different other modules are under development in the frames of p-medicine project.

The data stored in ObTiMA are relevant for the Health Avatar to enhance the system with relevant clinical trial data. On the other hand the info stored in MHA might be of relevance for a clinical trial. As result, the bidirectional data upload from MHA to ObTiMA is needed. This Scenario / Use Case describes the bilateral linkage between ObTiMA and MHA by being focused on the Operational Data Model (ODM).

There are also a few other dummy systems available at FORTH, which can be used to mimic the external hospital system.




Figure 4. The sequence diagram for 'Link MHA to HIS and CTMS' Scenario / Use Case (Source: D 3.2)

5.3.5 3D Avatar Visualization (3DS)

MyHealthAvatar platform would propose an avatar - a 3D representation of the human body - to allow End Users (e.g. patients, doctors) to visualize patient medical records in a new way. The avatar will be used as a means for presenting general medical knowledge to the citizen users.

Users will be able to select individual parts and see related medical information such as anatomy. The information may also include medicine and food.

5.4 MHA Virtual Community (VC)

This case describes the search framework from end-users' perspective and it is focused on listing all MHA registered end-users with ability to apply advanced search filters:

Age

- Gender
- Votes (Likes)
- Treatment
- Symptom
- Interests
- Country
- City
- etc.

It is important to mention that every end-user should confirm the possibility to visualize his/her profile publically or privately. Only public profiles should be visible in search results. Additionally, the search function is suggested to be accessible only for end-users with public profiles.

This case also provides a social media that allows patients to build up a virtual community by sharing their daily activities (e.g. how many exercises they have done), exchanging their experiences. It should also provide a link to Facebook/Twitter.

The social media service will be used to allow the interconnection of end users. This social media service, accessible by smart phones, will be used in a dual mode allowing the users to insert information about themselves (like they do in common social media technologies) but also will be a mean of supporting personalized services to them from the system in the form of alerts and guidance (i.e. post therapy monitoring of user's behaviours after orthopaedics operation, cancer patients reaction to treatment, etc.).

More specifically, patients will be able to

- 1. Find patients with similar condition, symptom and treatments
- Find out symptoms and treatment for their conditions by looking at other fellow patients
- Find out possible conditions for their symptoms by looking at other fellow patients
- 4. Find out possible treatments for their conditions by looking at other fellow patients
- 5. Find out "friends" and allow "followers" as in Facebook/Twitter
- 6. Share activities, exercise experiences etc with friends and followers.

5.5 MHA Toolbox (TOOL)

5.5.1 Remote Monitoring

The Remote Monitoring tool/frame collects and processes patient care information from supported healthcare devices that conform to standards (preferably selected by the Continua Health Alliance).



End User uses a glucose meter and MyHealthAvatar platform to monitor his/her blood sugar levels. The MyHealthAvatar platform reminds to check the blood sugar regularly during the day, and the glucose meter should be able seamlessly to transmit the measurements to the Avatar after each use. The data is saved that maintains the Avatar's long-term history and looks for possible abnormal events. If the saved data is unusual, or the End-User skips a test, the MyHealthAvatar platform automatically generates an alert message.

The monitoring data will be made available through the citizen self-monitoring case (which is another use case). To allow for remote monitoring from the doctors using the avatar system, we need to link the avatar system to the hospital information system (which is again another use case). This will subsequently allow the transfer of the avatar data into the hospital records.

5.5.2 MHA Simulation Models

End-User has the GUIs, functionalities and tools in the frames of MHA platform to create and execute a biological simulation scenario. End-User selects one of the biological simulation models available in the Model Repository and one of the sets of clinical data available in the Clinical Data Repository (or uploads a set from his computer). Afterwards he/she executes a biological simulation. Finally he/she retrieves the results of the simulation and proceeds to their evaluation.

5.5.3 Knowledge Discovery

Patients are interested in the most recent and personalized information about their disease, treatment and prognosis. MHA platform could contain a ontology-based Knowledge Discovery (KD) module able to connects highly heterogeneous data and textual information. The semantic framework could be based on gene, tissue, disease and compound ontologies (important for drugs and clinical research frames). This framework could contain information from different organisms, platforms, data types and research areas that is integrated into and correlated within a single searchable environment using search algorithms. It could provide a unified interface for all MHA users to formulate, explore and identify new information (according to specific preferences and needs) across vast collections of available experimental and research data.



6 High-End Scenarios / Use Cases

6.1 Introduction

High-end Scenarios / Use Cases are predictably divided in two major groups:

- Scenarios / Use Cases for Patient empowerment for long-term diseases.
- Scenarios / Use Cases for Clinical Researchers
- Scenarios for emergency contact

6.2 Scenarios / Use Cases for Patient Empowerment

6.2.1 Pre-Diabetes (UC-DIAB)

MyHealthAvatar platform aims to provide an unique citizen/patient empowered system that can be used, in particular for pre-diabetes care in addition to the health care system.

The avatar system will support the storage the behaviours and daily activities of citizen. The platform will function as a supportive environment from healthcare providers to the individual by means of offering advice, assistance and assessments; and by means of allowing for health promotion.

6.2.2 Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services (UC-CHF)

In order to tailor the proposed system to the patient's profile and assist physicians in selecting people who are predisposed by coronary disease, hypertension, or valvular heart disease; we build a CHF related risk profile based on a risk appraisal function that is based on the diagnostic criteria. The predictors used are based on Age, Coronary heart disease and Valve disease status provided by the patient Electronic Health Record (EHR), as well as on HR, on blood pressure and on Body Mass Index (BMI) provided by the pulse oximeter, the blood pressure monitor and the weight scale respectively. The calculated risk probability may be used to alter the default threshold values (higher risk probability adds more constraint on the physiological patterns). Furthermore we present what else data regarding patient's health status could be embed into the platform towards the creation of a profile with necessary information for both patient and treating physicians. To this respect an approach of presenting data regarding demographic, physiology, diagnostic test results and disease management (i.e. prescribed drugs) is provided.

6.2.3 Osteoarthritis (UC-OST)

This Scenario / Use Case aims at the development of MHA technology as an individualized medicine platform by the utilization, interpretation and integration of personal genomic information into health medical history record. This technically high-level and complex Scenario / Use Case involves a number of health and lifestyle related processes, tools and services which translate genomic data to genetic predisposition evaluation and health risk estimation, pharmacogenomic predictions, histology and pathway visualizations etc. in order to support and facilitate advanced individualized



medical decision making (i.e. integrative individual patient case view, specification of simulation models, therapy selection etc.) and provide with guidelines for preventive medicine.

6.2.4 Brain Trauma (UC-TBI)

A pre-injury clinical profile of patient is a critical aide that can help the clinicians by providing a better insight and possibly improve the clinical outcomes by circumventing the barriers imposed by the heterogeniety of traumatic brain injuries. Individualized treatment and targeted therapies based on patients' data are imperative both from the patients' perspective and also from the clinicians point of view and can ensure more promising outcomes and better prediction and prevention. Such a profile can be used to establish models of pathphysiologic mechanisms significant to pathoanatomic presentations of brain injuries.

6.2.5 Anti-Platelet & Anticoagulation Therapy in the Pre-Operative Patients (UC-APLA)

Anti-platelet and anticoagulant agents that are administered in clinical practice, appear to have a wide inter-subject variability in their pharmacokinetics and thus in pharmacodynamics. Antiplatelet and anticoagulation therapies are typical examples where therapeutic drug monitoring is applied for every patient as well as pharmacogenomics information are taken into account and several algorithms have been created in order to integrate data and improve pharmacotherapy. Moreover, there are emergency cases such as pre-operative status, where an adjustment in dose should be applied for patients following anti-coagulation and anti-platelet therapies in order to avoid bleeding problems during surgery or during recovery.

6.3 Scenarios / Use Cases for Clinical Researchers

6.3.1 Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial (UC-NEPH): In-silico Profiling of Patients and Predictions

Nephroblastoma is the most common malignant renal tumor in children. Treatments are based on prospective multicentre trials and studies conducted by the International Society of Pediatric Oncology (SIOP) in Europe and the Children's Oncology Group, North America (COG) in North America. Information from these nephroblastoma studies have allowed the identification of prognostic indicators independent of whether patients are treated by immediate surgery (COG) or surgery after preoperative chemotherapy (SIOP).

The Wilms' Oncosimulator is an integrated software system simulating the growth of nephroblastoma tumors and their in vivo response to chemotherapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients.

The nephroblastoma simulation model is a predominantly discrete, clinically oriented multiscale model of solid tumour response to treatment. Preoperative chemotherapy is the simulated form of treatment. A "top-down" simulation approach is adopted. The simulation method starts from the macroscopic imaging data, representing a high biocomplexity level, and proceeds towards lower biocomplexity levels. Clinical orientation of the model has been a fundamental guiding principle throughout its development. A finite number of states of the model is defined by several different

types of biological cells. The transition rules of the cells from one state to another form the "decision calculators" and define the evolution and interaction rules between the predefined number of finite states of the model. In this way, several cellular-level biological phenomena that are reported in literature are incorporated in the model such as cell proliferation, quiescence, differentiation and death (normal and chemotherapy-induced).

Stage 1:

Nephroblastoma diagnosis is based on a variety of multiscale data. These data constitute the multiscale clinical profile of the tumour. After the necessary pre-processing of the available data of nephroblastoma patients, the data are fed into the nephroblastoma simulation model. By integrating insights from the personalized multiscale clinical profile of the patient, numerical parameter studies and any information that can be gleaned from the experimental and theoretical biology literature, semi-automatic adaptation of the model parameters is conducted. The determined model parameter values serve as a patient record for in silico tumor characteristics and form the 'in-silico profile' of the patient (fig. 5). Training the model with a patient's data gives a more accurate description of the specific kinetics of disease progression.




Figure 5: Schematic representation of stage 1 of the nephroblastoma use case (UC-NEPH, stage 1): 'In-siico profilng' of patients with Wilms' tumor

Stage 2:

The paediatric oncologist runs a number of experiments in silico (= on the computer) simulating the most likely response of the tumour to the most relevant candidate chemotherapeutic schemas. The outcomes of the simulations (predictions) help the oncologist decide the appropriate treatment plan (fig. 6).




Figure 6: Schematic representation of stage 2 of the nephroblastoma use case (UC-NEPH): Prediction simulations.

The identification of histological subtypes of Wilms' tumor in addition to stage classification and response to treatment is of prognostic value. In this way, the SIOP trials and studies largely focus on the issue of preoperative therapy. Response to treatment can be measured individually by tumour volume reduction and percentage of therapy-induced necrosis or remaining vital blastema at the time of surgery in the histological specimen. In nephroblastoma, the blastemal subtype after preoperative chemotherapy is recognized as an unfavourable entity. This gives an early individual prognostic parameter and is used for further stratification and more individualization of the postoperative treatment.

The nephroblastoma case is ideal for the development and validation of in silico models since the highly successful treatment rate in SIOP provides an excellent, reliable reference for both developing and validating such models. The main goal in this context is to quantitatively predict the response to preoperative chemotherapy in every case. The model aims at avoiding unnecessary treatment in non-responding tumors and applying chemotherapy only to those patients that would benefit most. At the same time, the provision of a clinical decision support tool for the less experienced clinicians treating this disease is of particular importance.

The spatiotemporal simulation module embedded in the Oncosimulator is based on the multiscale, predominantly top-down, discrete entity-discrete event cancer simulation technique developed by the In Silico Oncology Group, National Technical University of Athens. [3]

The 'in-silico profile' created in stage 1 of the use-case could be further used from clinicians as a tool to provide insight into individualized biological characteristics of the tumour, an input for future model use and an input for the use of other models (e.g. within CHIC platform). It could also serve as a statistical tool to categorize the patients (by associating their clinical and in silico profiles) and define a range for model parameters to guide model adaptation for new patients. It is widely accepted that the more quantitative clinical data are available to build and constrain the parameter values, the more likely models are to accurately describe observed behaviors.



6.3.2 Emergency Contact (UC-EME)

This use case describes the situation where a patient is unconscious in Accident and Emergency Units in hospitals, and where some of the information within the avatar could be crucial for the clinical decisions to be taken by the doctors. Though some data access (in the patient's vital interests) is permitted without consent, the bounds of this exception are uncertain, and there may be issues in authenticating the doctor's legitimate access interest.

We envisage a Europe-wide MHA service center as a solution to this case. Each avatar user will have the option to sign an agreement to authorize the data access to the doctors, who may treat him/her under a future emergency situation. For the signed users, the doctors can contact the MHA service center to obtain their data in the MHA for the treatment purpose under an emergency situation.

6.4 Granularity of the High-End Scenarios / Use Cases

All high-end use cases include different granular use cases. **Table 5** shows the composition of all high-end use cases as described above.

ID	Scenario / Use Case	Legal and Ethical	Data Access and Collection
TOOL	MHA Toolbox and MHA Simulation	Information Sheet	UAC, DB, DCU. HIS, 3DS
	Models	Privacy Policy	
CHF	Personalized CHF Related Risk	Information Sheet	UAC, DB, DCU. HIS, 3DS
	Profiles and "Real-Time	Privacy Policy	
	Monitoring" Services		
OST	Osteoarthritis	Information Sheet	UAC, DB, DCU. HIS, 3DS
		Privacy Policy	
DIAB	Pre-Diabetes	Information Sheet	UAC, DB, DCU. HIS, 3DS
		Privacy Policy	
NEPH	Nephroblastoma (Wilms Tumour)	Information Sheet	UAC, DB, DCU. HIS, 3DS
	Simulation Model and clinical trial	Privacy Policy	
EME	Emergency Contact	Information Sheet	UAC, DB, DCU. HIS, 3DS
		Privacy Policy	
TBI	Brain Trauma	Information Sheet	UAC, DB, DCU. HIS, 3DS
		Privacy Policy	
APLA	Anti-Platelet & Anticoagulation	Information Sheet	UAC, DB, DCU. HIS, 3DS
	Therapy in the Pre-Operative	Privacy Policy	
	Patients		

Table 5. Granularity of the High-End Scenarios / Use Cases



7 Further links with external projects

7.1 MyLifeHub

Visual impairment is one of the most feared forms of medical disability, which imposes a great social and economic burden on our society. In the UK, the number of visually impaired people is almost 2 million, with total annual costs estimated over £13,000 million. Notably, age-related increase of visual impairment has been well-documented and is set to be on constant rise owing to the growing ageing population nowadays. Visual impairment has significant impact on quality of life (QoL), as reduced visual acuity seriously affect patients' daily and social activities, with substantial increase of risk of mortality, fracture and falls, depression and other emotional distress.

A variety of responsive instruments for quantifying functional impairment related to vision have been developed. Also, there are well-recognised generic instruments for the assessment of QoL in general health terms. These instruments contain questionnaires referring to a broad range of physical, social and psychological aspects, offering the basis for establishing the QoL profiles of the individuals under concern.

Any changes in the QoL profile, for instance, the increase or drop of the level of physical and social activities before and after an eye surgery, can be used as important indicators for the outcome of the treatment.

However, QoL assessment through written questionnaires has several significant drawbacks. Many answers often rely on participants' memory over a long period of time; people may read differently into the questions with their own interpretations; often there is no way of validating the truthfulness of many responses. These limitations raise serious questions on the reliability and validity of the measurements.

Remarkably, the rapid advance of the Internet of Things (IoT) technology grants us opportunities to build QoL profiles of individuals with increased reliability and validity by monitoring their life logging data captured by a variety of IoT assets (namely objects, sensors, mobile apps, web-objects, etc.) with constant connectivity and interaction in a pervasive network. MyLifeHub is an UK EPSRC project and it is such an attempt with focus on the interoperability of the IoT assets, aiming at a common, interoperable and internet-based environment for long-term lifestyle information for individuals. The system will keep users well informed about their daily activities, diet, sleep, mood, blood pressure, pulse, etc., enhancing self-awareness in health and encouraging positive attitudes towards lifestyles. Data sharing among different users will also be enabled to allow for experience exchange and to build healthcare social-networks among users.

Especially, MyLifeHub will feature new techniques enabling simultaneously and long-term quantifying the functional impairment related to vision underpinned with smart glasses (e.g. Google-Glass), which provide wearable sensors to connect with the environment through RFID, infrared, Bluetooth or QR code, allowing for a constant monitoring of the behaviours of people's vision.

MyLifeHub will be utilized as a platform to assess the impact of visual impairment on the QoL of ophthalmic patients both in general health terms and in vision specific terms. The research will be conducted "in the wild" through direct exposure to potential beneficiaries. Our clinical collaborator, Moorfields Eye Hospital (MEH), is the largest eye hospital in the UK and earns a reputation worldwide. The outcome of MyLifeHub will be evaluated by the end users (namely MEH and its patients).

The technical development of MyLifeHub can utilise the existing work of MyHealthAvatar (which are delivered as open sources), including NoSQL data repository, system security, semantics, visualization and social network. While MyHealthAvatar is a feasibility study to build up the entire concept of "digital patient" for demonstration purpose, MyLifeHub could make significant effort to,

- Extend the data collection capacity by introducing a wider variety of IoT assets for lifelogging, featuring techniques tailored for capturing and assessing vision related behaviours.
- Enhance the technical scalability for handling the large-scale lifelogging data.
- Add features that are friendly to ophthalmic patients, such as big fonts and voice messages.

7.2 CARRE

CARRE is a EC FP7 project that addresses comorbidity management via an approach that first fosters understanding of the complex interdependent nature of comorbidities in general and as specialized for the specific patient, then calculates informed estimations for disease progression and comorbidity trajectories, and finally compiles a variety of personalized alerting, planning and educational services so that patients (and professionals) are empowered and can make shared informed decisions. CARRE research aims at a technological infrastructure for visual understanding of disease progression pathways and comorbidity trajectories, enriched with medical evidence and personalized for the individual patient. Based on this, CARRE will develop personalized shared decision support services for the patient & the professional. CARRE innovation lies in semantic interlinking of 3 types of data (a) medical ground knowledge; (b) up-to-date medical evidence; and (c) personal patient data, in order to create a personalized model of the disease and comorbidities progression pathways. Visual presentations of this personalized model (against ground knowledge and against statistical views of 'similar' patient groups) will form the basis for patient empowerment services. Finally, the personalized model of comorbidities will be used for shared decision support services targeting personalized education, complex risk calculation for disease & comorbidities progression, alerts for adverse events of multiple treatments and personalized planning. The ultimate goal is to provide the means for patients with comorbidities to take an active role in care processes, including self-care and shared decision making, and also to support medical professionals in understanding and treating comorbidities via an integrative approach. CARRE will address the specific medical domain of cardio-renal disease comorbidities and will provide proof-of-concept via deployment and validation in two different healthcare settings.

BED is currently exploring the possibility of linking CARRE with MyHealthAvatar by allowing the participants in CARRE to use MyHealthAvatar as an empowerment platform.



8 Conclusions

The main goal of this document has been successfully accomplished by presenting the summary (Chapter 3) and the detailed description of the final set of MHA's Scenarios / Use Cases (Chapter 4). All Scenarios / Use Cases, based on the results of WP2, have been updated with insights and contributions received from all projects partners. The final Scenarios / Use Cases have are ranked (Chapter 3.3) with option to define (in case of availability) the updated version in the frames of the next project's tasks, and, close to the ranking approach, an additional clustering and granulatity option (Chapter 5) has been applied. Criteria for prioritization were given via Scenarios / Use Cases clustering model and it would serve as a background for the required timeframes for realization of selected scenarios within MHA.

MHA Scenarios / Use Cases are clustered (Chapter 5) under 2 different topics:

- 1. Granular Scenarios / Use Cases
 - a. Legal and Ethical Scenarios / Use Cases (Chapter 5.2)
 - b. Scenarios / Use Cases for Data Access and Collection (Chapter 5.3)
- 2. High-End Scenarios / Use Cases (Chapter 6)
 - a. Scenarios / Use Cases for Patient Empowerment
 - b. Scenarios / Use Cases for Clinical Research

The linkage and references to other WPs have been mentioned, a special attention has been paid to data collection utilities and data repository to store health related data of individual citizens.

An overview about the conducted requirement analysis for the final set of MHA Scenarios / Use Cases has been presented in **Chapter 3.4**. All presented data resources have been (re)analysed in the terms of the identified end user needs and requirements. As result, the concluding table from D 2.3 has been refreshed with new data and insights.

Close to the clustering option this document presented as well the first outline of the end-user Information Sheet / Privacy Policy (**Chapter 5.2**) with a preliminary draft and terms linked to the legal and ethical aspects.

Criteria for prioritization have been elaborated at the beginning of this task and presented according to the need in high-end and granular Scenarios / Use Cases. The ranking (low, medium, high) has been applied to prioritize the MHA platform development activities.

The ranking of MHA Scenarios / Use Cases is accepting updates and will be used in special for internal platform development process with direct impact on next project's tasks and the final ranking set will be presented in **D 9.1**: Definition of demos.

This document concludes that the timeframe required for realization of the final set of MHA Scenarios / Use Cases is in line with MHA project DoW (Description of Work) document. The **Task 9.1** will develop a flow diagram for every tool that is developed along a timeline.

8.1MyHealthAvatar Global Meeting

The final set and the description of MHA Project Scenarios / Use Cases have been discussed and agreed by all project partners in the frames of the last MHA Global Meeting from Homburg Germany, 18 - 19th September, 2014 (**Appendix 3** – MyHealthAvatar Global Meeting Agenda). We are proud to acknowledge the attention, support and contribution received from all project

partners. Meeting's presentations and discussions allowed us to refresh, update or mention new insights in the final set of MHA Project Scenarios / Use Cases, all contributions served as a solid background for this document. Additionally, the final Scenarios / Use Cases have been ranked, clustered and the granularity option has been successfully applied and described in this document (**Chapters 3, 4, 5, 6**).















8.2 MyHealthAvatar Scenarios / Use Cases with 'High' Development Priority

MHA Global Meeting in Homburg was a successful and very productive event, very useful and with important insights / contributions for the final version of this document. Special attention has been paid to the conclusion of the projected for implementation MHA Scenarios / Use Cases. The final set of the agreed MHA High-End Scenarios / Use Cases, marked with 'High' ranking (**Chapter 3.3**) and top development priority is presented below.

ID	Scenario / Use Case Name	
CHF	Personalized CHF Related Risk Profiles and "Real-Time Monitoring" Services	
OST	Osteoarthritis	
DIAB	Diabetes	
NEPH	PH Nephroblastoma (Wilms Tumour) Simulation Model and Clinical Trial	
EME	Emergency contact	

It is important to mention that due to granularity and clustering approach the MHA Scenarios / Use Cases with 'High' priority are in linkage with granular Scenarios / Use Cases and in special with Scenarios / Use Cases for Data Access and Collection (**Chapter 5.3**).

MHA Global Meeting agenda allowed all project partners to present in details their Scenarios / Use Cases (**Appendix 3**) and after active concluding discussions and by taking into account previous reviewers' comments and the available resources were decided to focus our efforts in a small set of MHA Scenarios / Use Cases with highest impact and added value for patients / citizens empowerment.



References

- [1] Scenario Based User Needs and Requirements (MHA D 2.2)
- [2] Architecture Design (MHA D 3.2)
- [3] Stamatakos G, Dionysiou D, Lunzer A, Belleman R, Kolokotroni E, Georgiadi E, Erdt M, Pukacki J, Rüeping S, Giatili S, d'Onofrio A, Sfakianakis S, Marias K, Desmedt C, Tsiknakis M, Graf N. The technologically integrated oncosimulator: combining multiscale cancer modeling with information technology in the in silico oncology context. IEEE J Biomed Health Inform. 2014 May;18(3):840-54. doi: 10.1109/JBHI.2013.2284276.
- [4] Initial report on data collection methods and plans (MHA D 6.5)
- [5] User requirements and specifications for the linkage to external sources such as social networks and for the collaboration with other existing research projects (MHA D 2.3)



Appendix 1 – Abbreviations and Acronyms

CHF Congestive Heart Failure

DoW Description of Work

EHR Electronic Health Record

ICT Information and Communications Technology

MHA MyHealthAvatar

PHR Personal Health Record



Appendix 2 – The Initial Set of MHA Scenarios / Use Cases

Enter, import, store and export personal medical data

Use Case ID:	UC-1					
Use Case Name:	Enter, import, store and export personal medical data (e.g. Electronic Health Records)					
Use Case Owner:	USAAR	Last Updated By:	:	Haridimos Kondylakis		
Technical Collaborators:	TBD	Clinical Collabora		USAAR		
Date Created:	02.05.2013	Last Revision Dat	te:	01.07.2013		
Description:	End User has the GUIs, functionalities and tools in the frames of					
	MyHealthAvatar plat	form to enter, impo	rt, store a	ind export personal medical		
	data.					
Actors:		End User & MyHealthAvatar platform				
Trigger:	User accesses the section "Personal Medical Data"					
Preconditions:	User has to Log-in or to create a New Account (New Avatar)					
Successful End condition:						
Fail End condition:						
Basic Flow:	The basic steps are:					
		• ,	nt creation	on) by using Username or		
	Email and Password					
	2. Select your Avatar					
	3. Click Enter/Import personal medical data for your Avatar					
	4. The list of available HIS (by location) is presented, if not applicable,					
	skip to the next step					
	5. Import personal medical data from PHR system (Microsoft					
	HealthVault, IndivoX, etc.), if not applicable, skip to the next step					
Alternate Flows:	6. Enter Personal medical data (Conditions, Treatment, Symptoms) Two alternative flows are in place:					
Alternate Flows.	Import personal medical data (HIS and/or PHR)					
	Enter personal medical data					
Postconditions:	The next step is to store the entered/imported medical data on your Avatar					
1 osteonarions.	("Save" button). After successful data save, the option "Export data" is					
	activated and/or available.					
Dependencies:	This use case extends to the following use cases:					
- r	Successful Log In (TBD)					
	2. Creation of New (account) Avatar, plus the acceptance of					
	MyHealthAvatar platform's Privacy, Terms and conditions (TBD)					
	3. New Avatar creation functionality (TBD)					
	4. Other Use Cases (TBD)					
Required External	[x] Data, please spec	ify:	Access to	HIS and/or PHR		
Resources:	[x] Tools, please spec	cify:	Access to	ObTiMA		
	[x] Services, please s	pecify:	PHR expo	rt/import functionality		
	[] Models, please sp	ecify:		<u> </u>		
		,				
	[] Other, please spec	city:				
Frequency of Use:	Frequent use is expected due to the general and basic character of this Use					
	Case					
Who are the users?			=	1 111 1 2 2 2		
Special Requirements:	The interface and tools to assure the access to HIS should be described and					
	implemented. Access to ObTiMA tool should be described as a separate use					
	case.					



	The minimum medical dataset should be defined and described (compatible and/or similar to Continuity of Care Record (CCR) and the Continuity of Care		
	Document (CCD) formats/standards)		
Assumptions:	UC-1 would play the central role in MyHealthAvatar platform.		
	MyHealthAvatar should support the Continuity of Care Record (CCR) and the		
	Continuity of Care Document (CCD) formats/standards.		
Questions:	Who will be responsible for this Use Case development/implementation?		



Informed Consent and Privacy

Use Case ID:	UC-2		
Use Case Name:	Informed Consent and Privacy		
Use Case Owner:	USAAR	Last Updated By:	
Technical Collaborators:	TBD	Clinical Collaborato	r: USAAR
Date Created:	03.05.2013	Last Revision Date:	
Description:	MyHealthAvatar could be treated as a platform for End-Users who want to share their health information to create collective knowledge about disease, health, and treatments. In order to achieve this goal advanced Informed Consent and Privacy Policy Scenario / Use Case should be implemented. End User has the GUIs, functionalities and tools in the frames of		
			print or revise at any time the
	Privacy and Informed (
Actors:	End User & MyHealth		
Trigger:	User accesses the sect		
Preconditions:	User has to Log-in or to	o create a New Accou	nt (New Avatar)
Successful End condition:			
Fail End condition:			
Basic Flow:	 The basic steps are: Successful Log-In (or New account creation) by using Username or Email and Password Select your Avatar Click Accept/Revise link named "Privacy and Informed Consent" of your Avatar The Privacy and Informed Consent description with checkboxes is shown. End User has the option to select any checkbox according his/her preferences End User has the option to "Edit", "Save" and "Print" the Accepted "Privacy and Informed Consent" preferences. 		
Alternate Flows:	The alternative flows are possible by allowing the End Users to access the "Privacy and Informed Consent" section from any location of the MyHealthAvatar platform.		
Postconditions:	The important post condition is the ability to "Print" the accepted "Privacy and Informed Consent" preferences. It would be great to have in place the "Track Changes" frames, the kind of history of changes with dates.		
Dependencies:	Guidance messages should be in place (i.e. if the End User selects to not share any anonymous Avatar data he/she will not have access to any other anonymous Avatar data)		
Required External	[] Data, please specify	:	
Resources:	[] Tools, please specify	<i>/</i> :	
	[] Services, please spe	сіту:	
	[] Models, please spec	cify:	
	[x] Other, please speci		rage to the results of CONTRACT
Frequency of Use:	Frequent use is expected due to linkage with existing functionalities. The access to some functionalities of MyHealthAvatar will be restricted as soon as the End User didn't accept the related "Privacy and Informed Consent"		

⁴ CONTRACT Project, http://www.contract-fp7.eu (May 2013)



	conditions.	
Who are the users?		
Who are the users? Special Requirements:	Privacy and Informed Consent should be in details explained. Examples of shared data that End Users may submit at the MyHealthAvatar platform, including through their Avatar, may include ⁵ : • Biographical information, e.g. photograph, biography, gender, age, location (city, state and country), general notes; • Condition/disease information, e.g. diagnosis date, first symptom, family history; • Treatment information, e.g. type of treatment/ medication, treatment start dates, stop dates, dosages, side effects, treatment evaluations; • Symptom information, e.g. severity, duration; • Primary and secondary outcome scores over time, e.g. ALSFRS-R, MSRS, PDRS, FVC, PFRS, Mood Map, Quality of Life, weight, InstantMe; • Laboratory results, e.g. CD-4 count, viral load, creatinine; • Genetic information, e.g. information on individual genes and/or entire genetic scans; • Individual and aggregated survey responses; • Information shared via free text fields, e.g. the forum, treatment evaluations, surveys, annotations, journals, feeds, adverse event reports; and • Connections to other Avatars.	
	In the course of using the MyHealthAvatar platform, End Users should be aware that other End Users may share information that could be used to reasonably identify them ("Personal Information"), including name, medical images, and email address. When a Member chooses to share Personal Information via a free text field (e.g. forum, treatment evaluations, annotations, journals, feeds and adverse event reports) and photos or images, the information shall be treated as Shared Data.	
Assumptions:	UC-2 would require continuous revisions in close collaboration with MyHealthAvatar project partners.	
Questions:	Could we implement the Privacy, Informed Consent related frames in line with the bellow guidelines? Final Guidelines for Informed Consent and Data Security, Deliverable 4.2, CONTRACT Project, http://www.contract-fp7.eu/site/images/Documents/D4.2Final%20guidelines.pdf	

⁵ <u>http://www.patientslikeme.com/about/privacy</u> (June 2013)



Interactive 3D Model of the Human Body (Patient Education & Serious Game)

Use Case ID:	UC-3		
Use Case Name:	Interactive 3D Model of the Human Body (Patient Education & Serious Game)		
Use Case Owner:	USAAR Last Updated By:		
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR
Date Created:	03.05.2013	Last Revision Date:	
Description:	MyHealthAvatar platform would propose an avatar - a 3D representation of the human body - to allow End Users (e.g. patients, doctors) to visualize patient medical records in a new way. Similar to IBM's Anatomic and Symbolic Mapper Engine (ASME), this visualization method would allow the End User to click with the computer mouse on a particular part of the avatar "body" to trigger a search of medical records to retrieve relevant information. "The ASME system will allow doctors to "click" on different parts of the 3-D avatar of the human body - for example, the spine - and instantly see all the available medical history and information related to that patient's spine, including text entries, lab results and medical images such as radiographs or MRIs. Or the doctor might be interested only in information related to a particular part of the spine; in this case, the practitioner can zoom in,		
Actors: Trigger:	End User & MyHealthA User accesses the Avat	·	
Preconditions:		o create a New Account (New	v Avatar)
Successful End condition:	1 10 01 11		,
Fail End condition:			
Basic Flow:	 The basic steps are: Successful Log-In (or New account creation) by using Username or Email and Password Select your Avatar Click on different parts of the 3-D Avatar of the human body (e.g. kidney) See all the available medical history and information related to that patient's parts of the human body (e.g. text entries, EHR, lab results and/or medical images). Browse the available information with ability to Add, Edit, Save, Change the Privacy Settings, or Delete the existing entries. End messages (e.g. "Success", "Error") in case of any of the above performed actions. 		

⁶ http://www-03.ibm.com/press/us/en/pressrelease/22375.wss (June 2013)

Page **76** of **127**



	7. Log-Out option with related message.			
Alternate Flows:	The alternative flows are possible by allowing the End Users to access his/her			
	Avatar from any location of the MyHealthAvatar platform.			
Postconditions:		e the end messages in case of any		
	performed actions (e.g. Add, Edit	, Save, Change the Privacy Settings, Delete,		
	etc.)			
Dependencies:	Dependencies are related to UC :	1 and UC 2		
Required External	[x] Data, please specify:	EHR, PHR		
Resources:	[x] Tools, please specify:	Semantic Core Ontology		
	[] Services, please specify:			
	[x] Models, please specify:	3-D models of the human body		
	[] Other, please specify:			
Frequency of Use:	Frequent use!	Frequent use!		
Who are the users?				
Special Requirements:	The key technologic challenge is	the integration of heterogeneous data		
	sources and complex text-based information (unstructured data) and linking			
	that data to the anatomical model in a meaningful and easy-to-navigate way.			
	Strong linkage to:			
	 WP 3 (Architecture and integration) 			
	WP 4 (Semantic interoperability)			
	WP 8 (Avatar centred visual analytics)			
Assumptions:	UC-3 would require a close collab	poration and contribution from all		
	MyHealthAvatar project partners.			
Questions:	Who is elaborating the mockups?	?		



Collecting, saving and sharing data from third party social networks

Use Case ID:	UC-4		
Use Case Name:	Collecting, saving and sharing data from third party social networks		
	(Facebook, Twitter)		
Use Case Owner:	USAAR Last Updated By:		
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR
Date Created:	13.05.2013	Last Revision Date:	
Description:	This Use Case is in stro	ng relationship with project	's tasks bellow:
	 This Use Case is in strong relationship with project's tasks bellow: T3.4 Methodologies to support link with external data sources:		
	Twitter and/or Facebo		
Actors:	End-User, MyHealthAv		
Trigger:	End-User accesses the section "My Social Networks" with options: • Add "Social Network Account"		
		etwork Account"	
	Delete "Social Network Account" Follow "Social Network Account"		
	 Follow "Social Network Account" Share your data (data has to be defined) to "Social Network Account" 		
Preconditions:	User has to Log-in or to create a New Account (New Avatar). Is important to mention that End-Users could have the option to create a New Account (New Avatar) with or without the linkage to the third party social networks.		
Successful End condition:			
Fail End condition:	T		
Basic Flow:	 The basic flow is: Create a New Avatar (select the option with or without the third party social networks) The flow ends here if the End-User selects the option "without the third party social networks" The flow continues if the End-User selects the option "with the third party social networks" End-User has the option to add his social network account (Facebook and/or Twitter) The account information (User Name and Password) is requested and provided The last status messages from the added social network account are shown in a separate Avatar's frame/section 		



		1		
Alternate Flows:	Alternative flows are related to the	ne available options like:		
	Edit "Social Network Account"			
	Delete "Social Network A	Account"		
	Follow "Social Network A	Account"		
	Share your data (data ha	s to be defined) to "Social Network		
	Account"	,		
Postconditions:	The postcondition is to make visib	ole (or hide) the status messages from the		
	added social network account to	other Avatars.		
Dependencies:	The only dependence is the option	n presented above, and in special, to create		
	a New Avatar with or without the	third party social networks.		
Required External	[] Data, please specify:			
Resources:				
	[] Tools, please specify:	[] Tools, please specify:		
	[x] Services, please specify: Twitter and Facebook APIs			
	[] Models, please specify:	[] Models, please specify:		
	[] Other, please specify:			
	-			
Frequency of Use:	Frequency of use could be high			
Who are the users?				
Special Requirements:	The special requirement is an advanced integration of Twitter and Facebook			
	APIs into MyHealthAvatar platform			
Assumptions:		This Use Case could serve as an advanced dissemination tool in special by End		
	Users active in third party social networks.			
Questions:	We have to identify who has the experience and skills to integrating/use			
	Twitter and Facebook APIs.			



Remote Monitoring

Use Case ID:	UC-5		
Use Case Name:	Remote Monitoring (Diabetes, blood sugar level)		
Use Case Owner:	USAAR		
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR
Date Created:	13.05.2013	Last Revision Date:	
	13.03.2013	Lust Nevision Date.	
Description:	Image source: Cont The Remote Monitorinformation from surpreferably selected End User uses a gluthis/her blood sugar the blood sugar reg	Managing Chronic Disease are at the center of ever inua Health Alliance, http://w pring tool/frame collects and pupported healthcare devices to by the Continua Health Alliance cose meter and MyHealthAvatar pularly during the day, and the transmit the measurements to	www.continuaalliance.org processes patient care hat conform to standards nce). tar platform to monitor platform reminds to check glucose meter should be
	•	ransmit the measurements to nat maintains the Avatar's long	
		events. If the saved data is uni	
	a test, the MyHealt	hAvatar platform automatical	ly generates an alert
	message.		
Actors:	End-User, MyHealth enabled)	nAvatar platform, Glucose Me	ter (Bluetooth or USB
Trigger:	End-User accesses t the access of the GI (computer or other wireless adapter or		oth or USB connection pped with a Bluetooth
Preconditions:	End-Users could have	or to create a New Account (No ve the option to create a New age to the remote monitoring	Account (New Avatar) with

Successful End condition:			
Fail End condition:			
Basic Flow:	 The basic flow is: Create a New Avatar (select the option with or without the remote monitoring devices) The flow ends here if the End-User selects the option "without the remote monitoring devices" The flow continues if the End-User selects the option "with the remote monitoring devices" End-User has the option to "Add" the monitoring device, at the 		
	 End-User has the option to Add the monitoring device, at the initial stage only a glucose meter could be added The monitoring devices parameters (Bluetooth or USB) are settled. The glucose meter starts sending data. End user has the option to visualize the collected data (to be discussed) Collected data could change the appearance of the Avatar and/or alert messages are sent if the End-User skipped a test 		
Alternate Flows:	Alternative flows are related to the available options like: Visualize collected data (blood sugar levels) Share collected data (blood sugar levels) Archive collected data (blood sugar levels) Send/Remove Reminders and/or Alerts messages		
Postconditions:	The postcondition is to make visible (or hide) the collected data (blood sugar levels)		
Dependencies:		n presented above, and in special, to create linkage to the remote monitoring devices.	
Required External Resources:	[] Data, please specify:		
	[x] Tools, please specify:	Glucose Meter with Bluetooth or USB connection	
	[] Services, please specify:		
	[] Models, please specify:		
	[x] Other, please specify: Continua Health Alliance standard		
Frequency of Use:	Frequency of use could be high		
Who are the users?			
Special Requirements:	The special requirement is an advanced integration and interoperability of Glucose Meter (Bluetooth or USB connection) with MyHealthAvatar platform		
Assumptions:	This Use Case would serve as an example of the advanced integration of the remote monitoring devices. The open access to MyHealthAvatar API would allow the developers to add more devices and solutions.		
Questions:	Who has the experience and the skills to implement Continua Health Alliance standards?		



Mobile Driven 3D Virtual Lung

Use Case ID:	UC-6				
Use Case Name:	Mobile Driven 3D Virtual Lung				
Use Case Owner:	FORTH	Last Updated By:			
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR		
Date Created:	20.06.2013	Last Revision Date:			
Description:	This use case has strong relationship with the following project's tasks:				
·	T5.1 Development of the models repository				
	T5.2 A data repository for models				
	T4.5: Semantic Reasoning for Decision Support				
	T6.1 Data collection utili	T6.1 Data collection utilities			
	T6.2 Data collection from	T6.2 Data collection from online patient diary			
	T6.3 Data repository for	health information			
	T7.1: Scenarios and use	cases for MyHealthAvatar			
	Task 8.2 Key techniques				
	Task 8.3 A visual data ar	nalysis suite			
	Moreover it is related to	o the following project obj	jectives:		
	 ICT utilities that 	t support data collection, in	ncluding web information		
	extraction and				
		itation of the avatars in mu			
		ort a body (anatomy) cente	red visualization of health		
	status data				
	Visual analytics within the ICT toolbox that offers valuable				
	information blending and analysis from heterogeneous data sources				
	Details:				
	In this use case we will capture breathing movements from lung from				
			tion using a mobile smart		
	phone. Using personaliz	zed information, additiona	Il to the acoustic breathing		
	signal, like the age, gen	signal, like the age, gender, height, and possible diseases (i.e. cancer) we will			
	use the MyHealthAvatar model to represent a 3D visualization avatar of the				
	lungs' function. This will be used in order to allow for the visual comparison				
	of the normal function or the goals of the patient. The envisaged application's				
			ent, using MyHealthAvatar		
	T = 1	or the patients which will e	encourage them to regulate		
	their breath.				
Actors:	End User & MyHealthAv	atar platform			
Trigger:	End User				
Preconditions:		smart-phone application th			
	_	component, a lung capacity	•		
		omponent. All the components are the	_		
	order to produce appropriate output including the				
	3-D animations component of the human lung moving according to the corresponding breathing movements of a specific person. Data from MHA				
	and external data source should be mapped to this component.				
Successful End condition:	and external data source should be mapped to this component.				
Fail End condition:					
Basic Flow:	Acoustic signal	recording (using mobile ph	none)		
		entation) of the acquired si			
		omputation (FVC)	.0		
	4. Classification to identify breathing movements				
	5. Visualization				
	1				

Alternate Flows:		
Postconditions:		
Dependencies:		
Required External	[x] Data, please specify:	If MHA wants to retrieve external
Resources:		information, the relevant data sources should be available and accessible
	[x] Tools, please specify:	Android/iOS development tools Mobile phone 3d visualization
	[] Services, please specify:	
	[] Models, please specify:	
	[] Other, please specify:	
Frequency of Use:	Frequently	1
Who are the users?		
Special Requirements:	A proper interface should be available	able for searching and visualizing results.
Assumptions:		
Questions:		



Mobile Lifestyle and Social media

Use Case ID:	UC-7		
Use Case Name:	Mobile Lifestyle and Social media		
Use Case Owner:	FORTH	Last Updated By:	
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR
Date Created:	20.06.2013	Last Revision Date:	
Description:	This use case has strong relationship with the following project's tasks:		
-	T6.1 Data collection utilities		
	T6.2 Data collection from online patient diary		
	T6.3 Data repository for health information		
	Task 8.2 Key techniques of	•	
	Task 8.3 A visual data ana	lysis suite	
	Moreover it is related to		
			ncluding web information
	extraction and m		det la company de la compa
	•	ation of the avatars in mu	
	status data	t a body (anatomy) cente	red visualization of health
	Status data		
	Details:		
	In this use case we aim to	create a symbiotic relati	onship of available
		•	ealthAvatar platform. The
	goal is to respond to the f	• • •	·
	technologies and services	for mobile/health applic	ations supporting wellness,
	fitness and prevention of	the most common chron	ic diseases (i.e. cardio-
	vascular and stroke, diabe	etes, rheumatic problems	, respiratory problems and
	COPD, etc.). Mobile applications will monitor user's "health-status", "lifestyle" and "wellness" and upload data to the MyHealthAvatar system for close monitoring of health conditions and prevention of many diseases. The system then will be able to analyse user's lifestyle and medical data. Special "alerts" will be applied to support end users with feedback supporting and assisting their daily activities and well-being. A social media service will be		
	used to allow the intercor		node allowing the users to
	insert information about		_
	technologies) but also wil		
	them from the system in		
	-	_	s operation, cancer patients
	_		o take advantage of mobile
	digital technology using 3		
	3. 3.		- · ·
Actors:	End User & MyHealthAva	tar platform	
Trigger:	End User		
Preconditions:	This use case will use a sn		
	social media service that will be deployed but also other MyHealthAvatar		
	enabled social media services available today.		
Successful End condition:			
Fail End condition:			
Basic Flow:			
Alternate Flows:			
Postconditions:			
Dependencies:			



Required External Resources:	[x] Data, please specify:	If MHA wants to retrieve external information, the relevant data sources should be available and	
		accessible	
	[x] Tools, please specify:	Android/iOS development tools	
		Mobile phone 3d visualization	
	[] Services, please specify:		
	[] Models, please specify:		
	[] Other, please specify:		
Frequency of Use:	Frequently		
Who are the users?		·	
Special Requirements:	A proper interface should be available for searching and visualizing results.		
Assumptions:		·	
Questions:		·	



Compile and perform a simulation using a biological model

Use Case ID:	UC-8			
Use Case Name:	Compile and perform a simulation using a biological model			
Use Case Owner:	ICCS			
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR	
Date Created:	19.06.2013	Last Revision Date:		
Description:	End-User has the GUIs, functionalities and tools in the frames of MyHealthAvatar platform to create and execute a biological simulation scenario. End-User selects one of the biological simulation models available in the Model Repository and one of the sets of clinical data available in the Clinical Data Repository (or uploads a set from his computer). Afterwards he/she executes a biological simulation. Finally he/she retrieves the results of the simulation and proceeds to their evaluation.			
	This use case has strong relationship with the following project task: T.3.5 Investigation of local cloud T.3.7 Platform integration T.5.1 Development of the model repository T.5.2 Development of the data repository for models T5.3 Integration with the security framework			
Actors:	End User & MyHealth			
Trigger:	 User accesses the section "Simulation Interface". User "clicks" on a specific area of the 3-D avatar of the human body, for example the kidney, is directly or indirectly (by a menu) redirected to the "Simulation Interface" and is guided to the proper biological simulation model/-s (for example the kidney simulation model/-s). 			
Preconditions:	 The User has to Log-in or to create a New Account (New Avatar). The option to "perform simulations using biological models" must be enabled in the user's profile. The user must have the proper access rights in order to use a biological simulation model from the Model Repository. The biological simulation model must be already imported to the Model Repository. The user must have the proper access rights in order to use a set of clinical data from the Clinical Data Repository. The clinical data that the biological simulation model needs in order to run must be already imported into the Clinical Data Repository or it must be provided (uploaded) by the user just before the start of the simulation. The clinical data must be compatible, in terms of format and content, with the selected biological simulation model. The user must have the proper access rights to a computational platform. The computational platform must have enough available resources 			
Successful End condition:	5. 46. 101 11	ne simulation to be performe		
Fail End condition:				
Basic Flow:	The basic steps are: 1. Successful Log Email and Pas	g-In (or New account creatio	n) by using Username or	



Alternate Flows:	simulations using biolog 4. The flow continues if the simulations using biolog 5. End-User creates a biolo simulation model from t the Clinical Data Reposit 6. End-User starts the simu 7. When the simulation is of displayed, either a succe 8. End-User user has the position of the simulation is of the simulation in the simulation is of the simplication is of the simulation is of the simulation is of the si	 The flow ends here if the End-User doesn't have the option "Perform simulations using biological models" enabled. The flow continues if the End-User has the option "Perform simulations using biological models" enabled. End-User creates a biological simulation scenario, by selecting a simulation model from the Model Repository and a set of data from the Clinical Data Repository. End-User starts the simulation process. When the simulation is completed, the proper ending code is displayed, either a success message or an erroneous message. End-User user has the possibility to download the results of the simulation to his computer, either the simulation ended successful or with errors. 		
	 In step 5 of the basic flow be guided by narrowing ones related to a specific 3-D representation of hu In step 6 of basic flow, E 	 In step 5 of the basic flow, the selection of the simulation model can be guided by narrowing the available simulation models to only the ones related to a specific part of the human body, by clicking on the 3-D representation of human body. In step 6 of basic flow, End-User can upload a set of data from his computer instead of using a set of data provided by the Clinical Data 		
Postconditions:				
	 The user must have the Repository. The user must have the repository. 	Repository. The user must have the proper access rights to the Clinical data repository. The user must have the proper access rights to a Computational		
Required External Resources:	[x] Data, please specify:	Clinical data (already preprocessed), ready to be used by the simulation models		
	[x] Tools, please specify:	 Model Repository Clinical Data Repository (related to simulation models) 		
	[x] Services, please specify:	 Query the Model Repository for available models. Query the Clinical Data Repository (related to biological simulation models). Copy a selected model to the computational platform. Copy a set of selected preprocessed data to the computational platform. Execute the simulation scenario (by sending a computational job to the computational platform). Retrieve the result of the 		



		execution of a simulation model.
	[x] Models, please specify:	Simulation Models
	[x] Other, please specify:	Computational Platform: Can be either a personal computer, a cloud virtual machine, a High Performance Computer (HPC) or any other system able to perform computational simulations.
Frequency of Use:	Medium frequency.	·
Who are the users?		
Special Requirements:		
Assumptions:	 The biological simulation model is already imported in the model repository. A set of clinical data compatible with the aforementioned biological simulation model is already imported in the clinical data repository. Appropriate computational resources are available for running the simulation. The security framework is responsible for controlling the access to the model repository, the clinical data repository and the computational platform. 	
Questions:	used in the MyHealthAvatar dem	n model (nephroblastoma) planned to be onstrator doesn't use proprietary software, software, like a model developed in Matlab



Manage the content of the Model Repository and the Clinical Data Repository

Use Case ID:	UC-9			
Use Case Name:	Manage the content of the Model Repository and the Clinical Data Repository			
	(related to simulation models)			
Use Case Owner:	ICCS	Last Updated By:		
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR	
Date Created:	29.06.2013	Last Revision Date:		
Description:	End-User has the GUIs, functionalities to manage the content of the Model Repository and the Clinical Data Repository (related to simulation models). This use case has strong relationship with the following project task:			
	_	T.3.7 Platform integration T.5.1 Development of the model repository		
	-	f the data repository for mo	dels	
	•	the security framework	40.3	
			led description is redundant.	
Actors:	End User & MyHealth			
Trigger:	User "clicks"	on links available in the ma	ain MyHealthAvatar web	
	interface.			
	User accesse	es the Model Repository UR	L or the Clinical Data	
	Repository L			
Preconditions:		dition applies to both Mode	el Repository and the Clinical	
	Data Repository:			
Constant Ford and Miles	The User has	s to Log-in to the interface o	of the Repository	
Successful End condition: Fail End condition:				
Basic Flow:	The following basis fl	ow applies to both Model P	anasitarias and Clinical Data	
Dasic Flow.	The following basic flow applies to both Model Repositories and Clinical Data Repository. The basic steps are: 1. Successful Log-In (or New account creation) by using Username or			
	Email and Pa	_	, , -	
	2. Manage (add, edit, upload, delete) the content of the Repository.			
Alternate Flows:	The alternative flow is:			
		_	s he/she can have access to	
		nagement interface and per	form the corresponding	
Destagnistions	actions.			
Postconditions: Dependencies:				
Required External	[] Data, please specif	·v·		
Resources:		•		
	[] Tools, please speci			
	[] Services, please sp	ecify:		
	[] Models, please spe	ecify:		
	[] Other, please spec	ifv		
Fueron est these				
Frequency of Use: Who are the users?	Medium frequency.			
Special Requirements:				
Assumptions:				
Questions:				
Questions.				



Tools for browsing medical images in avatar

Use Case ID:	UC-10			
Use Case Name:	Tools for browsing medical images in avatar			
Use Case Owner:	LIN Last Updated By:			
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR	
Date Created:	04.07.2013	Last Revision Date:		
Description:	Tools which will help t	he user to analyze medical i	mage	
Actors:	End User & MyHealth	Avatar platform		
Trigger:	User accesses the sect	ion "Tools"		
Preconditions:	User has to Log-in or t	o create a New Account (Ne	w Avatar)	
Successful End condition:				
Fail End condition:				
Basic Flow:	The basic steps are:			
	 Successful Log 	g-In (or New account creation	n) by using Username or	
	Email and Pas	ssword		
	2. Select your A	vatar		
	3. Click Enter on	the 'Tools' section and mar	nipulate the 3D Body	
Alternate Flows:	The 'Tools' section mu	st be accessible from any lo	cation of the	
	MyHealthAvatar platform.			
Postconditions:				
Dependencies:	The platform must provide library consisted by information regarding several			
	anatomy objects with 3D navigation			
Required External	[] Data, please specify	<i>y</i> :		
Resources:	[] Tools, please specif	iy:		
	[] Services, please spe	ecify:		
	[] Models, please spec	cifv:		
	[] Other, please specif	·		
	1	·		
Frequency of Use:	Frequent use is expect	Frequent use is expected		
Who are the users?				
Special Requirements:	Tools			
	Select a set of medical images within the avatar			
	Load and Browse the selected images			
	Allow zoom in/out at particular areas of the images			
		mages at corresponding par	_	
Assumptions:	To be accessible in all browsers.			
Questions:				
• • •				



Tools for the analysis of medical images in avatar

Use Case ID:	UC-11		
Use Case Name:	Tools for the analysis of medical images in avatar		
Use Case Owner:	LIN	Last Updated By:	
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR
Date Created:	04.07.2013	Last Revision Date:	
Description:	Tools which will help the	he user to analyze medical ir	nages
Actors:	End User & MyHealth	· · · · · · · · · · · · · · · · · · ·	
Trigger:	User accesses the sect	ion "Tools"	
Preconditions:	User has to Log-in or to	o create a New Account (Nev	w Avatar)
Successful End condition:			
Fail End condition:			
Basic Flow:	The basic steps are:		
		g-In (or New account creatio	n) by using Username or
	Email and Pas		
	2. Select your Av		
		the 'Tools' section and man	
Alternate Flows:	The 'Tools' section must be accessible from any location of the		
	MyHealthAvatar platform.		
Postconditions:	<u> </u>		
Dependencies:	The platform must provide library consisted by information regarding several		
	anatomy objects with 3D navigation		
Required External	[] Data, please specify:		
Resources:	[] Tools, please specify:		
	[] Services, please spe	ecify:	
	[] Models, please spec	cify:	
	[] Other, please specif	y:	
Frequency of Use:	Frequent use is expect	ed	
Who are the users?			
Special Requirements:	Tools		
	 Perform basic 	image processing, such as I	mage filtering, and
	enhancement, etc.		
	Perform segmentation of region of interests (lesions or anatomies)		
	on selected images		
Assumptions:	To be accessible in all browsers.		
Questions:			



Utilization of personal genomic information for the individualization of MHA platform

Use Case ID:	UC-12			
Use Case Name:	Utilization of personal genomic information for the individualization of MHA			
	platform			
Use Case Owner:	FORTH Last Updated By:			
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR	
Date Created:	21.07.2013	Last Revision Date:		
Description:	Our health status and all our personal traits are the outcome of the			
	continuous interaction between our genomic background and the various environmental parameters. The present use case aims at the developmen MHA technology as an individualized medicine platform by the utilization			
			ic information into health	
	medical history record. T			
	involves a number of heal	• =	-	
	services which translate g			
	and health risk estimation		-	
	pathway visualizations et			
	individualized medical ded			
	view, specification of simu		= 1	
	with guidelines for prever		erection etc., and promae	
	This use case relates to th		roject:	
	T.3.7 Platform integration		. 0,000.	
	T4.5: Semantic Reasoning			
	T.5.2 Development of the		els	
	T6.1 Data collection utiliti			
	T6.3 Data repository for health information			
	Task 8.2 Key techniques o			
	Task 8.3 A visual data ana	•		
Actors:	User, MyHealthAvatar platform, eHR, Genome Information			
Trigger:	User uploads file with genome information to MHA platform.			
Preconditions:	Inform consent should have been obtained for comprehensive genome			
			-	
	analysis and genetic counseling should be available. Further evaluation of the volunteer(s) could be considered (according to Personal Genome Project			
	criteria).			
	Personal Genome (or Exome) information at high coverage (>75%) should			
	have been obtained by Ne	-	= : :	
	MHA consortium) and at a	·	S (
	Personal genome data, bu	it with limited health rela	ited information, can be	
	downloaded from public of			
	Genomics initiatives (geno		,	
Successful End condition:	10			
Fail End condition:				
Basic Flow:	The basic (high-level) steps from the Genome information upload to the			
	creation of an individualiz			
		rison and alignment algo		
		the Human Genome Re		
	_	es, mutations and polymo		
		me. Other special algorit	•	
			rrations. Genome browser	
		•		
	tools can also be included as an option for the expert user.Identified genome variations are compared to reported Disease			
	related and Pharmacogenomic databases. Extensive lists of			



annotated variations	are generated
	pe evaluations are performed:
	m mutations related to monogenic disorders
	e than 10,000 diseases are known to be
	alassaemia, Cystic Fibrosis, Huntington's).
	es or SNPs are co-evaluated for genetic
· · · · · · · -	
	multigenic diseases (T2 diabetes, Obesity,
	pertension etc.) or protective alleles (in PCSK9
and Coronary dise	
· · · · · · · · · · · · · · · · · · ·	ic variations are identified in Phase I, II, other drug metabolism related genes.
4. Personalized Risk Gra	phs are generated presenting the current risks,
according to individua	l's epidemiological data and genotype. Re-
evaluation by compari	ison of the genetic predisposition and the
actual health status.	
5. Individual is classified	according to pharmacogenomics background
to Poor/Intermediate/	Extensive/Ultra-rapid metabolizer for various
drugs and active comp	oounds.
6. Evaluating the risks an	nd possibly considering the pharmacogenomics
background, specific, i	individualized, preventive medicine and
lifestyle counseling ca	nn be provided by experts (i.e. prescription of
Prasugrel instead of Pl	lavix for CVD in poor CYP2C19 metabolizer,
changes in fat diet and	d nutraceuticals i.e. plant sterols) according to
general guidelines.	
7. Visualization of this in	formation into the MHA platform in disease
and/or tissue specific	
	can also be implemented "off-line" using a
	atform (Partek genomics suite, Ingenuity
Systems, CLC genomics workbe platform.	ench etc.) and then introduced into the MHA
·	interested individual or "patient", the MHA
platform could provide special	
1. Mobile expert informa	ation, guidelines and suggestions about
lifestyle habits (exerci-	se, diet, food supplements) on an
individualized basis.	
2. Genetic counseling ser	rvices and awareness reports about certain
"actionable" genetic c	haracteristics and possible risks. Participation
to social networks and	d involvement in patient groups (as in UC-9:
Mobile Lifestyle and So	ocial media).
3. Capture everyday lifes	style information such as diet (fats, calorie
content, sweeteners e	etc.), health related habits (smoking etc.), work
environment (hazard a	agents etc.), exercise (distance walked etc.),
mood and physical cor	ndition, vital signals (blood pressure, sugar
levels etc.) and record	all this information together with the medical
Health Record and the	Personal Genomic Information in order to
create the most comp	rehensive health related information
	evaluation of genomic and environmental
determinants in healt	
4. Deviating from health	
_	applications, ethnic heritage information
based on mitochondri	applications, ethnic heritage information al DNA (matrilineal) and Y chromosome
based on mitochondri (patrilineal) haplogrou	applications, ethnic heritage information al DNA (matrilineal) and Y chromosome up information could be provided.
based on mitochondri (patrilineal) haplogrou Postconditions: Further directions for the utilization for t	applications, ethnic heritage information al DNA (matrilineal) and Y chromosome up information could be provided. ation of personal genomic information can be
based on mitochondri (patrilineal) haplogrou Postconditions: Further directions for the utilize the use of MHA platform as an	applications, ethnic heritage information al DNA (matrilineal) and Y chromosome up information could be provided.



Dependencies:	visualization and/or <i>in silico</i> models can be developed for: i) drug distribution to various tissues (according to pharmacokinetic measurements), ii) drug target expression and iii) individual's mutant and variant protein expression maps for those related to drug response (according to available data sources i.e. Human Protein Atlas), and iv) molecular pathways related to the particular tissues, drug target and therapy related proteins. Tissue, organ visualization tools (UC-3: Interactive 3D Model of the Human Body and UC-7: 3D Avatar Visualization and manipulation) and simulation tools (UC-10: Compile and perform a simulation using a biological model) described in other Use Cases could be utilized and further specialized in support of these further advancements of the MHA platform.			
Dependences:	that various procedures ar annotation). Specific techr predisposition gene lists) of Other existing dependenci covered in related use case	The present use case is presented as a high technical level scenario assuming that various procedures and tools are in place and operational (i.e. genome annotation). Specific technical developments (i.e. generation of predisposition gene lists) can be further elaborated as lower level use cases. Other existing dependencies, such as the availability of medical data, are covered in related use cases. (UC-1: Enter, import, store and export personal		
	medical data e.g. Electroni			
		at targeted genomic information could also be		
		ualize specific use cases such as UC-5: Remote		
	monitoring (Diabetes, bloc			
Required External Resources:	[x] Data, please specify:	Pharmacogenomics profile (DMET chip) and/or comprehensive genome or exome information (from Ion Proton HTP Sequencing platforms		
		available at IMBB-FORTH) and health records of 2-4 volunteers. Personal genome information with limited health data annotation from public sources		
	[x] Tools, please specify:	(1000genomes etc.) Genome browser and annotation: VEGA, Argo, Artemis, genome browsers Genomes unzipped, or Golden Helix Genome Browse, or		
	Integrative Genomics V Ingenuity (variant analy Genome Space tools (G DNAnexus Bioconductor (Variants			
	[x] Services, please specify:	Query databases: Annovar (biobase) The Human Gene Mutation Database Cosmic Database (human cancers) GWAS central The Cancer Genome Atlas		
	[x] Models, please	MutaBase Human Protein Atlas Pharmacodynamics and pharmacokinetics model		
	specify: for specific (demonstration) purposes. PharmGkb simCYP			
	[x] Other, please specify:	Disease-Tissue MHA Visualization tools		
Frequency of Use:		 mic information should be the basis of every A instantiation. In that sense, all platform tools		



should eventually become "individualized" utilizing and presenting genomic		
and genetic information		
Specialized Databases for providing specific disease and/or risk and/or		
lifestyle guidelines (step 6 and alternative step 2)		
Pharmacodynamics and pharmacokinetics data (step 5)		
A user friendly interface for introducing/recording everyday health and		
lifestyle information and for monitoring "biosignals" via a number of		
portable, mobile, wearable devices (alternative step 3)		
The present use case utilizes most of the available knowledge but for		
accurate risk calculations, health evaluations and therapy predictions		
detailed patho-physiological data and correlation information are needed.		
Although these are intensively gathered in a wide variety of studies,		
extensive detailed information is not yet available.		
The technical development of such a complex and high-level use case		
scenario into an individualized MHA platform is obviously demanding more		
than the available time and resources. Can the consortium identify a specific		
application (ie. blood sugar monitoring, specific drug and therapy modeling or monitoring etc.) in which there is available interest and expertise?		



Anti-platelet therapy in pre-operating period

Use Case ID:	UC-13			
Use Case Name:	Anti-platelet therapy in pre-operating period (The example of decision			
	making tool regarding emergency situations in clinical practice)			
Use Case Owner:	FORTH	Last Updated By:		
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR	
Date Created:	28/06/2013	Last Revision Date:	23/07/2013	
Description:	Hemostasis disorders can develop due to a deficiency or defect in an			
	· ·	r clotting factors. Dysfunctio		
	_	mophilia) or in over-clotting		
		ons that lead in thrombus fo		
		as cardiovascular disorders (
		tive heart failure and valve d		
		transient ischemic attacks, d ease (PVD), phlebitis and in		
		osed with over-clotting defi		
	_	latelet therapies as a preve		
		nisms (SNPs) are known rega		
		(mainly of Cytochrome P450		
	and anticoagulant ther	apies. Some well-known exa	amples are the Vitamin K	
	epoxide reductase con	nplex subunit 1 (VKORC1) wh	nere specific gene	
		elated with deficiencies in V		
	•	se to anticoagulant therapie		
		egarding metabolizing enzyr		
		etabolic enzyme for the act		
	agent clopidogrel. Clopidogrel is a pro-drug activated in the liver by cytochrome P450 enzymes, mainly CYP2C19. Genetic polymorphism (CYP2C19*2, CYP2C19*3 and CYP2C19*17) exists for CYP2C19 expression, with approximately 5% of Caucasian and 20% of Asian populations being poor metabolizers with no CYP2C19 function. Due to the above, Anti-platelet and anticoagulant agents that are administered in clinical practice appear to have a large inter-subject variability in their pharmacokinetics and thus in pharmacodynamics. Antiplatelet and anticoagulation therapies are typical examples where therapeutic drug monitoring is applied for every patient as well as pharmacogenomics information are taken into account and several			
		created in order to integrate		
		reover, there are emergency	•	
		re an adjustment in dose sh		
		tion and anti-platelet therap		
	bleeding problems dur	ing surgery or in the stage o	recovery.	
	A typical use-case scen	ario:		
		nat follows anti-platelet ther	apy, needs to go on	
		s to re-adjust the administra		
		ning surgery and wants to pe	· ·	
	soon as possible. General information are known for pre-operative care be how can the doctor avoid any guesswork and apply a personalized approa			
	for this case and possible for future patients?"			
Actors:	Avatar1(Doctor), Avatar2 (patient), (Avatar3) Research staff for in silico clinical trials platforms, genome information platform/tool, MyHealthAvatar			
Triagon	platform	notiont's alogteration beauty :-	acoud on during areation of	
Trigger:	'	patient's electronic health r	ecord or during creation of	
	patient's Avatar in MH	A piatrorm.		



	Alternative the use case can be triggered after the medical examination and			
	the decision that patient should go on surgery.			
Preconditions:	The facts that are true in this case are:			
	1. Anti-platelet therapy may lead in the appearance of bleeding in			
	the postoperative period.			
	2. Anti-platelet and anti-thrombotic agents that are administered			
	in clinical practice appear to have a large inter-subject variability			
	in their pharmacokinetics and thus in pharmacodynamics due to			
	genetic and epigenetic factors.			
	3. Anti-platelet therapy is a clinical case that personalized			
	medicine tools are essential. Therapeutic drug monitoring is			
	usually followed for the proper adjustment of the treatment			
	administered.			
	4. There are not many data available regarding the time that the			
	treatment will stop be active after the discontinuation. 5. Clinical trials regarding the above situation cannot be			
	Clinical trials regarding the above situation cannot be performed.			
Successful End condition:	performed.			
Fail End condition:				
Basic Flow:	Basic steps:			
	Gathering all the necessary data required from patients health			
	record. This step can be during the therapeutic drug monitoring			
	and dose adjustment prior to the emergency situation. Also this			
	step can be during utilization of personal genomics (Use-case			
	14)			
	2. Creating of MyHealthAvatar profile for this patient			
	3. Development of a workspace in a platform for in silico clinical trials			
	The basic things that are needed:			
	IV. Drug data regarding the pharmacokinetic and/or			
	pharmacodynamic parameters as well as for toxicity			
	V. Population data regarding demographic, genetic,			
	biochemical and physiological parameters			
	Patient's genetic data of drug-metabolizing enzymes which can influence drug concentrations in the hody.			
	which can influence drug concentrations in the body should be considered.			
	 Data for (I) and (II) could be available from literature and can be in the default parameters of the platform 			
	or can be enriched from patient's data			
	Data for (II) can be created from clustering of			
	MyHealthAvatar profiles of patients with same or			
	similar disease profile			
	VI. Clinical trial protocol and design. In this case the clinical trial			
	will need to estimate the drug concentrations in the body			
	for a period of time after the last administration (i.e. 48			
	hours after the last administration)			
	4. Simulation of virtual clinical trials in the specific "virtual population"			
	5. Embed results in an appropriate worksheet or in a different platform			
	6. Matching and identification of the Avatar from MHA with the "virtual			
	patient" from the "virtual population" of the simulated clinical trial			
	7. Identification of the time that anti-platelet's drug concentration is			
	below the minimum effective concentration			
	8. Evaluation for the time needed after the sub-therapeutic			
	concentrations of the drug in order the clotting activity to start			
<u> </u>	returning to the default values.			



	9. Evaluation of the obtained results and decision of the time that the				
	-	patient will be ready for surgery			
	10. Surgery performing and re-introduction of the anti-thrombotic				
		treatment			
		Note: This basic flow can be created during therapeutic drug monitoring of			
Alta-mata Flanca	patient's status after the diagnosis				
Alternate Flows:		if the patient is receiving treatments for			
	and/or any modulations regarding	possible evaluation of any interactions			
		ed taking into account the adding therapies			
		this patient (e.g. antibiotics, analgesics,			
	sedatives, antacids, anticoagulants				
	intravenous such as heparin etc.)				
Postconditions:		r surgery. Evaluating results and update			
		nulator platform. Re-adjust the therapy on			
	the recovery stage	, , , , , , , , , , , , , , , , , , ,			
Dependencies:		ion of drugs in emerging situations in			
•		period and for patients in intensive care			
		ple of how data can be created through in			
	silico clinical trials approaches esp	ecially in clinical cases where clinical trials			
	cannot be performed. It also tries	to represent how personalized information			
	regarding drugs, diseases and hea	Ith status information can be introduced			
	and exploited through MHA in ord	ler to create decision making tools and			
	approaches.				
	■ • • • • • • • • • • • • • • • • • • •	related with Use Cases 1, 2, 3 and 5.			
		with the Use Case 14 and utilization of			
		the individualization of MHA platform			
Required External	[x] Data, please specify:	Drug data			
Resources:		 Pharmacokinetic properties 			
		 Pharmacodynamic properties 			
		Population data			
	o Demographic				
		o Genetic			
		GeneticPhysiology			
		GeneticPhysiologyPathology			
		GeneticPhysiologyPathologyClinical trials protocols and			
		 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are 			
		 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory 			
	[v] Tools please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) 			
	[x] Tools, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed 			
	[x] Tools, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials 			
	[x] Tools, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform 			
	[x] Tools, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools 			
		 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform 			
	[x] Tools, please specify: [x] Services, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools 			
		 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools Links with databases: 			
		 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools Links with databases: Genomic databases (see use-case 14) 			
		 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools Links with databases: Genomic databases (see use-case 14) Drug databases (PharmKGB, Pubmed, 			
	[x] Services, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools Links with databases: Genomic databases (see use-case 14) Drug databases (PharmKGB, Pubmed, DrugBank) 			
	[x] Services, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools Links with databases: Genomic databases (see use-case 14) Drug databases (PharmKGB, Pubmed, DrugBank) Physiologically-Based 			
	[x] Services, please specify:	 Genetic Physiology Pathology Clinical trials protocols and parameters (as they are described in regulatory organizations FDA and EMA) PCs with related software installed regarding in silico clinical trials MHA platform Genomic platforms/tools Bioinformatic tools Links with databases: Genomic databases (see use-case 14) Drug databases (PharmKGB, Pubmed, DrugBank) Physiologically-Based Pharmacokinetic/Pharmacodynamic 			



Frequency of Use:	The in silico application of virtual clinical trials can be used in every emergency case where a following treatment may influence the post-operating recovery of a patient after surgery. The development of databases and generation of data prior to the emergency situation could be more helpful regarding the faster fitting of the patient with Avatar.		
Who are the users?			
Special Requirements:	Familiarity of doctors and generally of the medical staff with MHA technologies Linking of MHA data between research and medical organizations and personnel applying MHA technologies		
Assumptions:	Necessary drug data for the generation of the in silico clinical trials are available in the literature and easily accessed Full and detailed patient's health history record Platforms used for in silico clinical trials have been evaluated with clinical results from other studies (Validity of the platform) Continuous development and simulation of clinical trials from in silico platforms in order to create databases for patient's avatar fitting		
Questions:	The new era in health care towards the "stratified medicine" and personalization of treatment demands the development of approaches and tools such as MHA platform. The question that rises is how an education program could be introduced for medical society (especially staff that work in the point of service such as hospitals etc.) in order to get familiar with user-friendly platforms and tools and also stay up to date with these approaches?		



Multi-scale visualization of biomedical data

Use Case ID:	UC-14					
Use Case Name:	Multi-scale visualization of biomedical data					
Use Case Owner:		FORTH Last Updated By:				
Technical Collaborators:	TBD		Clinical Collaborator:	USAAR		
Date Created:	25.07.2	013	Last Revision Date:			
Description:			nges for MyHealthAvatar is	the interactive visualization		
	which togethe going fr comput 3D+t).	of multi-scale biomedical data. The typical data will be a 3D+time dataset of which multiple instances at different scales will have to be displayed together. Information will be on very different spatial and temporal scales going from the molecule up to body level, in different forms (medical images, computer models, signals etc.) and of heterogeneous dimensionality (2D, 3D, 3D+t).				
			o the following tasks of the pand rendering suite	noject.		
		_	visual analysis			
		risual data anal	· · · · · · · · · · · · · · · · · · ·			
	"Visual	representation		r geometries and colours to		
	disease followir 1.	used to look for the presence of a specific gene that has been identified as a risk factor for Alzheimer's disease. Urinalysis tests detect abnormalities, such as improper levels of sugar or protein. 4. Lumbar puncture/spinal tap is a procedure in which the fluid surrounding the spinal cord is withdrawn through a needle and examined in a laboratory. This test can help your doctor diagnose disorders of the central nervous system. 5. Computed tomography (CT) scan creates a series of cross-sectional "slices" of the body. CT scans often can reveal certain changes that are characteristic of Alzheimer's disease in its later stages.				



Γ	7		
	with Alzheimer's disease. 7. Electroencephalography (EEG) measures brain function by analyzing the electrical activity generated by the brain. This activity is measured through special electrodes applied to the scalp. It is most helpful in identifying disorders that can mimic Alzheimer's disease. 8. Electrocardiogram (ECG or EKG) is a recording of the heart's electrical activity, showing the heart's rate and rhythm. In addition, the following tests also might be done to help diagnose and		
	monitor the progression of Alzheimer's disease: Neuropsychological testing, Positron emission tomography (PET) scan, Single photon emission computed tomography (SPECT) scan and Magnetic resonance spectroscopy imaging (MRSI).		
	Considering that Alzheimer is a chronic disease, the above multi-level medical data will exhibit a strong dynamic and temporal nature. Interactive multi-scale visualization is necessary for supporting data reasoning and search. This will offer a useful input to doctors and will help them to carry out personalized healthcare. A first step target multi-scale visualization is the use of different markers on the avatar, presenting the existence and the location of available datasets on different levels, from molecule to body level.		
Actors:	End User & MyHealthAvatar platform		
Trigger:	User accesses the Avatar		
Preconditions:	User has to Log-in Biomedical data have been imported to the platform for the specific avatar.		
Successful End condition:			
Fail End condition:			
Basic Flow:	 Select the avatar. The visual markers are presented on the avatar, indicating the available datasets on different locations of the body. Mouse over a marker, a popup window with basic information for the specific dataset is presented. Click on a desired marker and a navigation window is opened. The navigation window presents the complete description of the dataset and a list of all available children datasets. Navigate on different levels (from body to molecule level and reverse) by clicking on the corresponding datasets icons on the navigation window. For temporal multi-scale data, the representation is obtained by 		
	 "animating" the visualization over the time. Each frame displays the value of each parameter at a given time point (e.g. predictive models). For spatial multi-scale data, user can configure multiple views of the same dataset. The user can move from one scale to other by clicking on the visual markers, which show the presence of lower scale data. 		
Postconditions:	-		
Dependencies:	Dependencies are related to UC 1, UC 3, UC 5, UC 7		
Required External Resources:	[x] Data, please specify: Medical Data		
	[] Tools, please specify: [] Services, please specify:		
•	<u> </u>		



	[x] Models, please specify:	3D Models of the human body	
	[] Other, please specify:		
Frequency of Use:	Frequently		
Who are the users?			
Special Requirements:			
Assumptions:	User friendly interface, accessible by all browsers		
Questions:			



Bidirectional linkage to ObTiMA

Use Case ID:	UC-15			
Use Case Name:	Bidirectional linkage to ObTiMA			
Use Case Owner:	USAAR Last Updated By:			
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR	
Date Created:	02.08.2013	02.08.2013 Last Revision Date:		
Description:	ObTiMA, an ontology-based clinical trial management system, has been developed as a proof-of-concept application to highlight the possibilities of ontology based creation and managing of clinical trials within the ACGT (Advancing Clinico-Genomic Trials on Cancer) project. ObTiMA has a modular architecture with a core basic module for data management of clinical trials. Different other modules are under development in the frames of p-medicine project. The data stored in ObTiMA are relevant for the Health Avatar to enhance the system with relevant clinical trial data. On the other hand the info stored in			
	upload from MHA to O the bilateral linkage be Operational Data Mod	bTiMA is needed. This etween ObTiMA and Mi el (ODM).	As result, the bidirectional data Scenario / Use Case describes HA by being focused on the	
Actors:	Patients and healthcar			
Trigger:		second trigger interfac	atients with an account in ce is required for healthcare MA platforms.	
Preconditions:	The major precondition is the presence of the confirmed accounts in two platforms (MHA and ObTiMA)			
Successful End condition:	Successful data exchan	ige		
Fail End condition:	Failed data exchange			
Basic Flow:	The basic steps are:			
Alternate Flows:				
Postconditions:	Data export/import co	nfirmation		
Dependencies:	Presence of data export/import frameworks in two platforms (MHA and ObtiMA)			
Required External Resources:	Health Avatar with clini		with filed in data from ObTiMA th Avatar with clinical trial ed data (i.e. laboratory results, operative state, etc.)	
	[x] Tools, please specify: ObTiMA platform			
	[] Services, please spe	cify:		
[x] Models, please specify: The Operational Data Models is designed to facilitate to and interchange of the model of the				
			cted from multiple sources.	
	[] Other, please specif		cted from multiple sources.	



to be validated?	user frames.	
Frequency of Use:	Frequent in case of enrolment in clinical trials	
Who are the users?	Healthcare professionals and Patients enrolled in clinical trials.	
Special Requirements:	Export/ import interfaces in both platform according to CDISC ODM standard	
Assumptions:		
Questions:		



Consultation Scenario: Interaction between the patient and physician

Use Case ID:	UC-16			
Use Case Name:	Consultation Scenario: Interaction between the patient and physician			
Use Case Owner:	USAAR Last Updated By:			
Technical Collaborators:	TBD	Cli	nical Collaborator:	USAAR
Date Created:	02.08.2013	Las	t Revision Date:	
Description:	The MyHealthAvatar system can be used for direct interaction between the patient and the physician. Such an interaction might provide the following functionalities: 1. Making appointments with the physician 2. Asking questions to the physician 3. Giving advice to the patient by the physician			
Actors:	Patients and	healthcare pro	ofessionals	
Trigger:	-	_		nterface and selects his/her ed healthcare professionals
Preconditions:	registrations	in the frames	professionals should of MHA platform.	
Successful End condition:	consultation	interface	nnd to select his/her p	
Fail End condition:	The patient is consultation		nd and to select his/h	ner physician from the
Basic Flow:	 The basic flow is: patient finds and selects his physician from consultation interface the option to write a message and/or invite to view his/her Avatar is given patient specify his request with possibility to attach (or provide the access) to his/her avatar the notification message is sent to the selected physician the selected physician is receiving a related notification with ability to access all additional provided information (patient avatar) or with possibility to request more information a feedback message is sent back to the patient all sent/received messages are stored with possibility to access or delete them 			
Alternate Flows:	Alternative flows could be available in case if patient is requesting any information from his/her physician by visualizing the 3D avatar. Vice-versa flow as well should be possible (healthcare professional is asking questions to his patient or is requesting the access to his avatar)			
Postconditions:				
Dependencies:	 Many dependences are in place, end users should be able to: create accounts to visualize the avatar; access the avatar with related healthcare data; share their data and/or avatar. 			
Required External	[x] Data, plea	se specify:	Avatar	with healthcare related data
Resources:	[] Tools, pleas [] Services, p [] Models, pl	lease specify: ease specify:		
How this use-case is going to be validated?	[] Series, piece			



Frequency of Use:	Frequent			
Who are the users?	Healthcare professionals and patients			
Special Requirements:	Advanced end-users usability frames should be implemented			
Assumptions:				
Questions:				



Patient Diary

Use Case ID:	UC-17				
Use Case Name:	Patient Diary				
Use Case Owner:	USAAR	Last Updated By:			
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR		
Date Created:	02.08.2013	Last Revision Date:			
Description:	An interface for patients writing a diary is very helpful to collect patient specific data related to their disease. This can be partly structured: e.g. body weight, heart rate, blood pressure, temperature, medicine taken, etc. It can also include structured data of scoring systems, e.g. physical and/or psychological and/or emotional status. In addition free text entry needs to be allowed.				
Actors:	MHA platform end-use	ers (patients)			
Trigger:					
Preconditions:	Confirmed registration	and the access to the	Diary interface		
Successful End condition:	Access Diary interface				
Fail End condition:	No access to Diary inte	erface			
	 The basic steps are: Successful Log-In (or New account creation) by using Username or Email and Password Select your Avatar Click Diary section from your Avatar The Diary interface is shown with ability to enter and or visualize data by date, week, month, year. End User has the option to select any date or any diary entry with possibility to update it (in case of updates the update date is shown) Some diary entries could be in linkage with avatar appearance. End User has the option to "Edit", "Save", "Print" or "Share" the Diary info. 				
Alternate Flows:	Alternatively flows are accessible from any pa	•	to have the Diary interface		
Postconditions:	accessible from any pa	ge of Mina platform.			
Dependencies:	Diary structured data (or minimum data set sh	ould be specified		
Required External Resources:	[x] Data, please specify	/: Diary data	structured data or minimum set		
	[x] Tools, please specif	·	rt tools from other patients systems could be required		
	[] Services, please spe	cify:			
	[] Models, please specify:				
	[] Other, please specify:				
How this use-case is going to be validated?	By project partners an	d end-users			
Frequency of Use:	Frequently in special case of patients with chronic conditions				
Who are the users?	Patients as end-users of	of MHA platform			
Special Requirements:					
Assumptions:					
Questions:		<u> </u>			



Patient Devices SDK

Use Case ID:	UC-18				
Use Case Name:	Patient Devices SDKs				
Use Case Owner:	USAAR Last Updated By:				
Technical Collaborators:	TBD	Clinical Collabor	rator:	USAAR	
Date Created:	02.08.2013	02.08.2013 Last Revision Date:			
Description:	Today many different devices are available that collect data, e.g. blood pressure, heart rate, blood glucose levels, etc. The approach for direct storage of these data in MHA is possible by implementing an advanced Patient Devices Software Development Kit (SDK or "devkit"). A SDK will represent a set of software development tools that will allow healthcare professionals the creation of applications for MHA able to access and store data from any patient monitoring device. Patient Devices SDK may be something as simple as an application programming interface (API) in the form of some files to interface to a				
	particular programming language or include sophisticated hardware communicate with MHA platform. SDK may also include sample code supporting technical notes or other supporting documentation to he points from the primary reference material.				
Actors:	IT professionals	•			
Trigger:	IT professionals may	request the access	to MHA Al	PI interface	
Preconditions:	IT professionals should register and provide some basic registration information.				
Successful End condition:	IT professionals have	the access to MHA	API		
Fail End condition:	IT professionals do n	ot have the access t	to MHA AP	1	
Basic Flow:	No flow is available, important is to develop from the very beginning the MHA platform with related API frames/functionalities				
Alternate Flows:	•	·			
Postconditions:	With access to MHA API software developers will be able to elaborate any services and software able to connect to avatars and store patient data from any device.				
Dependencies:	The MHA platform is proposed for implementation as a web-based API layer. It could include a web application that provides an explorer type UI for the MHA platform as well as being the key middleman web based authentication. This environment (API framework) will enable all interested software developers to create a comprehensive suite of functionalities that will leverage MHA core capabilities.				
Required External	[] Data, please specif	y:			
Resources:	[] Tools, please spec	ify:			
	[] Services, please sp	ecify:			
	[] Models, please spo	ecify:			
	[x] Other, please specify: Java Programming Language Application Programming Interfaces (APIs)				
How this use-case is going to be validated?	By project partners (T professionals)			
Frequency of Use:	Frequently in case of	API presence			
Who are the users?	IT professionals and (indirectly) all MHA end-users				
Special Requirements:					



Assumptions:	
Questions:	



Search for Similar Patients

Use Case ID:	UC-19					
Use Case Name:	Search for Similar Patients					
Use Case Owner:	USAAR	Last Updated I	3v:			
Technical Collaborators:	TBD	Clinical Collabo		USAAR		
Date Created:	02.08.2013	Last Revision D				
Description:	This Scenario / Use Ca	se describes the	search frai	nework from end-users'		
-	perspective and it is for	ocused on listing	all MHA re	gistered end-users with		
	ability to apply advan	ced search filters:				
	• Age					
	 Gender 					
	 Votes (Likes) 					
	 Treatment 	Treatment				
	 Symptom 					
	 Interests 					
	 Country 					
	• City					
	• etc.					
	•	•		ould confirm the possibility		
	be visible in search re		privately.	Only public profiles should		
	be visible ill search re	suits.				
	Additionally the sear	ch function is sug	gested to h	pe accessible only for end-		
	users with public prof	_	Bested to t	oc decessible only for end		
	accio intili pacilio pi ci					
	For an example of adv	anced search filt	ers, please	visit		
	•	http://www.patientslikeme.com/patients				
Actors:	Patients and other end-users of MHA platform					
Trigger:	User search for patients (other end users).					
Preconditions:		Confirmed MHA end-user profile should be in place (preferably) with				
	confirmation to visual	ize his/her profile	e publically	<i>'</i> .		
	The maintain and a second	and an and Eller				
	The minimum suggested search filters are:					
		• Age				
		• Gender				
	Votes (Likes)Treatment					
	• Symptom					
	Interests					
	• Country					
	• City					
Successful End condition:	Similar patients are fo	und				
Fail End condition:	No similar patients are					
Basic Flow:	No flow is available, important is to develop from the very beginning the					
	MHA platform with related API frames/functionalities					
Alternate Flows:						
Postconditions:	none					
Dependencies:	UC-2					
Required External	[x] Data, please specif	[x] Data, please specify: End user generated data.				
Resources:						
	[x] Tools, please speci	ty:	Advance	d semantic search		
	[x] Tools, please speci	fy:	Advance	d semantic search		



		interfaces.
	[] Services, please specify:	
	[] Models, please specify:	
	[] Other, please specify:	
How this use-case is going		
to be validated?		
Frequency of Use:	Frequently	
Who are the users?	All MHA platform end-users	
Special Requirements:	Presence of end-user generated data	
Assumptions:		
Questions:		



Knowledge Discovery

Use Case ID:	UC-20			
Use Case Name:	Knowledge Discovery			
Use Case Owner:	USAAR	Last Updated By	y:	
Technical Collaborators:	TBD	Clinical Collabor	rator:	USAAR
Date Created:	02.08.2013	Last Revision Da	ate:	
Description:				
Actores	ResearchGate, http://www.researchgate.net All MHA platform's end users			
Actors:	·		basad /tava	namy) (Table of Content)
Trigger:	Click on search button and/or ontology based (taxonomy) 'Table of Content'			
Preconditions:	End user has to have a confirmed MHA profile MHA platform has to have the access to external and/or local databases with publically available data (PubMed, Clinical Trials, News, etc.)			
Successful End condition:	Personalized search re according available tax	conomies.		sibility to refine them
Fail End condition:	No search results or no			
Basic Flow:	The basic steps are related search text fields and s		nteractions	s with search button,
Alternate Flows:	Alternative flows could be available in case of clicks to 3D Avatar body and the presentation of the available search results.			
Postconditions:	Search results could be saved			
Dependencies:	This use case extends all ontology related Scenarios / Use Cases			
Required External Resources:	[x] Data, please specify: [x] Tools, please specify: PubMed Repository, Clinical Trials information, news articles, etc. [x] Tools, please specify: Text mining tools; Apache			
			full-feature	I) is a high-performance, ed text search engine; ull-lifecycle open source



		solution for text processing	
	[x] Services, please specify:	OpenCalais Web Service will allow to automatically annotate the content with rich semantic metadata	
	[x] Models, please specify:	Semantic data model	
	[x] Other, please specify:	Advanced ontologies and taxonomies	
		(i.e. Gene Ontology (GO), Medical	
		Subject Headings (MeSH))	
How this use-case is going	Test of the Implemented search interfaces (KD module)		
to be validated?			
Frequency of Use:	Frequent		
Who are the users?	All MHA platform's end users		
Special Requirements:	Needs for proprietary search algorithms and the contribution of high skilled and experienced semantic and/or data mining experts would be required.		
Assumptions:	Term extraction experience from external data (PubMed abstracts, Clinical		
	Trial, News articles) and semantic benchmarking with GO and MeSH would be required.		
Questions:			



Building patient community among users

Use Case ID:	UC-21		
Use Case Name:	Building patient community among users		
Use Case Owner:	BED	Last Updated By:	
Technical Collaborators:	FORTH, ICCS, LIN, ANS	Clinical Collaborator:	USAAR
Date Created:	14.08.2013	Last Revision Date:	
Description:	The avatar system offers an ideal platform for interaction and communications among patients. They will be able to: • Find patients with similar condition, symptom and treatments • Find out symptoms and treatment for their conditions by looking at other fellow patients • Find out possible conditions for their symptoms by looking at other fellow patients • Find out possible treatments for their conditions by looking at other fellow patients		
Actors:	Patients		
Trigger:			
Preconditions:	Users need to have their	avatar accounts	
Successful End condition			
Fail End condition			
	 Upon successful Log-In (or New account creation) by using Username and Password, users will be able to carry out search among all the users of the avatar system for the following purposes: Search for patients with specific conditions, symptoms and treatments Find out symptoms and treatments for specific conditions Find out conditions from specific symptoms. Search for treatments for specific conditions 		
Alternate Flows:			
Postconditions:			
Dependencies:	Users need to have their	user account in the avata	ar system
Required External	[] Data, please specify:		
Resources:	[x] Tools, please specify:	Web service to	ools (in Java)
	[x] Services, please specify: Citizens who will use the avatar system for communication with other fellow patients.		
	[] Models, please specify		
	[] Other, please specify:		
How this use-case is going to be validated?	Usability test from users	,	
Frequency of Use:	Frequently		
Who are the users?	Citizens		
Special Requirements:			
Assumptions:			
Questions:			



Avatar Data Browse

Use Case Owner: E Technical Collaborators: F	BED					
Technical Collaborators: F			Avatar Data Browse			
		BED Last Updated By:				
	FORTH, ICCS, LIN, ANS	Clinical Collaborator:	USAAR			
Date Created: 1	14.08.2013	Last Revision Date:				
i	Upon log in to their own account, users will be able to browse their own data, including all the personal health status data collected through the avatar system, plus medical records and clinical data from the hospitals					
	The avatar system will need and search, such as filtering		ort effective data query			
ā	The 4D avatar will play an in able to select individual parto the selected parts.	•	_			
ā	Different colours or texture avatar to represent their he problem it will be highlight	ealth status. For example	e, if the heart has a serious			
	Citizens					
Trigger:						
C S	Users will need to sign up to the system, accept all the legal terms, and log onto the system, personal data (health, lifestyle, lab, clinical trial data etc.) should already be available on the MHA platform or user should be able to extract it from PHR or EHR etc					
	A smooth browse of all dat					
Fail End condition	Users fail to retrieve data t	hey need				
Basic Flow:	The basic steps are: 8. Successful Log-In (or New account creation) by using Username and Password 9. Use user interface (menus, dialog boxes etc). to see data 10. Allow to use filters for data filtering 11. View health status through the colours/textures of the 4D avatar					
Alternate Flows:	12. Click on individual parts of the avatar to view relevant data					
Postconditions: E	Browsing data is a fundame that require data informati	on				
-	Browsing data is a fundame that require data informati		ers to perform operations			
-	[x] Data, please specify:	· · · · · · · · · · · · · · · · · · ·	data and other publicly			
Resources:	[] -		lata from the web			
	[x] Tools, please specify:	Web servio	ce tools (Java)			
	[] Services, please specify:					
[[] Models, please specify:					
]	[] Other, please specify:					
How this use-case is going to be validated?	The feedback from the public (citizens)					
Frequency of Use:	Frequently					
Who are the users?	Citizens					
Special Requirements:						
Assumptions:						
Questions:						



Avatar Data Collection

Use Case ID:	UC-23				
Use Case Name:	Avatar Data Collection				
Use Case Owner:	BED	1000			
Technical Collaborators:	FORTH, ICCS, LIN, ANS	Clinical Collaborator:	USAAR		
Date Created:	14.08.2013	Last Revision Date:			
Description:	This case explores various ways for the data collection in the avatar to monitor users' health-status, lifestyle and wellness. These include:				
	 Web interface for data entry Sensors (e.g. blood pressure, heart rate, locations) Mobile apps Eletronic cards from daily life (e.g. shopping cards, gym cards, credit cards) Computer social network (e.g. Twitter, facebook, Internet forums) 				
	monitor his/her blood su Avatar's long-term histor saved data is unusual, or	For example, users uses a glucose meter and MyHealthAvatar platform to monitor his/her blood sugar levels. The data is saved that maintains the Avatar's long-term history and looks for possible abnormal events. If the saved data is unusual, or the End-User skips a test, the MyHealthAvatar platform automatically generates an alert message			
	Mobile apps will be used mood, feeling).	to monitor the health st	atus of the users (e.g.		
	We will also explore the possibility to extract health related information from electronic cards (e.g. purchase of food and drink, daily exercises in gyms), as well as from social network.				
Actors:	Citizens				
Trigger:					
Preconditions:	Users need to have their	avatar accounts			
Successful End condition:	Data collection without r	much effort from users			
Fail End condition:	Data collection that need	ds a lot effort from users			
Basic Flow:	The basic steps are:				
	For manual data entry:				
	 Successful Log-I 	n (or New account creati	on) by using Username		
	and Password				
	 Enter data from 				
	For automatic data colle				
		eed to register their avat			
		network account, electro			
			e automatic data collection		
Alta-mata Ela-	The data will go	into the avatar automat	ically		
Alternate Flows:	The determination of the state				
Postconditions:	The data will be key to all the activities in the avatar system				
Dependencies:	Users need to have their user account in the avatar system				
Required External Resources:	[] Data, please specify:				
nesources.	[x] Tools, please specify: Information extraction tool (Apache, Gate, etc.), mobile (Android), Twitter and Face APIs				
	[x] Services, please speci	•	vill use these data tools to automatically		



		collect data in their avatars.		
	[] Models, please specify:			
	[] Other, please specify:			
How this use-case is going	These will be validated from the users of the avatar system			
to be validated?				
Frequency of Use:	Frequently			
Who are the users?	Citizens			
Special Requirements:				
Assumptions:				
Questions:				



Knowledge Avatar

Use Case ID:	UC-24			
Use Case Name:	Knowledge Avatar			
Use Case Owner:	BED	Last Updated By:		
Technical Collaborators:	FORTH, ICCS, LIN, ANS	Clinical Collaborator:	USAAR	
Date Created:	14.08.2013	Last Revision Date:		
Description:	The avatar will be used as a means for presenting general medical knowledge to the citizen users. Users will be able to select individual parts and see related medical information such as anatomy.			
Actors	The information may also Citizens	include medicine and it	Jou.	
Actors:	Citizens			
Trigger:	Hanna will mand to sing we		U the classification and last	
Preconditions:	Users will need to sign up	to the system, accept a	if the legal terms, and log	
Cussessful Fund coundition	onto the system Users get information the	nu nood		
Successful End condition Fail End condition		•		
Basic Flow:	Users fail to get informat The basic steps are:	ion they need		
	 Successful Log-In (or New account creation) by using Username and Password Click on individual parts of the avatar to view associated medical information, including anatomical functions, relevant medicine/food. 			
Alternate Flows:				
Postconditions:				
Dependencies:	Users need to have their	user account		
Required External Resources:	[x] Data, please specify:		d health knowledge rom the Web.	
	[x] Tools, please specify:	Web service	e tools (in Java)	
	[x] Services, please specif	y: For citizens	s to get general health and owledge	
	[] Models, please specify:			
	[] Other, please specify:			
How this use-case is going to be validated?	The feedback from the pu	ublic (citizens)		
Frequency of Use:	Frequently			
Who are the users?	Citizens			
Special Requirements:				
Assumptions:				
Questions:				



Web Login

Use Case ID:	UC-25			
Use Case Name:	Web Login			
Use Case Owner:	BED Last Updated By:			
Technical Collaborators:	FORTH, ICCS, LIN, ANS	Clinical Collaborator:	USAAR	
Date Created:	14.08.2013	Last Revision Date:		
Description:	Users (citizens) will be able to log onto the system using their username and password. New users will be able to sign up to the system by creating basic personal information including security questions. Informed consent and privacy: Users will need to accept the privacy policy and the "terms and conditions" of using the MyHealthAvatar platform. Upon log into the system, users will be able to enter, browse their data, explore medical information, communicate with other fellow patients. Users will be able to view and interact with an avatar - a 3D representation of the human body. It will allow the End User to click with the computer mouse on a particular part of the avatar "body" to trigger a search of medical records to retrieve relevant information.			
Actors:	Citizens and patients			
Trigger:				
Preconditions:				
Successful End condition	Successful log in			
Fail End condition Basic Flow:	Fail to log in or register The basic steps are:			
	 After press a sign up button, new users will provide basic information (user name, age, gender etc.) and some security questions. They will also have to accept the privacy policy and the "terms and conditions" of using the MyHealthAvatar platform. Upon log in, users will be able to see the system menu, a visual avatar (presented in 4D form). Users will be able to perform operations described in all the other use cases. 			
Alternate Flows:				
Postconditions:	Users will be able to perform all the operations described in all the other use cases			
Dependencies:	This will be the basic step fuse cases	or all the operations des	cribed in all the other	
Required External	[] Data, please specify:			
Resources:	[x] Tools, please specify:	Web service	e tools (in Java)	
	[] Services, please specify:			
	[] Models, please specify:			
	[] Other, please specify:			
How this use-case is going to be validated?	The feedback from the pub	lic (citizens)		
Frequency of Use:	Frequently			
Who are the users?	Citizens			
Special Requirements:				
Assumptions:				
Questions:				



Brain Trauma

Use Case ID:	UC-26			
Use Case Name:	Brain Trauma			
Use Case Owner:	BED	Last Updated By:		
Technical Collaborators:	LIN	Clinical Collabora		BED
Date Created:	20.08.2013	Last Revision Dat	e:	
Description:	A pre-injury clinical profile of patient is a critical aide that can help the clinicians by providing a better insight and possibly improve the clinical outcomes. Individualized treatment and targeted therapies based on patients' data are imperative both from the patients' perspective and also from the clinicians point of view and can ensure more promising outcomes and better disease prediction and prevention. A clinical phenotype of the patient has to be developed based on pre-injury characteristics. The clinical and neurological findings can be combined with image features from CT scans to develop a prognostic model for traumatic brain injuries (TBI).Related studies show that prognosis after TBI is strongly correlated to the medical history of the patient and characteristics like age, alcoholism, drugs, cardiac problems, liver dysfunction, diabetes and renal impairment can affect the treatment regimen and morbidity and mortality. The data repository available within MyHealthAvatar can allow researchers develop mathematical and computational models based on gender, race, ethnicity categories, age, lifestyle, education and medical data and this can			
	significantly contribut		itticare p	ractices.
Actors:	Doctors and patients		nts	
Trigger:	Prognosis is needed for			atuma a an al ima a a
Preconditions:	The availability of den	nograpnic data, ciin	iicai pnen	otypes and image
Successful End condition:	phenotypes			
Fail End condition:				
Basic Flow:	The basic steps include:			
	 The patient share their avatar data with the doctors The doctor accesses the demographical data of the patient The doctor accesses the clinical and image data of the patient from the hospital system (e.g. PACS) The doctor assesses the patient using a prognosis model 			
Alternate Flows:			-	
Postconditions:	A treatment plan is dr	awn		
Dependencies:	_		-	nd their medical history
	and other characteristics data are available in their avatars.			
Required External Resources:	[x] Data, please specif			udies on patient cohorts,
	such as CRASH [x] Tools, please specify: Prognosis models and data mining tools			
	[x] Services, please specify: Provide prognosis for head injury patients			
	[] Models, please specify: Prognosis models			
	[] Other, please speci	fy:		



How this use-case is going By experts with clinical background in BED	
to be validated?	
Frequency of Use:	When a prognosis is needed for head injury patients
Who are the users?	Doctors and patients
Special Requirements:	
Assumptions:	
Questions:	



Personalised CHF Risk Analysis

Use Case ID:	UC-27		
Use Case Name:	Building personalized CHF related risk profiles and "real-time monitoring" services		
Use Case Owner:	FORTH	Last Updated By:	Vangelis Sakkalis
Technical Collaborators:	TBD	Clinical Collaborator:	USAAR
Date Created:	28/06/2013	Last Revision Date:	31/07/2013
Description:	A major challenge related to caring for patients with chronic conditions is the early detection of exacerbations of the disease that may be of great significance. The dedicated clinical personnel should be contacted immediately and possibly intervene in time before an acute state is reached, by changing medication, or any other interventions, in order to ensure patient safety. There is a need to support real-time remote monitoring of patients diagnosed with congestive heart failure and MHA, enhanced with semantic technologies, may host personalized, accurate and up-to-date clinical information. In order to tailor the proposed system to the patient's profile and assist physicians in selecting people who are predisposed by coronary disease, hypertension, or valvular heart disease; we build a CHF related risk profile based on a risk appraisal function that is based on the Framingham Heart Study (486 heart failure cases during 38 years of follow-up). The predictors used are based on Age, Coronary heart disease and Valve disease status provided by the patient Electronic Health Record (EHR), as well as on HR, on		
Actors: Trigger:	blood pressure and on Body Mass Index (BMI) provided by the pulse - oximeter, the blood pressure monitor and the weight scale respectively. The calculated risk probability may be used to alter the default threshold values (higher risk probability adds more constraint on the physiological patterns). Avatar1(Doctor),Avatar2 (patient) Upload of patient's physiological and imaging data and past diagnosis in patient's electronic health record or during creation of patient's Avatar in		
		e case can be triggered after the case can be triggered after the camination and confirmed with	
Preconditions:	Heart failure is caused by any condition, which reduces the efficiency of the myocardium, or heart muscle, through damage or overloading. As such, it can be caused by a diverse array of conditions, including myocardial infarction (in which the heart muscle is starved of oxygen and dies), hypertension (which increases the force of contraction needed to pump blood) and amyloidosis (in which protein is deposited in the heart muscle, causing it to stiffen).		
Successful End condition:			•
Fail End condition:			
Basic Flow:	Dependend 2. Creating of 3. Real-time p possible de	all the necessary patient data (cies). MyHealthAvatar profile for the patient data updates (if possible viations from normal values.	is patient
Alternate Flows:			are not provided in full.
Postconditions:	Alternative flows will be followed if patient data are not provided in full. Remote monitoring of patient health status after diagnosis. Risk assesment and update data in MHA.		
Dependencies:		nctionality the following devic	e and technologies should be



	 Wireless or wearable medical devices and sensors acquiring patient's vital signs. In our reference implementation the supported measurements are: Blood Pressure5 (BP), SpO2, Heart Rate (HR), body weight and 12-lead ECG monitoring. Monitoring application recording the aforementioned bio signals and hosting risk assessment algorithms to enable the alerting process. A full description of this application as applied in a clinical environment is described in. Ontology-driven application intelligence capable of reasoning on the patient data. 		
Required External Resources:	[x] Data, please specify:	Patient Electronic Health Record (EHR)	
	[x] Tools, please specify:	Server PC hosting the risk assessment algorithm. Smartphone if remote monitoring is to be used. MHA platform	
	[x] Services, please specify:	Links with EHR and PACS	
	[x] Models, please specify:	Risk Assessment model	
	[x] Other, please specify:	Normal values are provided in general and/or specific population	
How this use-case is going to be validated?			
Frequency of Use:	The proposed application can be used even in real time or selected time intervals, depending on the patient's initial diagnosis.		
Who are the users?			
Special Requirements:	Familiarity of doctors and generally of the medical staff with MHA technologies Linking of MHA data between research and medical organizations and personnel applying MHA technologies		
Assumptions:	 Some basic assumptions are: Necessary physiological and clinical data to run the model. Full and detailed patient's health history record. Monitoring Devices/ Sensors, if available. 		
Questions:			



Diabetes

Use Case ID:	UC-28		
Use Case Name:	Diabetes		
Use Case Owner:	BED	Last Updated By:	
Technical Collaborators:	BED	Clinical Collaborator:	BED (doctor), LIN (GP)
Date Created:		Last Revision Date:	
Description:	Diabetes is the world's fastest growing disease with substantial costs at individual and social economic level. Healthcare professionals ask patients with diabetes to carry out many self-care behaviours. These include dietary change, exercise, regular self-medication, insulin injection, self-monitoring of blood glucose, insulin dose adjustment, regular attendance at clinic and for screening programmes. Self-management means that people can take a more active role in decisions about their own treatment and about healthy lifestyle. It is a shared responsibility between individuals and service provider and the service providers recognise the individual's role in managing their health and well-being. Evidence suggests that assisting people in self-manage can result in significant gains in health status, increased symptom control, reduced use of general practitioners and reduced admissions to hospital. However, expected good behaviours of patients are often not achieved in practice, despite their value being well understood so far. The avatar system will support the storage the behaviours and daily activities of patients. The platform will function as a supportive environment from healthcare providers to the patients by means of offering		
	promotion.	assessments; and by means	or anowing for ficaltif
Actors:	Doctors and patients		
Trigger:			
Preconditions:			
Successful End condition			
Fail End condition	-		
Basic Flow:	Patient Diary patients and lifelogging, we behaviours of diet, quality of alcohol, smoke used to display interpretation the system, the movements, of the life interventions shared decision doctors will be between the "Behaviour pexpected to in calorie intake".	ent through the avatar system: Storage and management their behaviours. This will rehich will monitor a wide rand the patients, including their of life, environment, mood, liking, and other symptoms, early individual/aggregated date of the data from the patienthe users can easily send quediet, etc It allowing for multi-modal in on manner between the document of the treatment are scription" will be issued by include a set of targets in termination and energy consumption, eallowing for the progress review patient diary with the behavior of the progress review of the	of the health status of the ely on techniques of self- age of daily activities and ir locations, movements, blood pressure, glucose, etc. Visual analytics will be ta items to allow easy nts. With the search bar of eries about their activities, etcrention of lifestyle in a ctor and patients. The repatients the relations and the behaviour. The doctors, which is tems of daily activities, etc. View of the patients by



Alternate Flows: Postconditions:	 Warning: The avatar system will send reminding messages at various priorities in one of the following occasions: medication reminder, due hospital visit (for screening etc.), sign of change of conditions, early sign of one of the diabetic complications. Education: The avatar system will allow patient education on the knowledge of the diseases. It will also test the knowledge of the patients. It is expected that a good knowledge of the disease will lead to enhanced patient behaviours. Complication: The avatar system will be connected to the hospital system to allow for a full access of patients' clinical records and history, which will facilitate the management of complications from other possible conditions. GPs: The avatar system will be shared with GPs to allow coordinated care from the GPs of the patients. 		
Dependencies:	-		
Required External Resources:	[x] Data, please specify:	Patients' data from MyHealthAvatar, including daily activities, exercises, diet, mood, etc.	
	[x] Tools, please specify:	Visual analytics tools for data visualization & analysis	
		Statistical tools for computing standard indexes & charts (e.g. BMI, SAD)	
	[] Services, please specify:		
	[x] Models, please specify:	Statistical tools for computing standard indexes & charts(e.g. BMI, SAD)	
	[] Other, please specify:		
How this use-case is going		1	
to be validated?			
Frequency of Use:			
Who are the users?			
Special Requirements:			
Assumptions:			
Questions:			

Appendix 3 – MyHealthAvatar Global Meeting Agenda

Wohlfühlhotel "Rabenhorst", Am Rabenhorst 1, 66424, Homburg, Germany.

18-19th September, 2014

18 th Sept 2014			
	Agenda	Descriptions	Facilitator
9:00 – 9:30	Welcome/Coffee		
9:30 – 10:00	Introduction	Update of the progress of the project development with the possibility of a demo	BED
10:00 – 10:45	CHF	The implementation details of the CHF case	FORTH
10:45 – 11:30	Osteoarthritis/Genome	The implementation details of the OA case	FORTH
11:30 – 12:15	Nephroblastoma/OBTIMA	The implementation details of the Nephroblastoma/OBTIMA case	USAAR/ICCS
12:15 – 13:00	Diabetes/Geonome	The implementation details of the diabetic case with a possible link with genome	BED/FORTH
13:00 – 14:00	Lunch		
14:00 – 14:30	Emergence access	This describes the scenario of emergence data access	BED
14:30 – 14:45	Anti-Platelet	The implementation details of the anti- platelet case	FORTH
14:45 – 15:00	Brain trauma	The implementation details of the brain trauma case	BED
15:00 – 15:30	Discussion & Summary of the use cases		
15:30 – 16:15	WP6: Data repository	The latest progress in WP6	BED
16:15 – 16:30	Coffee break		
16:30 – 17:15	WP5: Model repository	The latest progress in WP5	ICCS
17:15 – 18:00	WP4: Semantics	The latest progress in WP4	FORTH
18:00 – 19:00	WP3: Architecture	The latest progress in WP3	TEI/FORTH



19:00	End of Day 1
	20:00 Joint Dinner

19 th Sept, 2014			
	Agenda	Descriptions	Facilitator
9:00 – 9:30	WP8: Visualization	The latest progress in WP8	BED
9:30 – 12:00	Discussions on the Architecture & Integration		
12:00 – 13:00	WP11: Legal	The latest progress in WP11	LUH
13:00 – 14:00	Lunch		
14:00 – 14:30	WP10: Dissemination	The latest progress in WP10 in dissemination	ICCS
14:30 – 15:30	WP10: Exploitation	The latest progress in exploitation and business	Larkbio
15:30 – 16:00	H2020 Opportunities		
16:00 – 16:30	Other business and conclusion		
16:30	End of Day 2		